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Background: Partner notiﬁcation is essential to the comprehensive case management of sexually
transmitted infections. Systematic reviews and mathematical modelling can be used to synthesise
information about the effects of new interventions to enhance the outcomes of partner notiﬁcation.
Objective: To study the effectiveness and cost-effectiveness of traditional and new partner notiﬁcation
technologies for curable sexually transmitted infections (STIs).
Design: Secondary data analysis of clinical audit data; systematic reviews of randomised controlled trials
(MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials) published from 1 January 1966 to
31 August 2012 and of studies of health-related quality of life (HRQL) [MEDLINE, EMBASE, ISI Web of
Knowledge, NHS Economic Evaluation Database (NHS EED), Database of Abstracts of Reviews of Effects
(DARE) and Health Technology Assessment (HTA)] published from 1 January 1980 to 31 December 2011;
static models of clinical effectiveness and cost-effectiveness; and dynamic modelling studies to improve
parameter estimation and examine effectiveness.
Setting: General population and genitourinary medicine clinic attenders.vii
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ABSTRACT
viiiParticipants: Heterosexual women and men.
Interventions: Traditional partner notiﬁcation by patient or provider referral, and new partner notiﬁcation
by expedited partner therapy (EPT) or its UK equivalent, accelerated partner therapy (APT).
Main outcome measures: Population prevalence; index case reinfection; and partners treated per
index case.
Results: Enhanced partner therapy reduced reinfection in index cases with curable STIs more than simple
patient referral [risk ratio (RR) 0.71; 95% conﬁdence interval (CI) 0.56 to 0.89]. There are no randomised
trials of APT. The median number of partners treated for chlamydia per index case in UK clinics was 0.60.
The number of partners needed to treat to interrupt transmission of chlamydia was lower for casual than
for regular partners. In dynamic model simulations, > 10% of partners are chlamydia positive with
look-back periods of up to 18 months. In the presence of a chlamydia screening programme that reduces
population prevalence, treatment of current partners achieves most of the additional reduction in
prevalence attributable to partner notiﬁcation. Dynamic model simulations show that cotesting and
treatment for chlamydia and gonorrhoea reduce the prevalence of both STIs. APT has a limited additional
effect on prevalence but reduces the rate of index case reinfection. Published quality-adjusted life-year
(QALY) weights were of insufﬁcient quality to be used in a cost-effectiveness study of partner notiﬁcation
in this project. Using an intermediate outcome of cost per infection diagnosed, doubling the efﬁcacy of
partner notiﬁcation from 0.4 to 0.8 partners treated per index case was more cost-effective than increasing
chlamydia screening coverage.
Conclusions: There is evidence to support the improved clinical effectiveness of EPT in reducing index case
reinfection. In a general heterosexual population, partner notiﬁcation identiﬁes new infected cases but the
impact on chlamydia prevalence is limited. Partner notiﬁcation to notify casual partners might have a
greater impact than for regular partners in genitourinary clinic populations. Recommendations for future
research are (1) to conduct randomised controlled trials using biological outcomes of the effectiveness of
APT and of methods to increase testing for human immunodeﬁciency virus (HIV) and STIs after APT;
(2) collection of HRQL data should be a priority to determine QALYs associated with the sequelae of
curable STIs; and (3) standardised parameter sets for curable STIs should be developed for mathematical
models of STI transmission that are used for policy-making.
Funding: The National Institute for Health Research Health Technology Assessment programme.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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of infected partners grouped into different look-back periods in order of their
break-up date. Steady-state chlamydia prevalence is 3% (dashed line). For each
strategy, means of 100 simulation runs are shown. Standard errors are small and
omitted for better visibility. Reprinted with permission from Althaus CL, Heijne
JCM, Herzog SA, Roellin A, Low N, Individual and population level effects of
partner notiﬁcation for Chlamydia trachomatis, PLOS ONE 2012;7:e5143849 44FIGURE 18 Population level effect of partner notiﬁcation. Graphs show the
reduction in the prevalence of chlamydia after screening for 5 years at a rate of
0.1 or 0.25 per year. (a), (c) and (e) show prevalence for different numbers
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For each strategy, means of 100 simulation runs are shown. Standard errors are
small and omitted for better visibility. 46FIGURE 19 Rates of co-infection with chlamydia and gonorrhoea. Increasing the
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’s Printer and Controller of HMSO 2014. This work was produced by Althaus et al. under the terms of a commissioning contract issued by the Secretary of State for
his issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
d to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
thampton SO16 7NS, UK.
LIST OF FIGURES
xvi
NIHR JoFIGURE 20 Effects of screening and partner notiﬁcation for chlamydia (a and b)
and gonorrhoea (c and d), assuming that the average screening interval for all
individuals is 5 years. The prevalence rates of four different scenarios are
contrasted with those in absence of any intervention. Strategy 1, routine testing
for chlamydia; strategy 2, APT for chlamydia; strategy 3, routine testing for
chlamydia and gonorrhoea; strategy 4, APT for chlamydia and gonorrhoea. Overall
(a and c): general population of 16- to 29-year-olds. High risk (b and d): individuals
with 10 new heterosexual partners per year (1.5% of the general population). 53FIGURE 21 Effects of screening and partner notiﬁcation for chlamydia (a and
b) and gonorrhoea (c and d), assuming that the average screening interval
for all individuals is 2 years. The prevalence rates of four different scenarios
are contrasted with those in absence of any intervention. Strategy 1, routine
testing for chlamydia; strategy 2, APT for chlamydia; strategy 3, routine
testing for chlamydia and gonorrhoea; strategy 4, APT for chlamydia and
gonorrhoea. Overall (a and c): general population of 16- to 29-year-olds.
High risk (b and d): individuals with 10 new heterosexual partners per year
(1.5% of the general population). 54FIGURE 22 Outbreak frequency of gonorrhoea. (a) 5-year screening interval;
(b) 2-year screening interval. Gonorrhoea prevalence is measured once a
year and an outbreak is deﬁned when the observed annual prevalence in
the general population exceeds 0.5%. The prevalence rates of four different
scenarios are contrasted to those in absence of any intervention. Strategy 1,
routine testing for chlamydia; strategy 2, APT for chlamydia; strategy 3,
routine testing for chlamydia and gonorrhoea; strategy 4, APT for chlamydia
and gonorrhoea. Overall: general population of 16- to 29-year-olds. High
risk: individuals with 10 new heterosexual partners per year (1.5% of the
general population). 55FIGURE 23 Reinfection rates of treated index cases by their untreated partners.
(a) Chlamydia; and (b) gonorrhoea. The ﬁgures show box plots of 1000 different
parameter combinations. 56
FIGURE 24 Flow chart of included studies. 60urnals Library www.journalslibrary.nihr.ac.uk
LDOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2
© Q
Hea
prov
add
Parkist of abbreviationsAPT accelerated partner therapy
AROT absolute reduction in onward
transmission
CASH Contraceptive And Sexual
Health (service)
CI conﬁdence interval
ClaSS Chlamydia Screening
Studies project
CSO Chlamydia Screening Ofﬁce
DARE Database of Abstracts of
Reviews of Effects
EPT expedited partner therapy
HADS Hospital Anxiety and
Depression Scale
HIV human immunodeﬁciency virus
HRQL health-related quality of life
HTA Health Technology Assessment
HUI2 Health Utilities Index Mark 2
IoM Institute of Medicine
IQR interquartile range
MAD median absolute deviation
MD mean difference
MOS Medical Outcomes Study
Natsal-2 second National Survey of Sexual
Attitudes and Lifestylesueen’s Printer and Controller of HMSO 2014. This work was produced by Althaus et al.
lth. This issue may be freely reproduced for the purposes of private research and study a
ided that suitable acknowledgement is made and the reproduction is not associated wi
ressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials
, Southampton SO16 7NS, UK.NCSP National Chlamydia
Screening Programme
NHS EED NHS Economic Evaluation Database
NICE National Institute of Health and
Care Excellence
NNTIT the number of partners that need
to be notiﬁed to interrupt one
secondary transmission
OR odds ratio
PCT primary care trust
PEACH PID Evaluation and Clinical
Health
PID pelvic inﬂammatory disease
QALY quality-adjusted life-year
RR risk ratio
SD standard deviation
SF-12 Short Form questionnaire-12 items
SF-36 Short Form questionnaire-36 items
STD sexually transmitted disease
STI sexually transmitted infection
TTO time trade-off
VAS visual analogue scale
WHO World Health Organizationxvii
under the terms of a commissioning contract issued by the Secretary of State for
nd extracts (or indeed, the full report) may be included in professional journals
th any form of advertising. Applications for commercial reproduction should be
and Studies Coordinating Centre, Alpha House, University of Southampton Science

DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2Scientiﬁc summaryBackground
Partner notiﬁcation is essential to the comprehensive case management of people with sexually
transmitted infections (STIs). As a multilevel process, the goals and outcomes of partner notiﬁcation vary
depending on the target level and on the sexual behaviour of the index case and type of sexual
partnerships that he or she has. The sexual partners of index cases can be reached with a range of
methods, each of which can be considered as a separate technology. Traditional methods of partner
notiﬁcation, including patient and provider referral, require sexual partners to attend a health-service
setting to be assessed clinically before antibiotic treatment can be dispensed or prescribed. Patient referral
methods can be separated into simple and enhanced, depending on the intensity of the intervention. New
technologies have been developed to allow partners to receive treatment without a face-to-face
assessment in a health-service setting. Expedited partner therapy (EPT) was developed in the USA and
involves giving index cases antibiotics or prescriptions for their partners without the need for a consultation
with a health professional. Its UK equivalent is accelerated partner therapy (APT), where the consultation
can be done by telephone or with a pharmacist.Objectives
The Health Technology Assessment (HTA) programme asked, ‘What is the clinical and cost-effectiveness
of providing treatment for the partner(s) of people with a STI without testing them for the STI ﬁrst?’
The project presented in this monograph addressed the question by investigating both traditional and
new partner notiﬁcation technologies for curable STIs. Methods were outlined in a protocol. Speciﬁc
objectives were:
l to compare the effectiveness of different partner notiﬁcation approaches to providing testing
and treatment for the partners of people with curable STIs by
¢ systematic reviews and analysis of secondary data to obtain estimates of outcome measures
¢ mathematical modelling to estimate impact. The modelling studies considered chlamydia and
gonorrhoea transmission in general heterosexual populations
l to determine the cost-effectiveness of different partner notiﬁcation approaches to providing testing
and treatment for the partners of people with curable STIs
l to provide recommendations for future research.Methods
The authors used a range of research methods: analysis of secondary data, systematic reviews, and static
and dynamic modelling studies.Secondary data
The authors analysed clinical audit data about partner notiﬁcation for chlamydia to estimate intermediate
outcomes of partner notiﬁcation for chlamydia in UK genitourinary medicine clinics. There were three
outcome measures: the number of partners per index case who were tested for chlamydia; the number ofxix
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xxpartners per index case with a positive chlamydia test; and the number of partners treated per index case.
Shewhart control charts (R, The R Foundation for Statistical Computing, Vienna, Austria) were used to
describe variability in outcomes across clinics and a hierarchical logistic regression model was constructed
to examine factors associated with partner notiﬁcation outcomes at the individual and clinic levels.Systematic reviews
The authors performed two systematic reviews. The ﬁrst examined the effects of traditional and new
partner notiﬁcation technologies in randomised controlled trials published from 1 January 1966 to
31 August 2012, searching MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials. The
populations studied were patients with chlamydia, gonorrhoea, non-speciﬁc genital infection, trichomonas,
pelvic inﬂammatory disease (PID), syphilis or co-infection with any of these STIs. The primary outcome was
reinfection of the index case, measured as repeated detection at a follow-up visit. Meta-analysis was
conducted where appropriate.
The second systematic review included published studies from 1 January 1980 to 31 December 2011
examining the evidence available for obtaining quality-adjusted life-year (QALY) estimates for female
reproductive tract outcomes of bacterial STIs. The databases searched were MEDLINE, EMBASE, ISI Web of
Knowledge, NHS Economic Evaluation Database (NHS EED), Database of Abstracts of Reviews of Effects
(DARE) and HTA. The population of interest was women. Outcomes were measures of health-related
quality of life (HRQL) and QALY weights. The analysis was descriptive.Static models
Two studies used static models. In the ﬁrst, the authors developed an algorithm to estimate the probability
of chlamydia transmission from index cases to the next two generations of sexual partners. Data inputs
included partnership numbers and types from a genitourinary medicine clinic audit, and estimates of
chlamydia transmissibility, adjusted for partnership type. Two new measures of partner notiﬁcation impact
were derived: (1) the absolute reduction in onward transmission and (2) its reciprocal, the number of
partners that need to be notiﬁed to interrupt one secondary transmission (NNTIT).
In the other study, a spreadsheet tool (Microsoft Excel, Microsoft Corporation, Richmond, WA, USA) was
used to compare the cost per new case detected through partner notiﬁcation and by increasing screening
coverage in the National Chlamydia Screening Programme (NCSP) in England. Costs were obtained from a
costing guidance initiative from the NCSP. The baseline programme was compared with one scenario with
increased screening in men, and with another scenario with increased efﬁcacy of notiﬁcation of partners of
index cases.Dynamic models
The authors ﬁrst conducted preparatory studies to improve parameter estimates and determine an
appropriate modelling framework. First, they used a simple compartmental model of chlamydia
transmission to examine the inﬂuence of different parameters on the predicted impact of an intervention
programme. Based on the ﬁndings, new estimates of the average duration of asymptomatic chlamydia and
the per-sex act and the per-partnership transmission probabilities of chlamydia were derived, based on
reanalysis of previously published data. The authors then compared three published individual-based
models of chlamydia transmission, using UK-population-based data about sexual behaviour and chlamydia
positivity. As a result, a new individual-based modelling framework for STIs was developed. This was used
to study the individual- and population-level effects of traditional partner notiﬁcation methods for
chlamydia, according to different numbers of partners traced or different look-back periods.
A new mathematical model of chlamydia and gonorrhoea co-infection was then developed, informed by a
reanalysis of previously published epidemiological data. The model was used to examine the effects of
traditional (partner attends clinic for treatment and STI testing) and new (APT, treatment without testing)NIHR Journals Library www.journalslibrary.nihr.ac.uk
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gonorrhoea. Reinfection of index cases with chlamydia and gonorrhoea by their untreated partners, after
different delays until partner treatment, was estimated using a simple probability model.Results
The systematic review of randomised controlled trials provided strong evidence that EPT is more effective
than simple patient referral in reducing reinfection in the index cases with curable STIs [risk ratio (RR) 0.71;
95% conﬁdence interval (CI) 0.56 to 0.89]. There was no evidence that EPT was better than enhanced
patient referral (RR 0.96; 95% CI 0.60 to 1.53). The evidence was insufﬁcient to determine which method
of enhanced patient referral was most effective in particular settings.
Analysis of UK clinical audit data showed a median of 0.47 partners tested for chlamydia per index case
and 0.60 partners treated per index case. Partner notiﬁcation outcomes were lower in London than
elsewhere (median number tested per index case 0.30 vs. 0.52) and lower in men who have sex with men
than in heterosexual men [adjusted odds ratio (OR) 0.34; 95% CI 0.17 to 0.68]. These levels of
intermediate outcomes of partner notiﬁcation are comparable with levels found in the randomised
controlled trials in the systematic review.
The static model estimating the impact of partner notiﬁcation for chlamydia in genitourinary medicine
clinic attendees found that fewer casual than regular partners need to be traced and treated to prevent a
secondary case. For example, the NNTIT for men aged < 25 years was 1.92 for casual partners and 3.25 for
regular partners. The algorithm provides a basic tool to support public health decision-making at the local
clinic level but a dynamic model is required for detailed analysis of the effects of partner notiﬁcation on
chlamydia transmission.
Modelling the transmission dynamics of Chlamydia trachomatis provides new estimates of the average
duration of asymptomatic chlamydia infection in women (433 days; 95% CI 420 to 447 days); the
heterosexual per-partnership transmission probability of chlamydia [55.5%; interquartile range (IQR)
49.2% to 62.5%]; and per-sex act probability (9.5%; IQR 6.0% to 16.7%). Comparison of three
individual-based models of chlamydia transmission showed that differences in sexual partnership dynamics
and in infection parameter estimates partly explained the differences in model predictions of preventative
interventions. A new framework for individual-based models of STI transmission was developed to improve
the modelling of the sexual partnership dynamics.
In an individual-based model of chlamydia transmission with baseline prevalence 3%, model predictions
show that 68% of current partners of chlamydia-positive index cases would be infected. A look-back
period of up to 18 months would identify > 10% positivity in notiﬁed partners. At chlamydia screening
rates of 0.1 per year, prevalence was reduced to about 70% of the baseline prevalence after 5 years. An
additional reduction in chlamydia prevalence is obtained with partner notiﬁcation, to about 60% of the
baseline. If each partner is successfully treated with a probability of 50%, notiﬁcation of the current
partner achieves most of the additional reduction.
A new individual-based mathematical model of both chlamydia and gonorrhoea transmission was
developed. To reproduce observed patterns of chlamydia and gonorrhoea prevalence and co-infection, an
interaction has to be assumed, in which infection with either chlamydia or gonorrhoea increases
susceptibility to the other. In the model, cotesting and treatment reduced the prevalence of both
infections. The effect of APT compared with standard patient referral was minor in reducing the
prevalence of both infections at the population level. Reductions in the time to treatment of partners,
which could be achieved with APT, could reduce index case reinfection rates substantially.xxi
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xxiiOur systematic review of HRQL studies for chlamydia infection found few robust and validated tools.
The only published QALY estimates were judged to be of too low quality to be used to study the
cost-effectiveness of partner notiﬁcation using this outcome. As a result, we did not estimate incremental
cost-effectiveness ratios using cost per QALY in this project.
Measuring the costs of chlamydia screening and traditional partner notiﬁcation technologies in the context
of the NCSP in England suggested that doubling the efﬁcacy of partner notiﬁcation (from 0.4 to
0.8 partners per index case) would reduce the costs per infection diagnosed for a limited additional
investment. In contrast, increasing the screening coverage of men to the same level as for women would
require an investment of six times more money but lead to only twice as many additional infections
being treated.ConclusionsImplications for health carel A range of enhanced patient referral methods is available. Genitourinary medicine clinics have staff
with the skills and resources for conducting enhanced patient referral. Patients with curable STIs in
primary care and community sexual health services should also be able to receive enhanced patient
referral as part of their management. Support from health advisers in genitourinary medicine clinics
and training for staff in primary and community health-care services might need to be strengthened.
l The ﬁndings of two studies in this monograph emphasise the importance of sexual history taking. First,
sexual histories need to cover look-back periods that identify previous partners because our
mathematical model predicted high percentages of sexual partners infected with chlamydia as far back
as 18 months or three previous partners. Second, it is important to ﬁnd out the type of sexual
partnerships of index cases. The need for health adviser support for notifying casual partners should be
considered because of the potential gains in interrupting transmission.
l The analysis of audit data shows that the outcomes of partner notiﬁcation in genitourinary medicine
clinics remain modest. The studies in this monograph show evidence of the gains of improving
outcomes. The economic evaluation suggests that relative costs (per case identiﬁed) of increasing
the success of partner notiﬁcation are less than the costs of increasing the coverage of
chlamydia screening.
l Although we examined the risk of gonorrhoea outbreaks as an unintended consequence of APT, this
technology also has implications for the underdiagnosis and undertreatment of other STIs, which we
did not consider. First, there are missed opportunities for diagnosing human immunodeﬁciency virus
(HIV) infection and the importance of STI testing needs to be explained to partners receiving APT.
Second, if an index case has chlamydia and gonorrhoea but is not tested for gonorrhoea or the test
gives a false-negative result, the APT antibiotic will be a single 1-g dose of azithromycin, which is an
inadequate treatment for gonorrhoea and could encourage antimicrobial resistance. Third, treatment
for uncomplicated chlamydia and/or gonorrhoea will not be adequate treatment if a female partner
has PID.
l The ﬁndings about the effects and impact of partner notiﬁcation technologies cannot be generalised to
men who have sex with men, as there is limited trial evidence and because the mathematical
modelling studies modelled a general heterosexual population. However, the audit showed that
partner notiﬁcation outcomes were worse in men who have sex with men. We show ﬁndings for a
population of high-risk individuals within a general population; these should be interpreted cautiously
when applying these to speciﬁc populations at high risk or in high-prevalence areas.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2Recommendations for research1. A randomised controlled trial of the effects of APT compared with traditional partner notiﬁcation
technologies should be conducted, with follow-up measuring biological end points beyond 3 months.
Determining whether or not the magnitude of beneﬁt found in trials of EPT can be generalised to APT
is a priority.i. Randomised trials should include interventions to increase rates of testing for other STIs and HIV in
partners notiﬁed by APT.
ii. Modelling studies of the effectiveness and cost-effectiveness of APT should be conducted alongside
a clinical trial. This should build on the dynamic models for single and dual infections developed
within this project.
2. Randomised trials to identify effective partner notiﬁcation technologies for men who have sex with men
should be conducted for both bacterial STIs and HIV.
3. Studies that use methods preferred by the National Institute for Health and Care Excellence (NICE) to
collect HRQL data, including the development of appropriate tools, should be commissioned so that
QALYs for temporary and permanent health states associated with bacterial STIs can be determined.
This is a priority so that robust cost-effectiveness analyses of APT and of other interventions to prevent
curable STIs and their consequences can be conducted.
4. Standard sets of disease-speciﬁc parameters for bacterial STIs should be developed to help researchers
compare the performance of mathematical models and to help policy makers to interpret their outputs.
Further research to develop these for gonorrhoea, trichomonas and syphilis is needed.
5. Basic science studies are needed to investigate the possible mechanisms for a biological interaction
between the susceptibility to C. trachomatis and to Neisseria gonorrhoeae. Additional modelling studies
of STI co-infections would be valuable.Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.xxiii
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Partner notiﬁcation is essential to the comprehensive case management of people with sexuallytransmitted infections (STIs). The World Health Organization (WHO) deﬁnes partner notiﬁcation as
‘public health services in which sexual partners of individuals with STD [sexually transmitted diseases, sic]
are notiﬁed, informed of their exposure and offered treatment and support services’.1 The aims of STI
control, including partner notiﬁcation, are to reduce morbidity and mortality, prevent human
immunodeﬁciency virus (HIV) infection, prevent serious complications such as tubal infertility, and to
reduce adverse outcomes of pregnancy.2 The WHO deﬁnition refers only to STIs that can be cured by
antibiotic treatment: syphilis, caused by Treponema pallidum; gonorrhoea, caused by Neisseria
gonorrhoeae; chlamydia, caused by Chlamydia trachomatis; and trichomonas, caused by Trichomonas
vaginalis. Likewise, this monograph does not cover partner notiﬁcation for HIV infection or other viral STIs.
The Health Technology Assessment (HTA) programme asked, ‘What is the clinical and cost-effectiveness of
providing treatment for the partner(s) of people with an STI without testing them for the STI ﬁrst?’ The
project presented in this monograph addresses the question by investigating the effectiveness and
cost-effectiveness of both traditional and new technologies for managing the sexual partners of people
with STIs. We deﬁne traditional methods as those in which the sexual partners have to attend a health
service setting to be assessed before treatment and new methods as those that have been developed to
facilitate rapid access to antibiotic treatment for sexual partners without them having to be assessed in a
health-service setting. This introduction describes the theoretical mechanism of action of partner
notiﬁcation, deﬁnes different partner notiﬁcation technologies, summarises outcomes and methods used
to measure the effectiveness and cost-effectiveness of partner notiﬁcation and deﬁnes the infections and
populations covered by the included studies. Finally, we present our speciﬁc objectives and describe the
way they are addressed in the monograph.
The terminology of partner notiﬁcation differs between countries. We use terminology recognised in the
UK, where ‘partner notiﬁcation’ and ‘contact tracing’ are synonymous. The term ‘notiﬁcation’ is
ambiguous, so we would like to distinguish the term ‘partner notiﬁcation’ from ‘disease notiﬁcation’ for
surveillance. ‘Disease notiﬁcation’ requires that details of cases of statutorily notiﬁable infections be sent to
national authorities. ‘Partner notiﬁcation’ refers only to the process by which a sexual partner is informed
(notiﬁed) that they have been in contact with a STI. Partner notiﬁcation is a conﬁdential process: details of
the index cases are known only to the health professionals treating them and are not divulged either to
sexual partners or to disease notiﬁcation systems. Partner notiﬁcation can be considered as a public good,
which beneﬁts the wider society and not just an individual, and should be available to all. There is,
however, a tension between protecting the welfare of the population and of exposed partners, and
protecting the liberty and right to privacy of the person infected with a STI.3 Both the practice of and
research about partner notiﬁcation offer additional challenges because they require inquiry into private
behaviour and because persons with STIs are often stigmatised. Although the authors approach partner
notiﬁcation in an objective and non-judgemental way, the societal and cultural factors that are likely to
affect its implementation and impact must be acknowledged, even though they are difﬁcult to measure.How partner notiﬁcation worksPartner notiﬁcation is a multilevel process. Its goals and outcomes vary depending on the target level
(Figure 1)4 and on the sexual behaviour of the index case and type of sexual partnerships that he or she
has (Figure 2).5 Partner notiﬁcation contributes to STI control by reducing the duration of the infectious
period at three levels.
First, partner notiﬁcation provides epidemiological treatment to sexual partner(s) of an index case
(e.g. Partners 1, 2 and 3 in Figure 2), which means giving antibiotics before the outcome of any diagnostic1
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FIGURE 1 Levels and outcomes of partner notification. Adapted from Low et al.4
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FIGURE 2 Mechanisms of action of partner notification in three different partnership types. Partner 1: ongoing
regular partnership. Partner notification leads to identification of Partner 1; treatment prevents reinfection between
index case and Partner 1; Partner 2: terminated partnership. Partner 2 was the source of index case infection. Partner
notification identifies Partner 2 as a new index case; treatment prevents transmission to Partner 2.1; Partner 3:
ongoing regular partnership of Partner 3 with index case and casual partnership with Partner 3.1. Partner notification
prevents reinfection; partner notification identifies Partner 3 and Partner 3.1 as new index cases; treatment prevents
transmission to Partner 3.1.1.
INTRODUCTION
2tests is known. If diagnostic tests are positive then new index cases are identiﬁed (e.g. Partners 2 and 3 in
Figure 2). Their infectious duration is shortened because these cases are likely to have been asymptomatic
and could have continued to transmit infection unknowingly. Case ﬁnding through partner notiﬁcation is
very efﬁcient, particularly for infections such as gonorrhoea, which are rare in the general population;
70–80% of partners of index cases with gonorrhoea are infected.6 For chlamydia, 60–70% of partners of
index cases are infected.6,7 Infected sexual partners can receive treatment, which might reduce their
probability of developing complications of infection. In turn, partner notiﬁcation with the new index case
can prevent transmission of infection to future partners (e.g. Partners 2.1 and 3.1.1 in Figure 2).
Second, partner notiﬁcation aims to prevent reinfection of the person who has been treated (the index
case) by untreated sexual partner(s) (e.g. Partner 1 in Figure 2). In principle, in an ongoing sexual
partnership, reinfection between index case and partner will be prevented if both are treated within a
short span of time and do not have unprotected sexual intercourse until antibiotic treatment has
eradicated the infection in both. Prevention of reinfection shortens the total infectious period within a
partnership and means that the index case is no longer infectious when they leave the partnership.
Third, in a sexual network, partner notiﬁcation is intended to interrupt chains of transmission. If the uptake
is high enough, the average duration of infection at the population level will be reduced and this should
reduce the prevalence of the STI.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2The effects of partner notiﬁcation can vary according to the type of sexual partnership in which the
infection occurred. The second National Survey of Sexual Attitudes and Lifestyles (Natsal-2) in the UK
shows that individuals with regular or live-in partners have fewer casual (usually short-term) sexual partners
than individuals who report having only casual partnerships.8 Treating the regular sexual partner of an
individual with chlamydia prevents reinfection within the partnership, but treating their casual partner(s)
could prevent both reinfection and onward transmission.9Deﬁnitions of partner notiﬁcation technologiesThis monograph assesses the health technologies known collectively as ‘partner notiﬁcation’. The sexual
partners of index cases can be reached with a range of methods, each of which can be considered as a
separate technology (Table 1). Different partner notiﬁcation technologies have developed over time in
response to changes in the epidemiology of STIs; changes in the organisation of, and resources available
for, sexual health services; and advances in technologies for testing, treating and communicating with
patients.3 In the traditional model of sexual health care, sexual partners identiﬁed through partner
notiﬁcation have to attend a health-service setting to be assessed clinically before antibiotic treatment can
be dispensed or prescribed. Clinical guidelines from the British Association for Sexual Health and HIV
recommend that sexual partners of index cases with chlamydia, gonorrhoea, trichomonas or non-speciﬁcTABLE 1 Deﬁnitions of partner notiﬁcation technologies and terminology
Term Deﬁnition
Partner notiﬁcation
(synonym: contact tracing)
The process by which a sexual partner is informed (notiﬁed) that they have been in contact
with a STI and is offered treatment and support services
Index case The person with a diagnosed STI
Patient referral The index case (patient) takes the responsibility for notifying their sexual partner(s) and
telling them that they need to be treated (referral to health services)
Simple patient referral Advice to the index case from a health professional that sexual partners need to be treated
and that the patient should inform them and tell them to go to their own doctor or to a
specialist clinic
Enhanced patient referral Patient referral with the addition of one or more of:
l written infection-speciﬁc information for index cases to give to their partners
l additional verbal information given during the consultation
l use of a website
l sampling kits for index cases to give to partners
Epidemiological treatment Antibiotic treatment given to the sexual partner when they ﬁrst attend, before knowing
whether or not they are infected. The antibiotics are for the same STI that the index case has
as well as any others for which the probability of infection is deemed to be sufﬁciently high
APT Facilitated access to antibiotic treatment for sexual partners to reduce the time between
index case diagnosis and partner treatment. It involves a consultation by telephone or with a
pharmacist to assess eligibility of the partner for treatment, but a face-to-face consultation
with a physician is not required. An adaptation of EPT (see below) that complies with UK
prescribing regulations
EPT Facilitated access to antibiotic treatment (as antibiotics or a prescription) for sexual partners
to reduce the time between index case diagnosis and partner treatment. No consultation
with a health professional is required. Developed in the USA, not used in UK
Provider referral A health-care professional (provider) takes responsibility for notifying the sexual partner(s) of
the index case
Contract referral The index case agrees to notify partners within a speciﬁed time period. If he or she has not
done so, the health adviser will do provider referral. This sometimes involves a written
agreement (contract) between the patient and the provider
APT, accelerated partner therapy; EPT, expedited partner therapy.
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4urethritis should be offered epidemiological treatment and testing for other STIs.10,11 New guidelines state
that epidemiological treatment could be offered to primary syphilis contacts, and that testing for syphilis
can be considered for men who have sex with men in outreach settings.12
New technologies have been developed to allow partners to receive treatment without a face-to-face
assessment in a health-service setting. These methods, in fact, simply formalise the reality of existing
practice in many places.13 If an index case has more than one partner, different partner notiﬁcation
technologies might be appropriate for different partners. The main features of partner notiﬁcation
technologies and their advantages and disadvantages for STI control are outlined below (Table 2).
Partner notification technologies requiring partner assessment at health services
In the UK, patient referral is the most commonly used partner notiﬁcation technology for curable STIs.14
When the number of cases of gonorrhoea increased markedly in the 1960s and 1970s, patient referral
was introduced as an efﬁcient way of bringing sexual partners to treatment.15 Before this, contact tracing
ﬁeld staff usually notiﬁed the partners of people who had either syphilis or gonorrhoea (provider referral).
Patient referral was then extended as a method of partner notiﬁcation for chlamydia, which has since
become the most commonly diagnosed STI in the UK.
A major advantage of patient referral, and other methods for which the partner has to attend the clinic, is
that tests for other STIs, including HIV, can be done and additional prevention education can be offered
at the same visit. The methods used to enable patient referral are now very diverse and can be separated
into simple and enhanced categories, according to the intensity of the intervention (see Table 1).
Enhancements to improve the effectiveness of simple patient referral include additional written
information, verbal advice and counselling, home-sampling kits for partners, and text messaging or
websites to facilitate communication.16–19
A health-care professional (the provider) can notify partners if the index patient does not want to or
cannot do it him or herself. In practice, contract referral is often not seen as a separate method but as an
extension of patient referral (if partners have not been notiﬁed by the time that a follow-up visit occurs), orTABLE 2 Advantages and disadvantages for STI control of partner notiﬁcation approaches
Partner notiﬁcation approach Advantages Disadvantages
Partner attends health services for assessment
Simple patient referral; enhanced
patient referral; contract referral;
provider referral
Face-to-face consultation for advice about
contacting partners and avoiding reinfection or
new infection
Inconvenient for partner(s), who
might not attend
Testing for HIV and other STIs can be done Delay between notiﬁcation and
attendance allows time for
onward transmissionEpidemiological treatment on day of attendance
Enhancements using additional written
information, home-sampling for partners,
websites, etc., can improve effectiveness
Partner does not attend health services for assessment
APT; EPT Treatment reaches partners who would not
attend health service
No testing for HIV and other
STIs
Reduced delay between notiﬁcation and
attendance of partner
No face-to-face consultation for
advice and information
Treatment package can include condoms,
additional written information, etc.
APT, accelerated partner therapy; EPT, expedited partner therapy.
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In the UK, advisers in sexual health (health advisers) are the specialist staff for partner notiﬁcation and they
usually work in genitourinary medicine (sexual health, STI) clinics. If the index case agrees that provider
referral is acceptable for a particular partner, the health adviser then contacts the partner by telephone,
post, e-mail, text message or, less frequently, by home visit. These approaches are most appropriate
in instances when attendance of the partner can be conﬁrmed, for example where a single clinic serves
a geographic area. They are often used for partner notiﬁcation for people with syphilis and
blood-borne virus infections, including hepatitis B and C.Partner notification technologies not requiring partner assessment at
health services
Accelerated partner therapy (APT) is a new partner notiﬁcation technology in the UK to provide quicker
access to antibiotic treatment for sexual partners to reduce the time between index case diagnosis and
partner treatment.20 APT is based on expedited partner therapy (EPT), which was developed in the USA to
increase efﬁcient use of partner notiﬁcation resources for the most common STIs, chlamydia and
gonorrhoea.21 EPT and APT can be considered as a speciﬁc type of enhanced patient referral;22 the
enhancement is the provision of antibiotics or prescriptions for index cases to give to partners.
Expedited partner therapy removes the requirement for consultation with a health professional by allowing
the index patient to give medication directly as a treatment package (patient-delivered partner therapy) or
as a prescription to their partner(s).21 In the UK, two models that comply with prescribing regulations have
been developed: in APT Hotline a health adviser or senior nurse practitioner assesses the eligibility of the
partner for treatment by telephone; in APT Pharmacy the sexual partner attends a community pharmacy
and is assessed by a pharmacist.20
The spread of undiagnosed and untreated STIs is the main concern regarding APT and EPT.21 When
antibiotics are provided without a clinic-based consultation, the sexual partner is not tested for STIs at the
time of treatment and will not be advised on how to reduce the risk of future infection. If an index case
diagnosed with chlamydia gives antibiotics for chlamydia alone to his or her sexual partner(s) and no tests
for STIs are done, partners who are co-infected with gonorrhoea or HIV will not have these infections
diagnosed. There is then a risk that untreated gonococcal and HIV infections could cause outbreaks, which
would have been detected and contained if the partners had been tested. APT consultations therefore
involve an ‘assertive invitation’20 to encourage partners to take antibiotics and to undergo testing for STIs,
including HIV. Missed opportunities for testing and sexual health counselling might, however, be
outweighed by the beneﬁt of interrupting transmission of the index-case STI by reaching sexual partners
who would otherwise have remained untreated.23Reported diagnoses of curable sexually transmitted infections
in the UKChlamydia is the most commonly curable STI diagnosed in England, followed by non-speciﬁc genital
infection, gonorrhoea and syphilis (Table 3).24 The distributions of cases by diagnosis, age and route of
acquisition are assumed to be similar in Northern Ireland, Scotland and Wales. Non-speciﬁc genital
infection is a clinical diagnosis, which includes cervicitis in women and urethritis in men in whom a speciﬁc
microbiological diagnosis, such as C. trachomatis or N. gonorrhoeae infection, has been excluded.
Chlamydia infections have been the most commonly reported STI since 1988, when the term was ﬁrst
introduced as a diagnostic category. In 1988, 30,145 cases of chlamydia and 17,062 cases of gonorrhoea
were reported from UK genitourinary medicine clinics. Numbers of diagnosed chlamydia cases now include
cases diagnosed in community settings (see Table 3), most of which are from the National Chlamydia
Screening Programme (NCSP), which was rolled out across primary care trusts (PCTs) in England from 2003
to 2007.5
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TABLE 3 Diagnoses of curable STIs in England, 2011
Infection Setting
Total cases
diagnosed, N
15- to 24-year-olds,
n (% of total)
Acquired heterosexually,
n (% of total)
Chlamydia All settings 186,196 157,594 (84.6) Not reported
GUM clinics 100,660 62,058 (61.7) 93,177 (92.6)
Community settings 85,536 85,536 (100) Not reported
Gonorrhoea GUM clinics 20,965 9074 (43.3) 13,478 (64.3)
Non-speciﬁc
genital infection
GUM clinics 61,931 Not reported Not reported
Syphilis GUM clinics 2915 435 (14.9) 728 (25.0)
GUM, genitourinary medicine.
Data from Public Health England: STI Annual Data tables.24
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6Co-infection with chlamydia and gonorrhoea is common, but is not reported in routine surveillance data.
Observational studies in different countries,6,25,26 and different settings in the same country,26,27 show that
30–40% of people with gonorrhoea are also infected with chlamydia and that 5–15% of those with
chlamydia are also infected with gonorrhoea. The co-infection positivity rates are much higher than for
either infection alone. Chlamydia is most commonly diagnosed in heterosexual women and men.
Conversely, two-thirds of gonorrhoea cases and three-quarters of syphilis cases are diagnosed in men who
have sex with men. The differences in the distribution of these STIs reﬂect the interplay between the
biological characteristics of the pathogens and the sexual behaviour and sexual networks of the host.Measuring the effectiveness and cost-effectiveness of
partner notiﬁcationMethods for measuring the effectiveness of health technologies can be broadly split into those that collect
primary data in empirical studies and those that synthesise existing data. This project used research
methods that synthesise the ﬁndings of existing data through systematic reviews of the results of primary
studies, reanalysis of data from primary studies, and modelling studies. The methods used to measure
the effectiveness and cost-effectiveness of partner notiﬁcation depend, like the goals, on the outcomes for
the level at which the technology is targeted. Table 4 lists the measures of effectiveness and
cost-effectiveness of partner notiﬁcation used in this monograph.
Clinical effectiveness outcomes
Direct, objective outcomes of the primary end points of partner notiﬁcation are the preferred measures of
effectiveness. Primary end points are often not collected; however, because they are less frequent and
more difﬁcult to collect than intermediate outcomes. Reinfection of the index case by an untreated partner
is now the preferred outcome of a failure of partner notiﬁcation. The availability of nucleic acid
ampliﬁcation tests for diagnosis on non-invasively collected specimens has facilitated this. In practice,
‘reinfection’ is measured as repeated detection of infection at follow-up, and misclassiﬁcation of the
source of the repeated infection can occur. Without the additional use of highly discriminatory gene
sequencing methods, repeated infection owing to antibiotic treatment failure or infection from a new
partner cannot be excluded.28 In addition, results can be biased if there is differential loss to follow-up
between intervention arms.
Biological outcomes of pelvic inﬂammatory disease (PID) in women and population STI prevalence are
difﬁcult to attribute speciﬁcally to the impact of a partner notiﬁcation intervention. To our knowledge,NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 4 Measures of effectiveness and cost-effectiveness of partner notiﬁcation used
Measure Level Type Deﬁnition
Effectiveness
Reinfection of
index case
Individual Primary Repeated detection of STI in index case at follow-up with evidence
of reinfection from an untreated partner. Measured as a rate per
100 index cases or per 100 person-years
Complications
of STI
Individual Primary E.g. incidence of PID per 100 index cases or per 100 person-years
Partners treated Partner Intermediate Number of partners of an index case who received treatment for the
same STI. Measured as partners per index case veriﬁed to have been
treated, OR partners per index case reported by index case to have
been treated, OR percentage of index cases with at least one partner
treated
Cases of
secondary
transmission
Network Intermediate The number of transmissions that might have occurred from index
cases’ partners to their sexual partners. Measured as AROT or NNTIT
Population
prevalence
Population Primary Prevalence of STI measured in a representative sample of the general
population. Measured as prevalence rate per 100 persons at risk
Cost-effectiveness
Cost per case Individual Intermediate Cost per natural unit of outcome of detecting a new case
Cost per
secondary case
Network Intermediate Cost per natural unit of outcome of preventing transmission to a
secondary partner
Cost per QALY Population Primary Measure of cost-effectiveness in units that can be compared directly
across different interventions and conditions. Requires appropriate
valuation of health states associated with the STI
AROT, absolute reduction in onward transmission; NNTIT, the number of partners that need to be notiﬁed to interrupt
one secondary transmission; QALY, quality-adjusted life-year.
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one trial of a cluster-randomised trial of EPT in Washington (state), USA, but results have not yet been
published.29 Mathematical modelling studies are therefore the only way to estimate the impact of partner
notiﬁcation on transmission at the population level (see Mathematical modelling for decision-making
about sexually transmitted infection control).
Intermediate outcome measures of the clinical effectiveness of partner notiﬁcation include the number of
partners of an index case that have been treated. In the UK, the number of partners treated per index case
is the outcome used to monitor partner notiﬁcation outcomes in health service evaluations, such as clinical
audit.30 Intermediate outcomes are often used as surrogates for successful partner notiﬁcation but the
relationship between the number of partners treated per index case and prevention of reinfection is not
known. First, a record that a partner received treatment does not guarantee that medication was taken at
all (unless directly observed). Second, the treatment has to be present in high enough concentrations to
interrupt replication. Third, sexual partners have to avoid unprotected sexual intercourse for long enough
to allow the treatment to work. For the sexual partner, the prevention of onward infection transmission is
an important outcome. This can be deﬁned as the number of transmissions that might have occurred from
index cases’ partners to their sexual partners.9 Secondary transmission is difﬁcult to measure empirically in
clinical studies because information about subsequent partners is often not collected and, if a secondary
partner is infected, the direction of transmission is not known. It can, however, be estimated in modelling
studies. In this monograph (see Chapter 2, Estimating the likely public health impact of partner
notification for a clinical service: an evidence-based algorithm) we examine two new intermediate
measures of the impact of partner notiﬁcation, based on the concept of the ‘number needed to treat’:7
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8the absolute reduction in onward transmission (AROT) and its corollary, the number needed to interrupt
transmission (NNTIT).9Cost-effectiveness outcomes
The UK National Institute for Health and Care Excellence (NICE) prefers the cost per quality-adjusted
life-year (QALY) as the primary outcome for cost-effectiveness. The challenges in measuring clinical
effectiveness in partner notiﬁcation studies therefore also affect the estimation of cost-effectiveness. If the
results of economic evaluations are to be presented in terms of cost per QALY, a valuation exercise is
necessary. Economic evaluations of STI control interventions such as chlamydia screening programmes
include the costs of preventing cases of PID, chronic pelvic pain, ectopic pregnancy and tubal factor
infertility. These outcomes are therefore also relevant to evaluating partner notiﬁcation as a health
technology. Measuring health-related quality of life (HRQL) for patients during an episode of chlamydia
infection presents several challenges. First, the asymptomatic nature of many STIs means that infections are
often undiagnosed, and thus there is no apparent detrimental impact on quality of life. Second,
instruments for measuring quality of life usually assume that a health state is chronic or permanent. This is
not the case for acute episodes of STIs and for some sequelae such as PID and ectopic pregnancy.
Infertility caused by a STI can be considered a permanent health state if a woman intended to start a
family but a temporary health state if she decides not to have children. Cost per major outcome averted is
often presented when utility weights cannot be determined. Presentation in natural units, however, cannot
be directly compared with the cost-effectiveness of other interventions.
Intermediate economic outcomes of partner notiﬁcation include the cost per new infection treated or of
secondary cases prevented.31 They are intermediate outcomes because they do not give a direct indication
of the ﬁnal outcome. These outcomes can be estimated in natural units (cost per case of chlamydia
infection averted), but not in terms of health utilities. In addition, the cost per secondary transmission
prevented cannot be measured directly and has to be estimated using transmission models of
the infection.Mathematical modelling for decision-making about sexually
transmitted infection controlMathematical models have emerged as a powerful tool for estimating and interpreting the potential
impact of a variety of STI control interventions.32 Mathematical models are needed to estimate the impact
of partner notiﬁcation because the indirect effects of STI transmission resulting from interactions between
individuals that transmit infection need to be taken into account appropriately.33 As noted above, empirical
studies, including randomised controlled trials, are rarely able to collect data about population level
changes in STI prevalence. In observational studies, it is difﬁcult to attribute changes in the prevalence of a
STI to any one particular intervention.
There is a wide range of different types of mathematical models that can be used to explain and
understand health-care systems and interventions. To study the effects of an intervention that is expected
to reduce the transmission of infection in a population, we need ‘dynamic models’ that can account for
changes in the force of infection, which describes the rate of infection per susceptible individual. Models
that cannot take changes in the force of infection into account are called ‘static’ or ‘constant force of
infection’ models.34 Static models can be appropriate if the intervention is studied over a time horizon that
is too short to affect the force of infection, or if the proportion of the population affected is too small.
Dynamic transmission models of STIs describe the transmission of infections between individuals and can
take into account the complex feedback mechanisms of interventions. However, the results of such models
depend heavily on the assumptions made during model development. Most models of STIs belong to one
of two types, both of which have advantages and disadvantages, and both of which have been used
extensively. Deterministic, population-based models group people according to sex, infection status orNIHR Journals Library www.journalslibrary.nihr.ac.uk
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and it is possible to track infections only within subpopulations of the total population. Stochastic,
individual-based models of STIs are characterised by the explicit representation of all individuals as single
entities. Individuals can also share sexual behaviour parameters with other individuals, but stochastic
effects can result in diverse outcomes. An important aspect of such models is that they allow the
representation of the entire sexual contact network, which means that one can, for example, trace the
previous partners of infected index cases. A disadvantage of individual-based models is that they are often
very difﬁcult to parameterise because many assumptions have to be made about factors for which there
are few or no empirical data. Also, since stochastic simulations can be computationally expensive, analysis
of such models is usually much more laborious than for deterministic models. In this report, we use both
deterministic, population-based models and stochastic, individual-based models, depending on the
research question.
Before developing new mathematical models to examine the effects of partner notiﬁcation, there are
speciﬁc challenges to overcome. Many dynamic models of the transmission of C. trachomatis and
N. gonorrhoeae have been developed, using both deterministic35–37 and individual-based38–40 approaches.
There is, however, a need for more certainty about the underlying disease parameters for individual STIs.
For example, three individual-based models have all been internally validated to generate realistic
age-speciﬁc patterns of chlamydia prevalence. In a direct comparison, predictions of the impact of the
same screening and partner notiﬁcation intervention were dramatically different.41 There are also examples
of contrasting predictions from deterministic models that conclude either that screening at high levels of
uptake can be very effective35 or that the effects might be counteracted by a loss of immunity against
chlamydia in the population.36 These challenges in interpreting model ﬁndings illustrate the importance of
studying the impact of different assumptions about critical parameters on model results, and, if necessary,
obtaining improved parameter estimates.
Lastly, evaluating the impact of APT requires the dynamics of both C. trachomatis and N. gonorrhoeae to
be incorporated into the same model, so that the effects of treating a co-infected individual for one STI
but not the other can be explored.ObjectivesSpeciﬁc objectives of the project were:
1. to compare the effectiveness of different partner notiﬁcation approaches to providing testing and
treatment for the partners of people with curable STIs by
i. systematic reviews and analysis of secondary data to obtain estimates of outcome measures
ii. mathematical modelling to estimate impact. The modelling studies considered chlamydia and
gonorrhoea transmission in general heterosexual populations
2. to determine the cost-effectiveness of different partner notiﬁcation approaches to providing testing and
treatment for the partners of people with curable STIs
3. to provide research recommendations for primary research.
This monograph comprises four sections. The studies focus on partner notiﬁcation technologies for
chlamydia and gonorrhoea in heterosexual populations (a) because these account for the majority of
curable STIs in the UK and (b) in order to be able to limit the development of mathematical models to the
sexual behaviour network of one type of population and of STIs requiring similar model structures.
Gonorrhoea is much less common than chlamydia but it is geographically concentrated in a small number
of inner-city urban areas,42 in which rates of diagnosed infection are disproportionately high in black
Caribbean minority ethnic groups.43 The impact of partner notiﬁcation in a population at high risk of9
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10gonorrhoea is therefore also considered. Although originally planned, mathematical modelling studies of the
impact of partner notiﬁcation technologies for syphilis and trichomonas or among men who have sex with
men were not included in this project owing to lack of time. The four sections are organised as follows.Clinical effectiveness of partner notification
The studies in this section address objective (i) by examining the effects of both traditional and new
partner notiﬁcation technologies on different measures of clinical effectiveness. First, we compare primary
outcomes of the clinical effectiveness of new technologies (EPT or APT) with traditional partner notiﬁcation
methods (simple and enhanced patient referral) for chlamydia, gonorrhoea and trichomonas, based on a
systematic review and meta-analysis of randomised controlled trials.44 Second, we reanalyse clinical audit
data to estimate current levels of numbers of partners treated (intermediate outcome) of partner
notiﬁcation for chlamydia as achieved in UK genitourinary medicine clinics.45 Third, we estimate the impact
on secondary transmission of traditional methods of partner notiﬁcation for different types of sexual
partner seen in UK genitourinary medicine clinics, using static modelling.9Mathematical modelling of the impact of partner notification technologies
Studies in this section address objective (ii). First, we describe the modelling studies that we conducted to
address uncertainties in estimates of the duration46 and transmissibility47 of C. trachomatis and to resolve
differences between the results of previous individual-based models of C. trachomatis transmission.48 We
focus initially on chlamydia because it is the STI for which partner notiﬁcation is now most often done. The
roll-out of the NCSP in England means that partner notiﬁcation has to be modelled as part of a screening
intervention. We then describe how we developed new individual-based models to examine the impact of
traditional partner notiﬁcation methods, depending on whether the outcome is measured at the individual
level or the population level49 (Table 5). Finally, we examine the effects of traditional (patient referral) and
new (APT) technologies among heterosexuals, using a deterministic model. We developed a new model
that allows the investigations of single infections with either chlamydia or gonorrhoea and co-infectionsTABLE 5 Overview of partner notiﬁcation strategies and scenarios investigated in dynamic mathematical models
Section Technology Target STI Strategy Scenarios Population Outcomes
Chapter 3,
Individual- and
population-level
effects of partner
notification for
C. trachomatis
Traditional Chlamydia Test partners,
but treat without
waiting for result
Different
look-back
periods;
different
numbers of
partners
General
heterosexual
Percentage
of infected
partners;
population
prevalence
Chapter 3,
The effects of
traditional and
new partner
notification
technologies for
C. trachomatis
and
N. gonorrhoeae
Traditional Chlamydia Test partners,
but treat without
waiting for result
Different level
of successful
partner
notiﬁcation
General and
high-risk
heterosexual
Population
prevalence;
reinfection
of index case
APT Chlamydia Treat partners
without testing
Traditional Chlamydia +
gonorrhoea
Test partners,
but treat without
waiting for result
Different levels
of successful
partner
notiﬁcation;
different levels
of STI screening;
different delays
to partner
treatment
General and
high-risk
heterosexual
Population
prevalence;
gonorrhoea
outbreak
frequency;
reinfection
of index case
APT Chlamydia +
gonorrhoea
Treat partners
without testing
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DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2to be examined, so that the effect of providing treatment for one STI without testing for the other could
be explored.
Cost-effectiveness of partner notification
Studies in this section address objective 2. First, we examine the evidence available for obtaining QALYs for
female reproductive tract outcomes of bacterial STIs for use in cost-effectiveness studies based on the
primary population level outcomes of partner notiﬁcation. Second, we used a static model to examine
the intermediate outcomes of cost per case and per secondary case for current traditional partner
notiﬁcation technologies.31Discussion and conclusions
This section synthesises the ﬁndings from the component studies and provides implications for health care
and recommendations for further research.11
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partner notiﬁcation
This section of the monograph reports the ﬁndings of both secondary data analysis and static modellingto estimate the outcomes of traditional and new partner notiﬁcation technologies. The ﬁrst study
summarises the available evidence in a systematic review and meta-analysis of randomised controlled
trials of partner notiﬁcation interventions for all STIs that are treatable with antibiotics, identiﬁed from
1 January 1966 up to 31 August 2012. The review provides data about the primary outcome of reinfection
of the index case and selected intermediate outcomes for a range of partner notiﬁcation technologies. The
second study provides clinical context by showing the levels of numbers of partners treated per index case
with chlamydia achieved in UK genitourinary medicine clinics in 2007. The data were collected for a
national audit and use the published audit outcome, which is an intermediate outcome of partner
notiﬁcation. The speciﬁc partner notiﬁcation technology is not deﬁned, but includes any traditional method
chosen by the health adviser, doctor or nurse seeing the index case. The third study uses a static model to
estimate the potential public health impact of traditional partner notiﬁcation technologies used in
genitourinary medicine clinics on preventing chlamydia transmission, depending on the type of sexual
partnership. The study examines two new intermediate outcome measures: the AROT and NNTIT for
different partnership types, using audit data from one UK genitourinary medicine clinic in 2011. APT was
not in use at the time of the audit and modelling studies.Clinical effectiveness of partner notiﬁcation technologies:
systematic review
Introduction
Randomised controlled trials are the least biased study design for measuring the causal effect of an
intervention on an outcome. Systematic reviews of randomised controlled trials about a speciﬁc research
question use explicit protocols to identify, collate and synthesise evidence. This allows results to be
combined statistically, where appropriate, and reasons for heterogeneous results between different trials to
be explored. Previous systematic reviews of the relative effectiveness of different partner notiﬁcation
strategies for curable STIs did not ﬁnd strong evidence for the superiority of simple patient referral,
provider referral or contract referral, based on the intermediate outcomes that have been measured.50 EPT
has been developed as a new partner notiﬁcation technology during the era of evidence-based medicine
and has been evaluated in several large randomised controlled trials with repeat infection as a primary
outcome.16,51–53 EPT involves the use of antibiotic treatment packages or prescriptions as enhancements to
patient referral for infected patients with curable STIs. For a comprehensive view of the role of EPT as a
new partner notiﬁcation strategy, it is relevant to describe comparisons between other forms of enhanced
patient referral and simple patient referral, provider referral and contract referral. The most up-to-date
evidence of the effectiveness of these technologies comes from the Cochrane Sexually Transmitted
Infections Collaborative Review Group’s 2012 update of its systematic review of strategies for partner
notiﬁcation.44 This chapter reports the ﬁndings relevant to the STIs, partner notiﬁcation technologies and
outcomes considered in this monograph.44Objective
To report the ﬁndings of randomised controlled trials comparing at least one method of enhanced patient
referral with another partner notiﬁcation technology in adults with curable STIs, evaluated using a
biological outcome.13
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14Methods
The protocol and methods are available in full from the Cochrane Database of Systematic Reviews.44 In
summary, the populations studied were patients with a diagnosis of chlamydia, gonorrhoea, non-speciﬁc
genital infection, trichomonas, PID, syphilis or co-infection with any of these STIs. The interventions were
strategies that aimed to enhance the effectiveness of patient referral using methods including health
education and counselling, health education materials (such as pamphlets, posters, and video and audio
productions), and patient assistance strategies directed at facilitating patient referral (such as referral cards,
incentives, reminders, and video and audio presentations). EPT (including APT) was considered as a
separate type of enhanced patient referral. Eligible comparisons were any other partner notiﬁcation
technology. The primary outcome was reinfection of the index case, measured as repeated detection at a
follow-up visit. Secondary outcomes were the numbers of partners per index case who were notiﬁed,
presented for care or treated and harms of partner notiﬁcation.Search methods and selection of studies
The search of MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials updated the original
search (1966 to July 2001) to 29 January 2012 (see Appendix 2) and was supplemented by hand-searching
of conference abstracts, review of bibliographies of included studies and previous reviews and contact with
authors and experts in the ﬁeld. There were no language restrictions. Selection of studies, extraction of
data and assessment of the risk of bias (using the Cochrane Collaboration tool) were all done by two
independent reviewers. Disagreements were resolved by discussion, or by the decision of a third
independent reviewer.Data synthesis
The treatment effect for the primary outcome was the risk ratio [RR, with 95% conﬁdence intervals (CIs)]
comparing reinfection in index cases using an enhanced patient referral strategy with reinfection in index
cases using the alternative strategy. The secondary outcome was the number of partners treated per index
case. The mean difference (MD, with 95% CIs) between comparison groups was calculated. Heterogeneity
was assessed using the I2-statistic. Meta-analysis was performed, where appropriate, using a
random-effects model to obtain the average effect size. Where heterogeneity was considered too great
to pool results, reasons for heterogeneity were explored by examining stratum-speciﬁc effects in
predeﬁned subgroups.Results
The full review in The Cochrane Library reports the results of the search strategy in detail.44 Twenty-one
randomised controlled trials16–19,50–65 reported on eight comparisons of a method of enhanced patient
referral compared with an alternative technology in patients with curable STIs (Table 6). The updated
search (5 January 2011 to 29 January 2012) identiﬁed 15 of these trials (9393 participants)16–19,51–57,59,61,64,65
and six (5331 participants)50,58,60,62,63 were included in the original review. Most trials (12) were conducted
in the USA,16,17,50–54,56,58,60–62 three were done in the UK,19,55,64 two in Denmark,63,65 and one each in
Australia,18 South Africa,50 Uganda57 and Zimbabwe.59 There were no randomised controlled trials that
evaluated the new UK partner notiﬁcation technology of APT and no trials with reinfection as an outcome
for syphilis, PID or for any STIs in men who have sex with men. There are no published results available for
the cluster-randomised trial of EPT for chlamydia and gonorrhoea.29
The results reported in the rest of this section are restricted to nine randomised controlled trials in which
reinfection of the index case was either a primary or a secondary outcome.16–19,51–55 Intermediate outcomes
in these trials, including the number of partners treated, are also reported.
The trials could be grouped into three comparisons: EPT versus simple patient referral,16,19,51–54 EPT versus
enhanced patient referral,16,19,53 and enhanced patient referral versus simple patient referral.16,18,19,53,55 The
methods used to enhance patient referral were EPT;16,19,51–54 use of booklets with tear-out information slips
for index cases to give to their partner(s);16,53 additional counselling sessions;54 patient referral by a nurse atNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 6 Summary of comparisons of partner notiﬁcation technologies, newest technology listed ﬁrst as
intervention. Adapted from Ferreira et al.44
Comparison, studies
(total participants);
ﬁrst author, year Country Participants Infections
Reinfection
outcome Follow-up test
EPT vs. simple patient referral, eight studies (n = 6537)
Cameron 200919 Scotland W Chlamydia Yes 3 months
Golden 200551 USA W, M Chlamydia/gonorrhoea Yes 10–18 weeks
Kerani 201156 USA MSM Chlamydia/gonorrhoea No NA
Kissinger 200516 USA M Chlamydia/gonorrhoea Yes 2–8 weeks
Kissinger 200653 USA W Trichomonas Yes 2–8 weeks
Nuwaha 200157 Uganda W, M STI syndrome No NA
Schillinger 200352 USA W Chlamydia Yes ≥ 3 weeks
Schwebke 201054 USA W Trichomonas Yes 1 and 3 months
EPT vs. enhanced patient referral, four studies (n = 1253)
Cameron 200919 Scotland W Chlamydia Yes 3 months
Kerani 201156 USA MSM Chlamydia/gonorrhoea No NA
Kissinger 200516 USA M Chlamydia/gonorrhoea Yes 2–8 weeks
Kissinger 200653 USA W Trichomonas Yes 2–8 weeks
EPT and enhanced patient referral vs. EPT or enhanced patient referral or simple patient referral, one study
(n = 75)
Kerani 201156 USA MSM Chlamydia/gonorrhoea No NA
EPT vs. contract referral, one study (n = 324)
Schwebke 201054 USA W Trichomonas Yes 1 and 3 months
Enhanced vs. simple patient referral, 16 studies (n = 7642)
Andersen 199863 Denmark W Chlamydia No NA
Apoola 200964 England W Chlamydia No NA
Cleveland 2001a USA W, M Gonorrhoea No NA
Cameron 200919 Scotland W Chlamydia Yes 3 months
Ellison 2001b South Africa W, M STI syndrome No NA
Kerani 201156 USA MSM Chlamydia/gonorrhoea No NA
Katz 198858 USA M NGU No NA
Kissinger 200516 USA M Chlamydia/gonorrhoea Yes 2–8 weeks
Kissinger 200653 USA W Trichomonas Yes 2–8 weeks
Low 200655 England W, M Chlamydia Yes 6 weeks
Moyo 200259 Zimbabwe W, M STI syndrome No NA
Ostergaard 200365 Denmark W, M Chlamydia No NA
Solomon 198860 USA M Gonorrhoea No NA
Tomnay 200618 Australia W, M Chlamydia/NGU Yes 2–12 weeks
Trent 201061 USA W PID No NA
Wilson 200917 USA W, M Chlamydia/gonorrhoea Yes 6 months
continued
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ABLE 6 Summary of comparisons of partner notiﬁcation technologies, newest technology listed ﬁrst as
tervention. Adapted from Ferreira et al.44 (continued )
Comparison, studies
(total participants);
ﬁrst author, year Country Participants Infections
Reinfection
outcome Follow-up test
Enhanced vs. other enhanced patient referral, two studies (n = 1336)
Ellison 2001b South Africa W, M STI syndrome No NA
Montesinos 199062 USA W, M Gonorrhoea/NGU No NA
Enhanced patient referral vs. provider referral, one study (n = 461)
Katz 198858 USA M NGU No NA
Enhanced patient referral vs. contract referral, one study (n = 1266)
Cleveland 2001a USA W, M Gonorrhoea No NA
M, heterosexual men; MSM, men who have sex with men; NA, not applicable; NGU, non-gonococcal urethritis; W, women.
a Unpublished study; cited in Mathews et al.50
b Unpublished study; cited in Mathews et al.50
CLINICAL EFFECTIVENESS OF PARTNER NOTIFICATION
16T
inthe time of receiving results at a general practitioners’ surgery rather than referral to a genitourinary
medicine clinic; and use of a website.18
The numbers of partners treated per index case randomised varied across trials and interventions (Table 7).
This outcome was not reported in four17,18,52,53 of the nine trials. The median was 0.57 partners per index
case (range 0.28–1.14). There was no clear relationship between the numbers of partners treated and the
percentage of index cases with infection detected at the follow-up visit.
There was a risk of bias in at least one domain in all included studies. Random sequence generation was
adequate in six16–19,53,55 of the nine trials that reported reinfection as an outcome. In three trials,51,52,54
random sequence generation was unclear. The method for allocation concealment was adequate in three
trials.18,52,55 In ﬁve trials,16,19,51,53,54 the method of allocation concealment was not sufﬁciently speciﬁed and
in one17 the method could have introduced a high risk of bias; Wilson et al.17 reported that participants
were assigned study identiﬁcation numbers sequentially as they enrolled in the study. Blinding of
participants and personnel was not possible in any of the trials. Explicit blinding of laboratory personnel
was reported in only one trial.19 The attrition rate was > 20% in four16,19,51,54 of the seven
trials16,19,51,54,56,59,61 in which repeat infection was the primary outcome and > 50% in both trials18,55 where
repeat infection was measured as a secondary outcome.Expedited partner therapy versus simple patient referral
Six studies (n = 6018) compared the rate of index patient reinfection EPT with simple patient referral
among patients with chlamydia,19,52 trichomoniasis,53,54 or gonorrhoea or chlamydia.16,51 The treatment
pack for partners in all trials included antibiotics, written information about the infection, a telephone
number for the study nurse and drug safety information. In addition, Cameron et al.19 included
information about genitourinary medicine clinics as alternative possibilities for seeking testing and
treatment, Golden et al.51 included condoms, and Schillinger et al.52 included instructions for the index
case to inform his or her partner about exposure to a STI and to abstain from sexual intercourse for 7 days
after treatment.
The pooled results of trials for all infections showed that index patients in the EPT group had a 29% lower
risk of being reinfected compared with index patients in the simple patient referral group (RR 0.71,
95% CI 0.56 to 0.89; heterogeneity p = 0.15, I2 = 39%) (Figure 3).NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 7 Numbers of partners treated per index case by study arm, in trials reporting repeat infection as
an outcome
Study and year Infections Interventions n
Partners treated
per index case
randomiseda
bCameron 200919 Chlamydia EPT 110 0.47
Enhanced patient referral 110 0.46
Simple patient referral 110 0.42
Golden 200551 Chlamydia/gonorrhoea EPT 1375 0.59
Simple patient referral 1376 0.53
Kissinger 200516 Chlamydia/gonorrhoea EPT 344 1.14
Enhanced patient referral 348 0.92
Simple patient referral 285 0.71
Kissinger 200653 Trichomonas EPT 154 Not reported
Enhanced patient referral 154
Simple patient referral 155
Low 200655 Chlamydia Enhanced patient referral 68 0.57
Simple patient referral 72 0.74
Schillinger 200352 Chlamydia EPT 887 Not reported
Simple patient referral 900
Schwebke 201054 Trichomonas EPT 162 0.79
Contract referral 162 0.56
Simple patient referral 160 0.28
Tomnay 200618 Chlamydia Enhanced patient referral 73 Not reported
Simple patient referral 32
Wilson 200917 Chlamydia/gonorrhoea Enhanced patient referral 304 Not reported
Simple patient referral 296
a Mean values calculate from aggregate data presented in published reports; no standard deviation available.
b Outcome reported as number of partners presenting for care (assumed to have been treated).
DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2There was a modest level of between-trial heterogeneity, despite marked differences in the infections
studied and follow-up testing interval. The size of the treatment effect appeared smaller in trials that
included only women with chlamydia (RR 0.90, 95% CI 0.60 to 1.35) than in trials that included patients
with either gonorrhoea or chlamydia (RR 0.61, 95% CI 0.39 to 0.94).
There were inconsistent ﬁndings about the effects of EPT interventions on intermediate outcomes. Three
studies16,19,51 (n = 3600) assessed the number of partners notiﬁed. In one study,16 slightly more partners of
index patients in the EPT group were notiﬁed (MD 0.45, 95% CI 0.28 to 0.62). In the other two
studies19,51 the differences included the null effect (Golden et al.:51 MD –0.05, 95% CI –0.12 to 0.01; and
Cameron et al.:19 MD 0.13, 95% CI –0.06 to 0.32).
Three16,51,54 studies assessed the number of partners treated. The studies showed results in the same
direction but were very heterogeneous (heterogeneity p < 0.001, I2 = 95%). In two16,54 of the three trials,
there was a moderate difference favouring EPT (Kissinger et al.:16 MD 0.43, 95% CI 0.28 to 0.58; and17
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FIGURE 3 Forest plot of randomised controlled trials of EPT vs. simple patient referral, by infection and overall.
PR, patient referral. Source: Reproduced from Ferreira A, Young T, Mathews C, Zunza M, Low N. Strategies for
partner notification for sexually transmitted infections, including HIV. Cochrane Database Syst Rev 2013; 10:
CD002843 http://dx.doi.org/10.1002/14651858/CD002843.pub2 with permission from John Wiley and Sons.44
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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18Schwebke et al.:54 MD 0.51, 95% CI 0.35 to 0.67). The difference between groups was very small in the
fourth trial (MD 0.06, 95% CI 0.01 to 0.12).51Expedited partner therapy versus enhanced patient referral
There were three trials16,19,53 that compared the effect on reinfection in the index case of EPT with
enhanced patient referral among women with chlamydia19 or trichomonas,53 and men with chlamydial or
gonococcal urethritis.16 There was no evidence of a difference in the reinfection rate between the two
groups (RR 0.96, 95% CI 0.6 to 1.53; heterogeneity p = 0.22, I2 = 33%) (Figure 4).
There was no consistent evidence of differences between the strategies in intermediate outcomes.
Cameron et al.19 (n = 220) found no evidence of a difference between groups in the number of partners0.2 0.5 1 2
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FIGURE 4 Forest plot of randomised controlled trials of EPT vs. enhanced patient referral. PR, patient referral.
Reproduced from Ferreira A, Young T, Mathews C, Zunza M, Low N. Strategies for partner notification for sexually
transmitted infections, including HIV. Cochrane Database Syst Rev 2013; 10:CD002843 http://dx.doi.org/10.1002/
14651858/CD002843.pub2 with permission from John Wiley and Sons.44 Copyright © 2013 The Cochrane
Collaboration. Published by John Wiley & Sons, Ltd.
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DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2presenting for care (MD 0.01, 95% CI – 0.02 to 0.03). Another study16 (n = 692) found a small increase in
the number of partners treated per index patient randomised to the EPT group compared with the
enhanced patient referral group (MD 0.22, 95% CI 0.21 to 0.23).Enhanced patient referral versus simple patient referral
Six studies16–19,53,55 examined reinfection of the index case as an outcome in comparisons of different types
of enhanced patient referral versus simple patient referral among patients with chlamydia,18,19,55
gonorrhoea or chlamydia,16,17 or trichomoniasis.53 There were six different types of comparisons. Enhanced
patient referral interventions included an additional counselling session;17 a postal testing kit for the
partners to use;19 patient referral by a nurse versus patient referral by a health adviser;55 an information
booklet to be given to the partner;16,53 and a disease-speciﬁc website that the partners were advised
to access.18
All six studies16–19,53,55 (n = 2007) assessed the index patient reinfection rate. In one comparison the index
patients had a 51% lower risk of being reinfected in the enhanced patient referral (additional counselling)
compared with simple patient referral (RR 0.49, 95% CI 0.27 to 0.89).17 In ﬁve studies16,18,19,53,55 there was
no evidence of a difference between simple patient referral and enhanced patient referral (Table 8). There
were no consistent differences in intermediate outcomes.
Discussion
The updated Cochrane systematic review shows that three additional randomised controlled trials
comparing EPT with simple patient referral and two trials comparing EPT with enhanced patient referral
have been published since an earlier review of EPT trials.22 When data for all curable STIs are pooled, EPT
results in a lower risk of reinfection in the index case when compared with simple patient referral, but not
when compared with enhanced patient referral methods.
The strengths of this systematic review are the rigorous and reproducible methods used to search and
appraise the literature. It is unlikely that the review missed trials that would change the conclusions. The
weaknesses of the review relate mainly to the small number of studies with differences between
interventions and reporting. This limits the ability to investigate differences in effectiveness for individual
STIs and for speciﬁc types of enhanced patient referral. It was also not possible to draw ﬁrm conclusions
about the relative effectiveness of EPT, enhanced patient referral and simple patient referral. Although EPT
was superior to simple patient referral, and there was no statistical evidence of a difference between EPT
and enhanced patient referral, there were too few comparable trials to estimate the direct comparison
between enhanced and simple patient referral. A meta-analysis of indirect comparison would be useful toTABLE 8 Enhanced patient referral vs. simple patient referral: effect on reinfection in index case
First author,
year
Enhanced patient referral
method vs. comparator
Studies,
n
Participants,
n RR (95% CI)
I2;
p-value
Cameron 200919 Postal test kit vs. simple
patient referral
1 220 2.14 (0.91 to 5.05) NA
Kissinger 2005,16
Kissinger 200653
Information booklet vs.
simple patient referral
2 942 0.55 (0.22 to 1.33) 76%; 0.04
aLow 200655 Nurse conducted vs.
health adviser conducted
1 140 0.35 (0.01 to 8.51) NA
aTomnay 200618 Disease-speciﬁc website vs.
simple patient referral
1 105 3.12 (0.17 to 58.73) NA
Wilson 200917 Additional counselling vs.
simple patient referral
1 600 0.49 (0.27 to 0.89) NA
NA, not applicable.
a Reinfection was not a primary outcome in these studies and data were available for < 50% of participants.
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20investigate this further. A further limitation results from measurement error in the primary outcome.
Repeated detection of infection at a follow-up visit includes reinfection from an untreated partner but also
persistent infection resulting from treatment failure and newly acquired infections. Misclassiﬁcation should
be non-differential, however.
The ﬁndings from the review of trials using primary biological outcomes cannot be extrapolated to syphilis
or viral STIs and cannot be generalised to men who have sex with men. EPT has not been recommended
as a partner notiﬁcation method for men who have sex with men.21
There were no randomised controlled trials evaluating the effectiveness of APT. Cameron et al.19 evaluated
an EPT intervention in Scotland by giving the index cases antibiotics to give to their partners. They noted
that this was possible only in a research setting. APT has been described as a new model of EPT,21 but it is
not clear whether or not the results of trials evaluating EPT, as developed in the USA, can be extrapolated
to APT. The requirement for an assessment by a health-care professional in the APT Hotline and APT
Pharmacy models might affect the potential uptake when compared with EPT. The ﬁnding that EPT can
reduce the risk of reinfection in the index case in comparison with simple patient referral, but not
enhanced patient referral, conﬁrms that of our earlier systematic review.22 It is not known whether or not
there was a speciﬁc effect of EPT, for example on reducing the time to partner treatment, because
information about treatment delays was not reported in any of the included trials. In a non-randomised
evaluation of APT in the UK, Estcourt et al.20 found that the numbers of days between the diagnosis of the
index case and treatment of the sexual partner was slightly shorter (median 1 day) when APT was used
than for routine partner notiﬁcation by patient referral (median 3 days; p = 0.11). These results cannot
necessarily be extrapolated to the randomised controlled trials in the Cochrane review. First, the routine
partner notiﬁcation described by Estcourt et al.20 would be classiﬁed in the Cochrane review as enhanced
patient referral because the consultation with a health adviser was supported with condoms, written
information about the infection and advice for the partner to seek treatment. Second, the need for a
partner assessment by telephone or pharmacist in the APT protocol might increase time to treatment,
although the median time to treatment for EPT could only be reduced to 0 days.
The effects of treatment delays on the effects of APT compared with traditional patient referral are
investigated in a modelling study (see Chapter 3, The effects of traditional and new partner notification
technologies for C. trachomatis and N. gonorrhoeae).Partner notiﬁcation outcomes for chlamydia in UK
genitourinary medicine clinicsSubstantial portions of the following section are reproduced from Variation in partner notiﬁcation
outcomes for chlamydia in UK genitourinary medicine clinics: multilevel study, Sex Transm Infect
Herzog SA, McClean H, Carne CA, Low N, vol. 87, pp. 420–5, 2011, with permission from BMJ Publishing
Group Ltd.45Introduction
Data about the outcomes of partner notiﬁcation, as achieved in routine clinical practice, can be used to
inform input parameters for the uptake of partner notiﬁcation in mathematical modelling studies. The
levels measured in randomised controlled trials represent those achievable under controlled conditions and
vary according to setting, infection, and type of partner notiﬁcation technology (see Table 7). The British
Association for Sexual Health and HIV carried out a national audit of case note documentation of
chlamydial infection management in UK genitourinary medicine clinics in 2007.66–68 These data allow
auditable outcomes to be analysed and sources of variation to be examined. Biological outcomes, such as
the rate of repeated detection, cannot be measured because repeat testing after treatment of positive
cases is not included in treatment guidelines.10 Similar audit data have previously shown markedNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2differences in partner notiﬁcation outcomes in genitourinary medicine clinics inside and outside Greater
London.30 This chapter reports data published by Herzog et al.45Objectives
To compare different ways of measuring outcomes for partner notiﬁcation with published standards; to
examine variability between clinics; and to examine factors at the individual and clinic levels that contribute
to variation in partner notiﬁcation outcomes.Methods
We analysed data extracted from case notes of patients seen between 2 January 2007 and 31 March 2007
and responses about clinic-level policies relating to partner notiﬁcation. Descriptions of the audit methods
and responses have been published.66–68Individual-level characteristics
We considered four characteristics: sex/sexual orientation of the index case (‘male heterosexual’, ‘men who
have sex with men’ and ‘female’, which included all women irrespective of sexual orientation); age group
(≤ 18, 19–24, 25–34 or ≥ 35 years); ethnic group (‘white’, ‘black African’, ‘black Caribbean/black other’,
‘other’ and ‘not documented’); and documentation of index case symptoms at baseline, including urethral
discharge, dysuria, post-coital or intermenstrual bleeding, lower abdominal pain, vaginal discharge, rectal
symptoms, pharyngeal symptoms or chlamydial conjunctivitis.Clinic-level characteristics
We used data about (1) the number of chlamydia episodes reported by each clinic during the 3-month
data collection period as an approximation of workload and (2) the type of health professional
providing partner notiﬁcation advice (‘health adviser only’, ‘health adviser, doctor or nurse’ or ‘any
health professional’).Outcome variables
There were three possible measures of partner notiﬁcation outcome: the number of partners per index
case who were tested for chlamydia (abbreviated as ‘tested’); the number of partners per index case with a
positive chlamydia test (‘tested positive’); and the number of partners per index case treated (‘treated’).
The primary outcome was the number of partners per index case tested for chlamydia, as veriﬁed by a
health-care worker or, if information about veriﬁcation was missing, as reported by the patient.Statistical analysis
To describe the variability in partner notiﬁcation outcomes between clinics we used a method similar to
that previously described to construct Shewhart control charts.30,69 First, for all index cases in each clinic,
we calculated the mean number of partners tested per index case. We used the ‘median absolute
deviation’ (MAD) method70 to calculate the median across all clinics and the control limits. The control
limits are approximately the 99% CIs. The MAD is deﬁned as the median of the absolute deviations. The
standard deviation (SD) is calculated as 1.48 ×MAD and control limits are MAD ± 3 × SD. Differences in
outcomes between centres that fall within the control limits are said to result from common causes that
might be expected to occur within the health care system. Data points lying outside the control limits are
said to result from special causes and such unintended variation should be controlled.69 We then examined
the inﬂuence of missing data about numbers of sexual contacts. For each outcome we estimated the
median and control limits for the number of partners per index case, assuming that if the data were
missing then the number of partners was zero, and excluding all index cases with missing data. We
displayed results for clinics inside and outside Greater London separately.
We used a hierarchical logistic regression model71 to examine factors associated with partner notiﬁcation
outcomes at the individual and clinic levels. We recoded the outcome as either zero or one or more
partners tested per index case and estimated the odds ratio (OR, with 95% CIs), which takes into account
the variation in outcomes between clinics. Data from patients with missing outcome data were excluded.21
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22Results
We merged data on 5032 individuals with chlamydia in 193 clinics with clinic-level data reported by
177 genitourinary medicine clinics. The merged data set consisted of 4616 individuals in 169 genitourinary
medicine clinics; this excluded 23 clinics with 415 index cases for which there was no information about
clinic policies, and one clinic with only one index case for whom there were no data for any outcome of
interest. The demographic characteristics of excluded index cases were comparable with those of included
patients (results not shown). The percentages of patients for whom there was no information about the
outcome of partner notiﬁcation were partners tested for chlamydia, 41%; partners with a positive test for
chlamydia, 43%; and partners treated for chlamydia, 32%.Variability between clinics in partner notification outcomes
Figure 5 shows the mean number of partners tested for chlamydia per index case for each clinic, when
health-care worker-veriﬁed data were supplemented with patient-reported values. The median across all
clinics was 0.47 when missing values were assumed to be 0 (0.30 for Greater London genitourinary
medicine clinics, 0.52 for all other clinics). No genitourinary medicine clinics were below the lower control
limit but most Greater London clinics were below the median. Only one clinic was above the upper control
limit, suggesting that most variation resulted from common causes. When index cases with missing data
were excluded from analysis, the median number of patients tested for chlamydia increased to 0.92 per
index case (1.00 in Greater London, 0.89 in all other clinics).
The other measures of partner notiﬁcation outcome were the number of partners per index case
with a positive chlamydia test (Figure 6, median 0.37 assuming missing values as 0 partners, and 0.75
excluding missing values) and the number of partners per index case treated for chlamydia (Figure 7)
(median 0.60 and 0.95).0
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FIGURE 6 Control chart for partners tested positive for chlamydia per index case. Combined outcome was defined as
outcome verified by a health-care worker or, if data were missing, as reported by the patient. All cases were included
and those with missing data were coded as having zero partners tested.
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FIGURE 5 Control chart for partners tested for chlamydia per index case. Combined outcome was defined as outcome
verified by a health-care worker or, if data were missing, as reported by the patient. All cases were included and
those with missing data were coded as having zero partners tested.
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FIGURE 7 Control chart for partners treated for chlamydia per index case. Combined outcome was defined as
outcome verified by a health-care worker or, if data were missing, as reported by the patient. All cases were included
and those with missing data were coded as having zero partners tested.
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Table 9 shows associations between individual- and clinic-level characteristics and the number of partners
tested for chlamydia per index case, taking into account the variability between clinics.
There was no information for the clinic-level variables for 16 clinics (163 index patients); results for
individual-level variables in the remaining clinics were the same as those obtained from the full merged
data set. Compared with heterosexual males, men who have sex with men were less likely to have at least
one partner tested in both univariable and multivariable analysis. There was no difference in numbers of
partners tested between women and men. There was no strong evidence of associations between the
numbers of partners tested and the age or ethnic group of index cases.
Index cases who were symptomatic at presentation were less likely to report having one or more partners
tested for chlamydia than asymptomatic cases in both univariable and multivariable analysis. There was no
statistical evidence of an association between the number of partners tested for chlamydia and the health
professional giving the partner notiﬁcation advice. As the number of chlamydia cases diagnosed by clinics
increased, the odds of at least one partner being treated increased (p for trend 0.031) when cases with
missing outcome data were not included in the model.
The patterns of associations for the other partner notiﬁcation outcomes were similar to that observed for
the number of partners tested for chlamydia, but there was no association with numbers of chlamydia
cases diagnosed. In addition, for the number of partners with a positive chlamydia test, women were less
likely than heterosexual men to have a partner with a positive chlamydia test (adjusted OR 0.77, 95% CI
0.63 to 0.94).Discussion
This study showed marked variation between genitourinary medicine clinics in outcomes of partner
notiﬁcation for chlamydia, most resulting from common causes. Men who have sex with men were less
likely than heterosexual men and symptomatic patients less likely than asymptomatic patients to have had
at least one partner tested for chlamydia. In clinics diagnosing greater numbers of chlamydia cases the
odds of recording at least one partner tested for chlamydia were higher than in smaller clinics. Findings
were similar with outcomes of the number of partners with a positive chlamydia test and number of
partners treated for chlamydia.
The main strength of this study was that it included information from about 5000 patients with chlamydia
in genitourinary medicine clinics across the UK. The main limitation of the study was related to the high
level of missing values for numbers of contacts, which resulted in a twofold difference in calculated values
for the outcome. Differences between index cases with and without information about the outcomes of
partner notiﬁcation mean that the observed outcomes are likely to be biased but it is not possible to state
the direction or degree. A further limitation was that the method of partner notiﬁcation for each index23
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TABLE 9 Factors associated with the number of partners tested for chlamydia per index case
Characteristic
Partners per index casea OR (95% CI)
p-valueb
0
(n = 697)
≥ 1
(n = 1835)
Missing
(n = 2084) Univariable Multivariable
Sex/sexual orientation
Male heterosexual 331 907 962 1 1 0.009
Men who have
sex with men
24 29 100 0.28
(0.14 to 0.56)
0.34
(0.17 to 0.68)
Female all 342 899 997 1.04
(0.85 to 1.28)
1.03
(0.83 to 1.28)
Missing NA NA 25
Age group, years
≤ 18 128 337 348 1 1 0.135
19–24 334 950 998 1.10
(0.83 to 1.45)
1.08
(0.82 to 1.43)
25–34 174 446 537 0.95
(0.70 to 1.30)
0.97
(0.70 to 1.34)
≥ 35 61 102 192 0.55
(0.35 to 0.85)
0.66
(0.41 to 1.05)
Missing NA NA 9
Ethnic group
White 584 1491 1562 1 1 0.075
Black African 10 42 58 1.36
(0.62 to 3.00)
1.41
(0.63 to 3.14)
Black Caribbean/
black other
33 86 146 0.91
(0.54 to 1.54)
0.90
(0.53 to 1.52)
Other 33 82 126 0.76
(0.46 to 1.25)
0.84
(0.51 to 1.39)
Not documented 37 134 192 2.30
(1.27 to 4.17)
2.15
(1.18 to 3.93)
Symptoms at presentation
No 366 1131 1119 1 1 < 0.001
Yes 331 704 965 0.61
(0.49 to 0.74)
0.62
(0.50 to 0.76)
Chlamydia episodes in 2007, quartilec
0–248 216 379 325 1 1 0.031
261–451 140 484 486 2.34
(1.20 to 4.54)
2.56
(1.29 to 5.11)
455–716 192 462 478 1.72
(0.89 to 3.32)
1.96
(0.98 to 3.90)
720–2179 149 510 507 2.23
(1.15 to 4.32)
2.47
(1.23 to 4.96)
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TABLE 9 Factors associated with the number of partners tested for chlamydia per index case (continued )
Characteristic
Partners per index casea OR (95% CI)
p-valueb
0
(n = 697)
≥ 1
(n = 1835)
Missing
(n = 2084) Univariable Multivariable
Person giving partner notiﬁcation adviced
Health adviser,
doctor or nurse
537 1318 1423 1 1 0.434
Health adviser only 77 253 323 1.12
(0.55 to 2.29)
1.14
(0.55 to 2.35)
Any health
professional
83 264 278 1.41
(0.69 to 2.85)
1.60
(0.78 to 3.30)
NA, not applicable.
a Analysis based on 2532 index cases from 153 clinics; 2084 cases had missing outcome data. ‘Partners tested per index
case’ was calculated from outcome as veriﬁed by health-care worker or, if missing, from outcome reported by patient;
cases with missing outcome data were not included in the model.
b p-value for multivariable model based on likelihood ratio test for all variables except age and number of chlamydia
episodes, which are based on a test for trend.
c Two hundred and eighty-eight are not documented for ‘Missing’ column.
d Sixty are not documented for ‘Missing’ column.
DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2case was not recorded. We assume that the majority of partners were notiﬁed following patient referral by
the index case him or herself.
In this study, we were able to investigate individual- and clinic-level factors inﬂuencing common causes69
of the variation in partner notiﬁcation outcomes. Men who have sex with men with gonorrhoea have
previously been observed to have fewer partners tested or treated, despite reporting higher numbers of
partners than heterosexual men.72 Symptomatic patients also had poorer partner notiﬁcation outcomes
than asymptomatic patients. This might be related to the differing look-back periods of 1 month for
symptomatic patients and 6 months for asymptomatic patients (as recommended by the Society for Sexual
Health Advisers73). Additionally, symptomatic and asymptomatic cases may differ in their relationship to,
and ability to contact, sexual partners, although data were not collected about these factors. The observed
association between numbers of chlamydia cases diagnosed and partner notiﬁcation outcomes was
difﬁcult to interpret. This ﬁnding might reﬂect biases for which we could not control in the analysis, for
example if patients in larger clinics reported more partners, or as a result of missing data, which was more
common in large clinics. There was a strong inﬂuence of missing information about partner notiﬁcation
outcomes on the denominator used to calculate the mean for each clinic, which then inﬂuenced the
estimates of the overall median: 0.47 partners tested for chlamydia per index case when those with
missing data were coded as having no partners tested and 0.92 when missing values were excluded.
There was wide variation in partner notiﬁcation outcomes across clinics, from 0 to 1.5 partners per index
case tested for chlamydia. The median number of partners per index case reported to have been treated in
this audit was similar to the median of the values observed in randomised controlled trials of a variety of
partner notiﬁcation technologies (see Table 7). The extent to which unintended variation in clinical
outcomes can and should be eliminated has been debated.69,74,75 If clinics took further measures to
improve their performance this would improve both the consistency and the quality of clinical care. The
data provided by this audit can be used in mathematical modelling studies as baseline values representing
current practice for patient referral. In practice, the completeness of recording needs to improve so that
levels of partner notiﬁcation outcomes can be measured more accurately in future. Further research is
needed to identify auditable measures that are associated with successful partner notiﬁcation that prevents
repeated chlamydial infection in index cases.25
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26Estimating the likely public health impact of partner
notiﬁcation for a clinical service: an evidence-based algorithm
Introduction
The previous two sections present clinical outcome measures of partner notiﬁcation, focusing on the
incidence of reinfection in index cases and the number of sexual partners treated per index case. These
outcomes are not usually reported according to the type of sexual partnership between an index case and
their partner(s). Partnership type, however, is likely to determine whether index cases operate as ‘spread’
networks or ‘dead–end’ networks for STI transmission.5 The impact of partner notiﬁcation can therefore
differ according to which partner types are sought. Dynamic mathematical models (see Chapter 3) are
used to examine the potential epidemiological impact of partner notiﬁcation at the population level, but
they are too complicated to be used by individual clinical services planning or assessing the impact of
partner notiﬁcation activity on local transmission patterns. Here, we use a simple algorithm that clinicians
and public health teams can use, without the need for onerous data collection or computational methods.9Objective
To estimate the likely short-term impact of partner notiﬁcation activity on preventing STI transmission
according to partner type, using data that are routinely collected in genitourinary medicine clinics.Methods
The authors developed an algorithm to estimate the numbers of cases of chlamydia transmitted to the
sexual partners of index cases and the number of secondary chlamydia transmissions from the partners of
the index cases. They then estimated the impact of partner notiﬁcation on preventing chlamydia
transmission. The development of the methods used has been described in detail.9 Here we applied the
methods using audit data collected for this project about patients diagnosed with chlamydia study at one
genitourinary medicine clinic in England, and estimates of C. trachomatis transmissibility that were
developed for this study (see Modelling the transmission dynamics of C. trachomatis).Assumptions about index cases
We stratiﬁed a sample of heterosexual index cases diagnosed with chlamydia by sex and age group,
reﬂecting how partner numbers and partnership type vary by these characteristics.8 The data came from a
retrospective review over a 3-month period of partner notiﬁcation records in one genitourinary clinic in
England. For each index case, we recorded the numbers of different types of heterosexual partnerships
reported in the year before their interview with a health adviser. Partnership types were labelled as live-in,
regular, casual or ex-regular/live-in. In the published study describing the development of the method,9
data about the distribution of partnership types were obtained indirectly from respondents to the Natsal-2
survey who reported attending a genitourinary medicine clinic in the 5 years prior to interview as the
group most closely comparable with the clinic population.76 The number of chlamydia positives in the
Natsal-2 data set was too small to stratify by sex and age group.77Estimating the number of primary transmissions
We used an estimate of the per-partnership probability of chlamydia transmission47 (see Modelling the
transmission dynamics of C. trachomatis) and applied this to the data about partnership numbers to
estimate the likely number of transmissions from index case to their partner(s) assuming no partner
notiﬁcation effort. As condoms are sometimes used, typically more often in casual and regular partnerships
than in live-in partnerships and by younger rather than older people,78,79 we assumed that among those
< 25 years old the probability of chlamydia transmission was lower, at 0.42 per casual partnership,
0.56 per regular partnership (and per ex-regular/live-in partnership) and 0.69 per live-in partnership,
whereas among those aged ≥ 25 years, we assume that these probabilities were 20% higher, at
approximately 0.50, 0.67 and 0.83, respectively.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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We next estimated the number of secondary transmissions, that is, the number of transmissions that may
occur from the chlamydia-positive partners of index cases to their sexual partners, and thus the number of
new chlamydia cases that are potentially preventable. Clinical services are unlikely to have aggregate data
on the number of partners index cases’ partners have had, so we estimated this using the median number
of new partners per year reported in Natsal-2. We stratiﬁed these medians by sex, age and partnership
type, and assumed assortative mixing (e.g. casual partners have sex with casual partners). Having obtained
an estimate of the number of partners that the infected partners of index cases are likely to have had, we
multiplied this by the assumed probabilities of chlamydia transmission (described above), to estimate the
number of secondary or onward transmissions.Quantifying the impact of partner notification definitions and
outcome measures
To quantify the impact of partner notiﬁcation, we propose that the commonly used epidemiological
measures ‘number needed to treat’ and the ‘absolute risk reduction’ can be usefully adapted to the
context of partner notiﬁcation. In medicine, the clinical effectiveness and cost-effectiveness of a medication
are often assessed using the number needed to treat. This states the number of individuals with a
speciﬁed condition who will need to receive a given therapy for a speciﬁed period in order to prevent the
occurrence of one speciﬁed outcome of the condition.80 The number needed to treat is the reciprocal of
the absolute risk reduction, deﬁned as the difference in risk of an outcome between the treated and
untreated groups. Here we propose that the NNTIT is the reciprocal of the AROT. The AROT is the
reduction in the number of onward transmissions achieved through successful partner notiﬁcation in a
population of index cases, expressed per partnership, for example a reduction from 0.8 to 0.6 onward
transmissions per partnership. The corresponding NNTIT is the number of partners who must successfully
receive partner notiﬁcation in order to prevent one new transmission. In this example, the reduction of 0.2
per partnership would generate a NNTIT of 1/0.2 = 5.
We deﬁne partner notiﬁcation success as the delivery of treatment to a partner that will eliminate
infectivity if it is present, however this may be achieved (e.g. patient referral or provider referral). Partner
notiﬁcation may involve various tasks such as identifying, contacting, testing and treating partners. (By our
deﬁnition, partner notiﬁcation success is not simply a question of drug delivery and dosing, as it would
thus exclude, for example, treatment taken while sexually active with an as-yet-untreated index case.)Results
Estimating numbers of primary transmissions
The 203 index cases (112 men and 91 women) reported a total of 346 partners in the past year (Figure 8).
Using the per-partnership probabilities of transmission described above, we estimate that a total of 190
primary chlamydia transmissions occurred between the index cases and their 346 partners.0
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FIGURE 8 Frequency distribution of partners over the past year, by partnership type, sex and age group of index case.
Numbers in parentheses correspond to the number of index cases in each group.
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28Estimated numbers of secondary transmissions
We assume no onward or secondary transmission within live-in partnerships where primary transmission
occurred because live-in partners are assumed to have a median of 0 new partners per year (Table 10).
In contrast, the median number of new regular partners per year is assumed to be one (except among
male partners of index cases aged < 25 years, for whom the median was two partners). As expected, the
number of new partners is highest for casual partners of index cases, ranging from two to four partners.
Multiplying the number of infected partners of index cases by these likely numbers of new partners and
then by the probability of transmission gives an estimated 200 secondary chlamydia transmissions betweenTABLE 10 Estimated numbers of primary and secondary chlamydia transmissions, assuming no partner
notiﬁcation effort
Age
group
(years)
Primary chlamydia transmissions Secondary chlamydia transmissions
Number of
partnerships
at risk
Assumed p
(transmission)
Estimated
number of
transmissions
Number of
partnerships
at risk
Assumed p
(transmission)
Estimated
number of
transmissions
Male index cases, by partnership type
Live-in <25 0 0.69 0 0 0.69 0
≥25 5 0.83 4 0 0.83 0
Regular <25 36 0.56 20 20 0.56 11
≥25 28 0.67 19 19 0.67 12
Casual <25 61 0.42 25 76 0.42 32
≥25 60 0.50 30 60 0.50 30
Ex-regular/
live-in
<25 12 0.56 7 20 0.56 11
≥25 14 0.67 9 19 0.67 12
All
partnershipsa,b
<25 109 NA 52 116 NA 52
≥25 107 NA 62 97 NA 55
Female index cases, by partnership type
Live-in <25 8 0.69 6 0 0.69 0
≥25 4 0.83 3 0 0.83 0
Regular <25 36 0.56 20 40 0.56 22
≥25 16 0.67 11 11 0.67 7
Casual <25 26 0.42 11 43 0.42 18
≥25 10 0.50 5 15 0.50 7
Ex-regular/
live-in
<25 19 0.56 11 42 0.56 23
≥25 11 0.67 7 22 0.67 15
All
partnerships
<25 89 NA 48 125 NA 64
≥25 41 NA 26 48 NA 29
NA, not applicable.
a Estimated number of chlamydia transmissions using assumed partner numbers in supplemental ﬁles 2 and 3 to Mercer et al.9
for index cases and infected partners of index cases, respectively.
b Due to rounding, totals may differ slightly to the sum of the numbers expressed to 0 decimal places.
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transmissions, the 203 index cases are estimated to generate a total of 388 new chlamydia cases. Given
these results, if partner notiﬁcation was successful only with live-in partners (i.e. only these partners were
identiﬁed, tested and treated, as a result of either provider referral or patient referral) then, regardless of
age group and sex, only 3.4% (13/388) of all primary and secondary transmissions generated would be
treated or prevented, as the greatest proportion of transmissions stems from casual and regular partners.Quantifying the potential impact of partner notification
We now use the AROT and NNTIT to compare the potential impact of different partner notiﬁcation
intensities by partnership type (Table 11). Given the assumptions described above, successful partner
notiﬁcation needs to be achieved with more than one partner per index case overall in order to prevent
one onward (secondary) transmission, as the NNTITs are greater than one for each sex/age group.
However, when the NNTIT is considered by partnership type, then a smaller number of partner notiﬁcation
successes for casual and ex-regular/live-in partners will prevent one onward transmission, relative to with
regular partners. Thus, for example, among male index cases aged < 25 years, the NNTIT is 1.92 for casual
partners, which means that 1.92 casual partners need to be successfully identiﬁed and treated via partner
notiﬁcation in order to prevent one onward transmission, whereas among regular partners, successful
partner notiﬁcation would need to occur with 3.25 regular partners of these index cases to have the
same impact.
There are also differences between sexes and between age groups, illustrating the relative intensities of
effort required with different population groups. For example, the NNTIT for men aged < 25 years is
3.25 regular partners in contrast to a NNTIT of 1.62 regular partners among women aged < 25 years,
i.e. half the number of regular partners of women < 25 years versus the number of regular partners ofTABLE 11 Estimated absolute risk of transmission and number needed to interrupt one onward transmission,
assuming no partner notiﬁcation effort
AROT NNTIT
Index case age group (years) <25 years ≥25 years <25 years ≥25 years
Male index cases, by partnership type
Live-in 0 0 NA NA
Regular 0.31 0.44 3.25 2.25
Casual 0.52 0.50 1.92 2.00
Ex-regular/live-in 0.92 0.89 1.08 1.13
All partnershipsa,b 0.49 0.51 2.02 1.95
Female index cases, by partnership type
Live-in 0 0 NA NA
Regular 0.62 0.44 1.62 2.25
Casual 0.69 0.75 1.44 1.34
Ex-regular/live-in 1.23 1.33 0.81 0.75
All partnershipsa,b 0.71 0.71 1.40 1.40
AROT calculated as the number of secondary transmissions divided by the number of infected partners of index cases;
NA, not applicable; NNTIT calculated as the reciprocal of the AROT.
a Estimated number of chlamydia transmissions using assumed partner numbers in supplemental ﬁles 2 and 3 to Mercer
et al.9 for index cases and infected partners of index cases, respectively.
b Due to rounding, totals may differ slightly to the sum of the numbers expressed to 0 decimal places.
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30men < 25 years would need to be successfully identiﬁed and treated via partner notiﬁcation to prevent one
onward transmission.
As behavioural parameters will vary between populations (e.g. by ethnicity), and as transmission
parameters are hard to measure and therefore uncertain, we undertook sensitivity analyses to check the
robustness of these patterns. In all scenarios, the number of partner notiﬁcation successes required with
ex-regular/live-in partners is considerably less than among casual partners and, in turn, regular partners
and then live-in partners.Discussion
This paper has described an evidence-based algorithm that clinicians and public health teams can use to
estimate the potential impact of their service’s partner notiﬁcation effort on preventing STI transmission.
Additionally, we have shown how the potential impact of partner notiﬁcation can be quantiﬁed for
different patient groups by using two new epidemiological measures: the AROT and the NNTIT.
The strength of this study is that routinely collected data can be used to adapt the algorithm to different
settings and populations. In contrast to the published paper,9 we used data on actual partner numbers as
reported in health adviser interviews, rather than estimates from Natsal-2. However, index cases reported
their partners by type, which was subjective, with women more likely than men, for example, to regard a
partnership as regular rather than casual.81 There are limitations inherent to the static deterministic
modelling approach used here. The algorithm makes a number of assumptions about the transmission of
chlamydia to secondary partners. Furthermore, we assumed that these potentially infectious encounters
were all susceptible to chlamydia (i.e. not already infected or immune), which is highly unlikely in contacts
who are closely linked to a case. It is not possible to infer whether or not the estimates of onward
transmission derived here are optimistic, as counting further generations of cases would increase the
estimate, whereas pre-existing infection, chance effects, and network structure would tend to decrease the
effect. The estimates of onward transmission given here should, therefore, be taken as broadly indicative
rather than precise. The transmission dynamic models used in Chapter 3 overcome these limitations
because they have partnerships explicitly modelled and take into account infection status.
There are additional limitations to the study. We treat age crudely, stratifying into two age groups, though
using 25 years old as a threshold does correspond to age groups currently used for UK surveillance. There
were insufﬁcient data in Natsal-2 to allow stratiﬁcation by ethnicity and sexual orientation, which are also
associated with both partner numbers and the probability of STI acquisition, though other data sources
could also be harnessed. Furthermore, we assumed assortative mixing by behaviour and partnership type,
owing to the difﬁculty of obtaining data on partners’ current behaviours and partnerships. This might be a
reasonable assumption given the extent of assortative mixing in the population.82 Although there is
uncertainty and variability surrounding the parameters used in our algorithm, sensitivity analyses
undertaken to explore the vulnerability of the algorithm to uncertainty were reassuring.
As provider referral (vs. patient-led partner notiﬁcation) is required more often with casual and ex-partners
than with regular partners (Gill Bell, Shefﬁeld Teaching Hospitals NHS Foundation Trust, 2012, personal
communication), realising the potential public health beneﬁts suggested by the NNTIT has cost implications
for services. However, as casual and ex-partners are likely to have greater numbers of partners themselves,
the potential for preventing onward transmission is greater, yielding greater public health beneﬁt.
Services should collect data from their index cases on the number and type(s) of partners, as well as the
partner notiﬁcation method(s) required (patient vs. provider referral). These data, when combined with cost
data on partner notiﬁcation, are key for demonstrating the cost–beneﬁt of provider referral in preventing
onward transmission in a local population.
Our analyses show that future debate and research about partner notiﬁcation provision need to develop a
partnership-orientated focus regarding which index cases should be offered more intensive support forNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2public health beneﬁt. The existing emphasis on different strategies for partner notiﬁcation (e.g. patient,
provider) has a service-orientated focus regarding the types of partner notiﬁcation services offered. This
now needs to be explicitly linked to strategic decisions about what index cases should be offered, according
to their different kinds of partnership history. Although clinicians recognise that a ‘one size’ approach to
partner notiﬁcation does not ﬁt all types of sexual partner, outcome measures must also reﬂect the public
health importance of partnership type. Patient-centric measures conceal huge variations in transmission
potential by partner type. Clinical services should routinely adopt partner-centric outcome data, and audit
their partner notiﬁcation data by partner type. This will allow them to explore the implications of different
approaches to targeting partner notiﬁcation activity, and assess the public health outcomes of the service.
Our partner notiﬁcation algorithm has a role to play in providing epidemiological evidence aimed at
assessing and justifying the public health value of more expensive and challenging partner notiﬁcation
activity with casual and former partners, which is provided to a variable extent.83 The algorithm can be
adapted to other STIs, such as gonorrhoea, and other infections where partner notiﬁcation is needed,
such as hepatitis B and tuberculosis. Without a better understanding of how to harness the relative
transmission prevention potential of different partnership types, evidence-based partner notiﬁcation
practice cannot progress.31
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of partner notiﬁcation
We planned to adapt two individual-based models of C. trachomatis transmission that were developedin the UK39,40 to investigate partner notiﬁcation technologies. In the introduction to this report (see
Chapter 1), we outlined how predictions from these and from a third model developed in the
Netherlands84 resulted in widely differing conclusions about the effects of the same hypothetical screening
and partner notiﬁcation intervention to prevent C. trachomatis.41 We use the ﬁrst part of this section to
resolve some of the uncertainties in the modelling of chlamydia transmission in general and to compare
the three models in detail. These studies were needed to determine the design of subsequent models.
In the second part of this section we investigate the impact of current recommendations for traditional
partner notiﬁcation technologies for chlamydia with outcomes at the individual level (case-ﬁnding) and
population level (prevalence) (see Table 5). In the third part of this section we investigate a range of
partner notiﬁcation scenarios for treating partners with or without testing for the STI ﬁrst.Modelling the transmission dynamics of
Chlamydia trachomatis
Introduction
We need to understand the transmission dynamics of STIs if we are to make accurate quantitative, as well
as qualitative, predictions about the impact of partner notiﬁcation and other preventative interventions.
Sexual partnership dynamics and the values for infection parameters are key determinants that affect the
spread of STIs. In this chapter, we investigate the effect of different assumptions about disease-speciﬁc
parameters for C. trachomatis on the predicted impact of interventions using a basic transmission model.
We then describe the derivation of improved estimates of the infectious duration and the transmissibility of
chlamydia. Finally, we present the results of a detailed comparison of the three individual-based models,
which allows us to draw more robust conclusions about the effect of screening and partner notiﬁcation
interventions on chlamydia transmission. We end with a brief summary of the insights that we have gained
into chlamydia transmission models, and a rationale for the model choice in subsequent chapters.Infectious duration of chlamydia
Different models of chlamydia transmission use widely different disease-speciﬁc parameters. We devised a
deterministic chlamydia transmission model with a SEIRS (susceptible-exposed-infected-recovered-
susceptible) structure. For simplicity, we assumed a closed population of young adults and a homogeneous
population where both sexes become infected and pass through the infected stages at equal rates. The full
details of the model can be found in Althaus et al.46
To understand what parameters are most important for predicting the impact of an intervention we
performed a univariate sensitivity analysis of disease-speciﬁc parameters, namely the duration of the
asymptomatic and symptomatic periods, the duration of temporary immunity and the fraction of infections
that become symptomatic. The pre-intervention prevalence of chlamydia in the population was assumed to
be 5%. This corresponds roughly to the prevalence observed in sexually active young adults.77
We investigated the impact of a screening intervention rather than partner notiﬁcation because the
simplicity of the model does not allow identiﬁcation and tracking of current and previous sex partners of
infected index cases. We then calculated the expected prevalence after the introduction of two different
screening scenarios: (1) an organised screening programme with a screening rate of 0.25 per year
implemented for 10 years and (2) opportunistic screening at a rate of 0.05 per year, in which the new
steady-state prevalence is shown after long-term implementation.33
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34Uncertainties in the duration of asymptomatic period and of temporary immunity resulted in large
differences in the predicted impact of a screening programme (Figure 9a and b). In contrast, varying the
fraction of infections becoming symptomatic and the duration of the symptomatic period within the range
of previously used parameter estimates caused little change in the predicted effect of interventions.
The long-term outcome of a screening programme appeared to be most sensitive to the duration of the
asymptomatic period. Figure 9a (grey area) shows the range of values for the asymptomatic period that
have been used in previous mathematical models of chlamydia transmission (180–420 days). The
long-term impact of screening at a low rate (dotted line) is much more pronounced if the asymptomatic
period is at the upper bound of the range.
The duration of temporary immunity also affected the predicted impact of screening. Increasing the
duration of temporary immunity substantially decreased the impact of screening (see Figure 9b). Here,
screening and treating asymptomatically infected people prevents the development of temporary immunity
and renders them immediately susceptible. This somewhat counterbalances the otherwise strong impact of
screening. The grey area, which covers the range of values used in previous modelling studies, shows the
uncertainty about the existence and duration of immunity after a chlamydia infection.
To obtain a robust estimate of the duration of asymptomatic chlamydia infection in women, we
ﬁtted a mathematical model to data from a study that followed a large number of asymptomatic
chlamydia-infected women and showed that the infection can persist for several years (Figure 10).850.05
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FIGURE 9 Prevalence of chlamydia after the introduction of a screening programme. Dotted line, baseline prevalence
in the absence of a screening programme; dashed line, long-term prevalence if the population receives screening at a
rate of 0.05 per year; solid line, prevalence after screening the population at a rate of 0.25 per year for 10 years; grey
area, parameter range; black dots, baseline scenario. (a) Chlamydia prevalence as a function of the duration of the
asymptomatic period. Most estimates on the duration of the asymptomatic period are within 200–400 days; and
(b) chlamydia prevalence as a function of the duration of temporary immunity. Reprinted from Epidemics, vol. 2,
Althaus CL, Heijne JCM, Roellin A, Low N, Transmission dynamics of Chlamydia trachomatis affect the impact of
screening programme, pp. 123–31, 2010, with permission from Elsevier.46
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FIGURE 10 Persistence of chlamydia in asymptomatically infected women. Data from Molano et al.85 and reprinted
from Epidemics, vol. 2, Althaus CL, Heijne JCM, Roellin A, Low N, Transmission dynamics of Chlamydia trachomatis
affect the impact of screening programme, pp. 123–31, 2010, with permission from Elsevier.46
DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2The model describes the clearance of chlamydia infections in all women who were infected at the
beginning of the study. We also took into account the possibility that women could have cleared their
infection naturally and become reinfected from their (presumed) untreated partners. Full details of the
model and the parameter estimation have been published.46
The estimated reinfection rate is low (0.01 per year, 95% CI – 0.01 to 0.03 per year), which indicates that
the data are mainly described by natural clearance. With an estimated clearance rate of 0.84 per year
(95% CI 0.82 to 0.87 per year), we obtain a mean duration of the asymptomatic period of 433 days (95%
CI 420 to 447 days).Transmissibility of chlamydia
The transmissibility of C. trachomatis through sexual intercourse cannot be observed in empirical studies.
Estimates of the transmissibility of chlamydia from epidemiological studies have usually been based on
data from couples with and without chlamydia infection and the proportions of concordant and discordant
pairs.6,7,86 Katz86 proposed an original approach for analysing such data using information about
heterosexual couples attending a STI clinic in Indianapolis, IN, USA. The expected numbers of concordant
and discordant couples before transmission takes place can be calculated if it is assumed that all couples in
the population with at least one infected individual have the same probability of observation, and that
sexual partnership formation is independent of infection status. After sexual partnerships have formed,
transmission can happen in discordant partnerships, resulting in a higher proportion of couples in which
both partners are positive.
Katz86 estimated the probabilities that transmission occurred within a couple at 0.395 from men to women
and 0.323 from women to men. But there are two major problems with this approach. First, the estimated
transmission probabilities do not represent the per-partnership transmission probability because infection
status is observed during the partnership and not at the end. The probabilities estimated by Katz are often
called per-partnership transmission probabilities, which imply that the partnership has been observed until
it has ended. Second, they do not take into account the natural history of chlamydia infection, where
spontaneous clearance and reinfection within sexual partnerships can occur.87 These complexities need to
be considered because different assumptions about infectious duration46 and reinfection in sexual
partnerships88 can affect the prevalence of chlamydia.
To obtain new estimates of the transmissibility of chlamydia we used data from a cross-sectional
partnership study that has frequently been cited as the source of estimates for chlamydia transmissibility.7
We described the transmission of chlamydia using the pair model framework, which has been used for
several STIs.88–91 The full details of the model and the parameter estimation procedure have been
published.47 In brief, we used maximum likelihood estimation92 to ﬁt the model to the data from the study
by Quinn et al.7 The study contains information about chlamydia infection status and sexual activity in35
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36494 heterosexual couples. The study reported 53 concordant chlamydia positive, 48 discordant and
393 concordant negative couples. We generated 1000 parameter combinations to account for
uncertainties in the duration of sexual partnerships and infections. Sexual behaviour parameters were
taken from the same study. We obtained model estimates of the per partnership transmission probability
for different values of the number of partners during the last 6 months (Figure 11a).
Higher number of partners resulted in lower estimates of the per partnership transmission probability.
However, partner numbers of three or more during the last 6 months resulted in poor ﬁts to the data. We
therefore consider two partners during the last 6 months as our baseline scenario, for which the median of
the estimated per-partnership transmission probability is 55.5% [interquartile range (IQR) 49.2–62.5%].
The estimates of the per-sex act transmission probability seemed to be less affected by the assumed
number of partners in the last 6 months (Figure 11b). Most values were around 10% with the median of
the baseline scenario at 9.5% (IQR 6.0–16.7%).1.5 2
Number of heterosexual partners
in last 6 months
Tr
an
sm
is
si
o
n
 p
ro
b
ab
ili
ty
p
er
 p
ar
tn
er
sh
ip
 (
%
)
2.5 3
100
80
60
40
20
0
(a)
Tr
an
sm
is
si
o
n
 p
ro
b
ab
ili
ty
p
er
 e
p
is
o
d
e 
o
f 
in
te
rc
o
u
rs
e 
(%
)
1.5 2
Number of heterosexual partners
in last 6 months
2.5 3
40
30
20
10
0
(b)
FIGURE 11 Estimated chlamydia transmission probabilities for different values of the number of partners in the last
6 months. (a) Per-partnership transmission probability of chlamydia; and (b) per-sex act transmission probability
of chlamydia. Each box plot represents estimates from 1000 different parameter combinations. The baseline
scenario, where it is assumed that individuals in a partnership at steady-state have on average of two heterosexual
partners during the previous 6 months, is in grey. It is assumed that individuals have one episode of heterosexual
intercourse every 5 days. Reprinted with permission from Althaus CL, Heijne JC, Low N, Towards more robust
estimates of the transmissibility of Chlamydia trachomatis. Sex Transm Dis, vol. 39, issue 5, pp. 402–4, 2012.47
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baseline values reported by Katz.86 This is expected because we report the probability of transmission
taking place by the end of a partnership and we assume that chlamydia can be cleared spontaneously
followed by reinfection. Our estimate is, however, lower than the percentages of concordantly infected
couples (70% of female partners of infected men and 68% of male partners of infected women). These
percentages are often interpreted as the per-partnership transmission probabilities,84,93 but they are not
because the direction of transmission cannot be reliably determined.87 This discrepancy illustrates the
importance of taking the natural history of chlamydia infection and the dynamics of sexual partnership
formation into account when estimating transmissibility from data of chlamydia positivity in couples. The
reﬁned estimates of the per-sex act transmission probability for chlamydia are consistent with those
obtained or used in other modelling studies.35,94,95 In two of the three individual-based models of
chlamydia transmission that we had compared, the per-sex act transmission probabilities were also within
the same range as our estimate, but the probability in the third model (3.75%) was lower.Comparison between three individual-based models
We evaluated further the three individual-based models of chlamydia transmission that showed conﬂicting
results about the impact of the same screening intervention.41 The names of the models are the same as
those used in the ﬁrst comparison: the ClaSS (Chlamydia Screening Studies project) model and Turner
model were both developed to examine the effects of different models of chlamydia screening in the UK;
the Kretzschmar model was developed in the Netherlands. The comparison has been published in full.48
First, we compared the sexual partnership dynamics of the models to population-based data from Natsal-2
about the durations of sexual partnerships, the length of gaps and overlaps between partnership and the
numbers of partners in the last year. We showed that although all models capture some aspects of the
sexual partnership dynamics reasonably, they fail in others. Overall, the Kretzschmar model performed best.
We then investigated the spread of chlamydia in the simulated populations with Natsal-2 (Figure 12). In
previous studies, the three models used different assumptions about the duration of infection and the
proportion of symptomatic and asymptomatic cases.41 To better compare their results, we used a
harmonised set of chlamydia infection parameters, based on a thorough evaluation of the parameter
ranges in the literature and our new estimate of the duration of the asymptomatic period.
The per-sex act transmission probabilities required to reproduce the estimated prevalence from Natsal-2
are lower than the estimates we obtained (see Transmissibility of chlamydia). This might be the result of
unrealistic assumptions about the sexual partnership dynamics in the three models. However, it could also
derive from our assumption of a relatively high frequency of sex acts during the ﬁrst 2 weeks of a sexual
partnership, which would balance the lower transmission probabilities per sex act.
We compared the model predictions with Natsal-2 data according to the distribution of chlamydia
infections according to numbers of sexual partners and the fraction of infections in individuals with
frequent partner change rates. As expected, the prevalence of chlamydia increases with an increasing
number of heterosexual partners within the last year (see Figure 12). Again, the Kretzschmar model
captures the overall distribution well and bears a striking resemblance to the proportion of people in each
‘risk category’ (shown in inset legend for each panel). The prevalence in the group of individuals with ﬁve
or more partners within the last year is, however, overestimated. The Turner model captures the overall
distribution of chlamydia infections in 18- to 44-year-olds but the ﬁgure excludes 16- to 17-year-olds
(because they were not included in Natsal-2) in whom chlamydia prevalence in the model was very high.
Furthermore, the mode results in an unrealistic outcome where no individual remains without a partner
throughout the 1-year period. In contrast to the other two models, chlamydia infections are too heavily
concentrated among ‘high-risk’ individuals in the ClaSS model. Furthermore, it becomes apparent that
sexual partnership dynamics are not captured well because too many individuals remain single throughout
the 1-year period.37
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DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2Finally, we implemented a standardised screening and partner notiﬁcation intervention and compared the
predicted impact after 5 and 10 years of intervention (Figure 13).
The harmonisation of disease-speciﬁc parameters resulted in more similar results for the Kretzschmar and
the ClaSS models. However, the Turner model still predicted a much stronger impact of the same
intervention. Part of this discrepancy can be explained by an overestimation of partner change rates
among young adults in the Turner model. The unrealistically high rates cause a large proportion of
chlamydia transmission to occur in exactly those individuals who become eligible for screening, rendering
the intervention more powerful.Discussion
We re-estimated the average duration of asymptomatic chlamydia infection in women at 433 (95% CI 420
to 447) days. We also obtained new estimates of chlamydia transmissibility and found that the
transmission probability per episode of heterosexual intercourse is 9.5% (IQR 6.0–16.7%). The
transmission probability per heterosexual partnership was estimated at 55.5% (IQR 49.2–62.5%). We
applied this parameter set to three individual-based models of chlamydia transmission and obtained similar
predictions of the impact of a screening and partner notiﬁcation intervention in two of the models. Part of
the discrepancies between the models was explained by their use of different assumptions about the
infectious duration of chlamydia.
To fully evaluate the role of immunity on the impact of chlamydia prevention, we need further insights
about the possibility of temporary immunity to C. trachomatis in humans and the timing of its
development. The development of immunity could interfere with the effect of screening on reducing the
prevalence of chlamydia. Whether or not natural clearance of asymptomatic infection is followed by a
period of temporary (or partial) immunity is still open to debate.96 We found that long duration of
temporary immunity can drastically diminish the effect of screening. If temporary immunity develops only
in asymptomatic individuals who clear the infection naturally, screening and treatment might directly
interfere with establishing immunity, causing a diminished effect of screening.36,96,97Pr
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FIGURE 13 Impact of a standardised screening programme on the prevalence of chlamydia. The proportion of
eligible people receiving screening at least once a year is 20%, and 40% of the current or most recent partners of an
index case are successfully notified and treated. Means of 100 simulations runs are shown together with the SD.
Reproduced with permission from Althaus CL, Turner KM, Schmid BV, Heijne JC, Kretzschmar M, Low N, Transmission
of Chlamydia trachomatis through sexual partnerships: a comparison between three individual-based models and
empirical data, J R Soc Interface 2012;9:136–46.48
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40The type and structure of models that describe the spread of STIs should depend on the question that one
wants to address.98 The duration and transmissibility of chlamydia infection were investigated with relatively
simple deterministic, population-based models. These models do not allow the identiﬁcation and tracking
of current and previous sex partners of infected index cases, which is needed for detailed investigation of
the effects of partner notiﬁcation. The three models that we investigated differed in their ability to
realistically describe the sexual partnership dynamics. Overall, the Kretzschmar model performed best in
terms of describing the sexual partnership dynamics and the distribution of chlamydia within the
population. The Turner model generated a good description of the distribution of chlamydia in the age
range investigated, but probably overestimated the effect of chlamydia screening due to an unrealistically
high prevalence in the youngest age class. The ClaSS model predictions of the impact of chlamydia
screening were similar to those of the Kretzschmar model after harmonisation of parameters, but the
distribution of chlamydia was too highly concentrated among those with a high number of sexual partners.
Based on these studies, we decided not use either the Turner or the ClaSS models to study the effects of
partner notiﬁcation interventions. We developed new individual-based models, which were simple enough
to allow interpretation of the ﬁndings, but which possessed the complexity necessary to construct the
sexual network and track individual partnerships.Individual- and population-level effects of partner notiﬁcation
for Chlamydia trachomatisSubstantial portions of the following section are reproduced with permission from Althaus CL, Heijne JCM,
Herzog SA, Roellin A, Low N. Individual and population level effects of partner notiﬁcation for Chlamydia
trachomatis. PLOS ONE 2012; 7:e51438.49Introduction
Partner notiﬁcation is known to be an efﬁcient method of case ﬁnding. There is, however, no consensus
about the most appropriate or efﬁcient window of time for past partner notiﬁcation (‘look-back period’).
The UK National Guideline for the Management of Genital Tract Infection with Chlamydia trachomatis
recommends notifying partners of an asymptomatic index case within a period of 6 months.10 The same is
standard in Sweden, but recommendations from the Swedish National Board of Health and Welfare are
changing, based on a recent study that found that extending partner notiﬁcation periods could improve
the identiﬁcation of new chlamydia cases.99 This is also supported by a study from the USA, where it was
observed that a partner notiﬁcation period of 6 months or more would help to identify more infected
cases.100 But the Sexually Transmitted Diseases Treatment Guidelines from the US Centers for Disease
Control and Prevention recommend notifying partners with whom the index case has had sexual contact
within the previous 60 days, or the most recent partner if no sexual contact occurred in this period.101Objectives
To investigate the impact of two partner notiﬁcation strategies – notifying partners in order of the most
recent date of sexual intercourse before the end of a partnership, or notifying all partners during a
speciﬁed look-back period – on outcomes at the level of individuals and the population.Methods
Individual-based modelling framework
We used a stochastic, individual-based (or agent-based) modelling framework that can simulate the
transmission of an arbitrary STI in a sexual partnership network of any level of complexity.49 Rstisim
(R package for STI simulation) is written in C++ and can be downloaded at www.stat.nus.edu.sg/∼staar/
rstisim as a package for the R software environment for statistical computing (The R Foundation for
Statistical Computing, Vienna, Austria; www.R-project.org).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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To investigate the transmission of chlamydia in a heterosexual partnership network we devised a model
with concurrent partnerships in a homogeneous population.49 The structure of the model described below
is implemented into Rstisim where event times (partnership formation and dissolution, sex acts and
clearance of chlamydia) are drawn from exponential distributions around mean values (Table 12). If not
otherwise indicated, we assume a total population size n = 20,000, equally divided into females and males.
Sex difference is indicated by the subscript i and 1 – i for i = 0, 1.
Our model is based on the pair model framework,89 in which singles Xi initiate partnerships, P, at a pair
formation rate ρ. This framework is extended to account for individuals who have two sexual partnerships
at the same time (concurrency).102 We assume that singles X and individuals who are in a P can accept
another partnership with a probability α (relative to the probability that a single X accepts). Such an event
can result in a triple T. Triples can then be elongated to form chains of contacts. We deﬁne the level of
concurrency at cross-section, c, as the ratio of individuals that have more than one partnership to all
individuals in a partnership.
The average duration of a partnership is given by 1/σ. Every partnership begins with an initial sex act
where chlamydia can be transmitted at rate π. In an ongoing partnership, the frequency of sex acts is given
by f and the transmission probability per sex acts is again π. The frequency of sex acts per partnership is
constant, that is, individuals who have two concurrent partnerships have twice as many sex acts per unit of
time compared with individuals who are in only one partnership.Sexual behaviour data and parameter derivation
To parameterise the heterosexual partnership dynamics, we use data from Natsal-2.103 We adjust the pair
formation rate, ρ, so that the model exhibits the same number of realised partnerships as in 16- to
25-year-old women and men in Natsal-2 (see Table 12). Assuming the sexual partnership dynamics has
approached steady state, the pair formation rate is given by
ρ = ½ð1þ cÞn / f2½1þ c − ðt − nÞg ð1ÞTABLE 12 Parameters determining the dynamics of sexual partnerships and the transmission of chlamydia.
Reprinted with permission from Althaus CL, Heijne JCM, Herzog SA, Roellin A, Low N, Individual and population
level effects of partner notiﬁcation for Chlamydia trachomatis, PLOS ONE 2012;7:e5143849
Parameters Value
Assumed parameters
Mean number of new heterosexual partnerships per individual, n 1.04 per year
Mean number of total heterosexual partnerships per individual, t 1.70 per year
Level of concurrency, c 8%
Frequency of sex acts, f 1 per week
Mean duration of infection 1 year
Prevalence of chlamydia 3%
Derived parameters
Pair formation rate, ρ 1.36 per year
Relative probability of accepting a partnership if already in a pair, α 0.28
Mean duration of partnership, 1/σ 0.65 years
The transmission probability is in good agreement with empirical estimates.47,86,95 Some parameters are given as
rounded values.
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42where n and t are the numbers of new and total heterosexual partners in the last year, respectively, and c
is the level of concurrency. The partnership dissolution rate is given by σ = n/(t – n). Note that t – n
corresponds to the proportion of individuals in a partnership. Finally, we varied the level of concurrency
between 0% and 100% and found that c = 8% provides the best match between the simulations and
data from Natsal-2.
Chlamydia prevalence rates for 18- to 24-year-olds in Natsal-2 were 3.0% in women and 2.7% in men in
the UK as a whole.77 Data from Natsal-2 were weighted to adjust for unequal selection probabilities and to
correct for the age and sex proﬁle in the population, and mean values were taken for women and men
together. We adjusted the transmission probability per sex act so that the steady state prevalence of
chlamydia is 3% in the model.Sexual network
Figure 14 shows the sexual partnership dynamics of the model where chains of contacts can occur at
cross-section. Over the course of 1 year, the sexual partnership network shows closely connected groups
or bigger circular structures.
Partner notification strategies
Using our individual-based modelling framework, we can follow an individual’s history of current and
previous partners. Figure 15 shows the complex partnership dynamics in which a new partnership can
replace a previous one, or where short episodes of concurrency can occur.
We explore two strategies in which partners of an index case can be notiﬁed. One strategy is to notify the
partners in order of their recency (by the time since their partnership ended). The other strategy is to notify
all partners within a certain look-back period. For each strategy, each notiﬁed partner is tested and
successfully treated with a probability of 50% (approximated from results; see Partner notification
outcomes for chlamydia in UK genitourinary medicine clinics).45 In practice, a partner who tests positive
could become a new index case. We did not include this feature because it made the model more
complicated but did not affect the results.Results
Individual-level effect of partner notification
At the level of individuals, partner notiﬁcation identiﬁes new index cases. It is therefore important to know
how many of an index case’s partners are infected. A Swedish study99 found that the proportion of
chlamydia-positive partners decreases as time since last sexual intercourse increases. In the simulations,
everyone who is chlamydia positive at cross-section is deﬁned as an index case. This corresponds to
infected individuals who would be detected through random screening or after developing symptoms,
assuming that symptoms occur uniformly throughout the course of infection. We can then go through all
current and previous partners of an index case and ‘test’ whether or not they are infected. When we used
the same time periods as in the Carré et al. study,99 chlamydia positivity in the model was similar to the
data (Figure 16).
The proportions of infected cases were examined in more detail in the individual-based modelling
framework. First, we investigated in order of recency the proportion of infected partners (Figure 17a). The
model gave consistent results: 67.5% of the most recent partners of an index case were infected with
chlamydia. The less recent a partnership or contact, the lower the probability that the partner is infected.
The proportion of infected individuals, up to the third most recent partner, was still substantially higher
than the population prevalence.
We could also group the partners of an index case in a look-back period since the partnership has ended
in greater detail than that shown by Carré et al.99 (Figure 17b). We found that as far back as 18 months, a
substantial proportion of partners (> 10%) were infected with chlamydia. This suggests that extendingNIHR Journals Library www.journalslibrary.nihr.ac.uk
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Partner notification period
Time
FIGURE 15 Partnership histories and partner notification strategies. The scheme shows an example of an individual’s
history of three sexual partnerships. The partnerships can either be separated by a period of being single (partnership 1
and 3) or be concurrent (partnership 1 and 2). One strategy is to notify partners of an index case in order of their
recency, e.g. the first, second or third most recent partner(s). Another strategy is to notify all partners from a
certain time period, e.g. the partners from partnership 1 and 2 only. Reprinted with permission from Althaus CL,
Heijne JCM, Herzog SA, Roellin A, Low N, Individual and population level effects of partner notification for Chlamydia
trachomatis, PLOS ONE 2012; 7:e51438.49
(a)
(b)
FIGURE 14 Sexual partnership networks from the individual-based model. Different sexes are indicated by filled and
empty circles. (a) At cross-section, individuals can be single, form a sexual partnership or have two concurrent sexual
partnerships; and (b) large connected components emerge during a period of 1 year. For illustrative purposes, the
population size was limited to 100, resulting in higher connected networks compared with larger population sizes.
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FIGURE 16 Simulated and empirical data of chlamydia positivity in partners of index cases. Black crosses correspond
to the proportion (with 95% CI) of positive partners out of those with a positive test.99 The black circles represent
simulated data from the model. In the simulations, the steady-state prevalence of chlamydia is 3%. Means of 100
simulation runs are shown. Standard errors are small and omitted for better visibility. Reprinted with permission
from Althaus CL, Heijne JCM, Herzog SA, Roellin A, Low N, Individual and population level effects of partner
notification for Chlamydia trachomatis, PLOS ONE 2012; 7:e51438.49
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FIGURE 17 Proportion of chlamydia-positive partners of index cases. (a) The proportion of infected partners in order
of their recency; and (b) the proportion of infected partners grouped into different look-back periods in order of
their break-up date. Steady-state chlamydia prevalence is 3% (dashed line). For each strategy, means of 100
simulation runs are shown. Standard errors are small and omitted for better visibility. Reprinted with permission from
Althaus CL, Heijne JCM, Herzog SA, Roellin A, Low N, Individual and population level effects of partner notification
for Chlamydia trachomatis, PLOS ONE 2012; 7:e51438.49
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DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2partner notiﬁcation periods beyond 1 year yields more new index cases for individual case management
than would be found through random screening.
Population-level effect of partner notification
At the population level, partner notiﬁcation can prevent onward transmission of chlamydia and reduce the
overall prevalence of the infection. Here, we investigated the effects of the different partner notiﬁcation
strategies if they were implemented as part of a population-wide screening programme. After the
simulations approached the steady-state prevalence of 3%, we introduced random screening of the whole
population of young adults. Every woman and man received screening at a rate of 0.1 per year, that is,
every 10 years on average. If partner notiﬁcation is performed, each notiﬁed partner is tested and
successfully treated with a probability of 50% (see Chapter 2, Clinical effectiveness of partner notification
technologies: systematic review).45
After 5 years of screening, assuming that there is no partner notiﬁcation, the prevalence of chlamydia was
reduced to about 70% (Figure 18). It can be clearly seen that the strongest effect of partner notiﬁcation
stems from notifying only the current partner. This suggests that notiﬁcation of current partners, or the
most recent partners if the index case is single, is sufﬁcient to achieve most of the additional reduction in
prevalence at the population level.
Sensitivity analyses
The results shown are from a model that assumes a homogeneous and closed heterosexual population.
Despite its simplicity, this model provides a good description of the chlamydia positivity in partners of index
cases (see Figure 16). Our general conclusions about the effects of partner notiﬁcation at the level of
individuals and the population were robust to different assumptions about the infectious duration (see
Modelling the transmission dynamics of C. trachomatis), with a shorter infectious duration in men and in
different screening and partner notiﬁcation scenarios.49Discussion
Our model simulations show that, while extending partner notiﬁcation periods beyond 1 year helps to ﬁnd
new index cases, notifying the current or most recent partner has the greatest effect on reducing
transmission in a general heterosexual population of young adults.
We made a number of simplifying assumptions in our model. First, we treat the population of 16- to
25-year-olds as a closed population that mixes homogeneously. This assumption probably resulted in
realistic chlamydia transmission dynamics in our study because it was restricted to the age group that
drives chlamydia transmission in the wider population. We have previously shown that this kind of model
results in a realistic distribution of chlamydia infection according to numbers of recent sexual partners,46
and provides conclusions in line with more detailed models that include age and risk stratiﬁcation.35,48
However, differences in sexual activity between women and men, and potentially higher concurrent
partnerships in men compared with women, are additional complexities that could be considered in
future studies.
Our simulation study examined a general strategy for partner notiﬁcation, which is similar to traditional
technologies where the partner attends a health service setting and receives both testing and treatment.
Our ﬁndings suggest that the choice of partner notiﬁcation strategy for chlamydia in a general
heterosexual population of young adults depends on the public health context in which it is applied. At
the individual level, our results suggest that tracing as many as three partners from the preceding
18 months can be helpful in ﬁnding new index cases. This is in line with recent recommendations for
partner notiﬁcation periods in Sweden, based on the ﬁndings of Carré et al.99 At the population level,
notiﬁcation of current partners of an index case should be a priority. But if previous partners are chlamydia
positive, they are likely to have been infected for a long time and thus notifying them will do little to limit
onward transmission in a general heterosexual population with limited levels of concurrent partnerships. In
all likelihood, they will have already transmitted the infection to others before clearing it spontaneously or45
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FIGURE 18 Population level effect of partner notification. Graphs show the reduction in the prevalence of chlamydia
after screening for 5 years at a rate of 0.1 or 0.25 per year. (a), (c) and (e) show prevalence for different numbers
of notified partners; (b), (d) and (f) show prevalence for different partner notification periods. The probability,
p, that each notified partner will be tested and successfully treated is set to 10% (a and b), 50% (c and d) or 90%
(e and f). For each strategy, means of 100 simulation runs are shown. Standard errors are small and omitted for
better visibility. (continued)
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46becoming symptomatic and seeking care. If screening is targeted at high-risk individuals, notifying previous
partners of index cases will likely have a stronger effect on limiting onward transmission because of their
higher partner change rates (see Estimating the likely public health impact of partner notification for a
clinical service: an evidence-based algorithm).9
Few modelling studies have examined the effects of partner notiﬁcation for chlamydia. Our ﬁndings are
consistent with those of Kretzschmar et al.,84,104 who also considered a dynamic sexual partnership
network but restricted partner notiﬁcation to current partners only. In contrast, Armbruster and
Brandeau105 found that increasing contact tracing capacity resulted in a substantial reduction of chlamydiaNIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 18 Population level effect of partner notification. Graphs show the reduction in the prevalence of chlamydia
after screening for 5 years at a rate of 0.1 or 0.25 per year. (a), (c) and (e) show prevalence for different numbers
of notified partners; (b), (d) and (f) show prevalence for different partner notification periods. The probability,
p, that each notified partner will be tested and successfully treated is set to 10% (a and b), 50% (c and d) or 90%
(e and f). For each strategy, means of 100 simulation runs are shown. Standard errors are small and omitted for
better visibility.
DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2prevalence, although with diminishing returns. They investigated the effects of partner notiﬁcation for
index cases who seek treatment for symptoms and assumed a static sexual network with a relatively high
prevalence of chlamydia. In our study using a dynamic sexual network, we found that previous partners of
an index case do not contribute to reinfection, which might explain our ﬁnding that notifying previous
partners had little additional effect on reducing chlamydia transmission.
In future modelling studies, different strategies for screening and partner notiﬁcation in groups with
frequent partner change rates could be investigated in models that incorporate heterogeneity in sexual
behaviour. The effects of different partner strategies for other bacterial STIs should also be examined. In47
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48the following section, we investigate testing and treatment strategies for both chlamydia and gonorrhoea.
The impact of partner notiﬁcation on syphilis would require a different model structure and should be
examined in a population of men who have sex with men, or heterosexuals with higher average levels of
sexual behaviour. In this study, we have shown that notifying three or more partners from the preceding
18 months is expected to yield substantial numbers of new chlamydia cases. In contrast, the successful
treatment of current partners is most important for preventing reinfection of index cases and reducing
further transmission of chlamydia at the population level. In the next section we therefore focus on the
effects of partner notiﬁcation for the current or most recent sexual partner.The effects of traditional and new partner notiﬁcation
technologies for Chlamydia trachomatis and
Neisseria gonorrhoeae
Introduction
The second most commonly diagnosed bacterial STI after chlamydia is gonorrhoea (see Table 3). In the
previous chapters, we investigated the effects of traditional technologies for partner notiﬁcation for index
cases with chlamydia only. We have assumed that notiﬁed partners will attend a health service setting and
be tested for other STIs. New partner notiﬁcation technologies, such as APT, which allow partners to
collect treatment without attending a health service setting, might leave partners with undiagnosed STIs.
It is therefore important to study the potential effects of cotesting and cotreatment for chlamydia
and gonorrhoea.
An important observation for studying combined interventions against both chlamydia and gonorrhoea is
the high rate of chlamydia infection in those who are infected with gonorrhoea. This is a consistent ﬁnding
in studies of different populations and with different study designs. For example, Nsuami et al.27 found
that 41.4% of female and 46.7% of male students tested positive for both gonorrhoea and chlamydia in
an urban school district in the USA where STI testing was offered systematically every year. In the US
National Health and Nutrition Examination Survey, a nationally representative population-based study, the
chlamydia co-infection rate was 45.7% in 14- to 39-year-old civilians with gonorrhoea infections.26 Similar
levels of co-infection are found in genitourinary medicine clinic attenders.25 These rates are much
higher than the population prevalence of chlamydia and even exceed the positivity rates of chlamydia in
high-risk populations.
It is important to investigate potential mechanisms for chlamydia and gonorrhoea co-infection on the
transmission dynamics in mathematical models. One hypothesis is that biological interactions between the
two organisms account for the high rates of co-infection. If such interactions exist, then understanding
them would enable us to improve guidelines for testing and treating a population for chlamydia and
gonorrhoea. Classical models, where chlamydia and gonorrhoea transmission does not depend on the
presence of another organism, generally fail to account for high co-infection rates.106Objectives
(1) To develop a dynamic transmission model of chlamydia and gonorrhoea infection in a heterosexual
population and (2) to use the model to investigate the effects of APT and traditional partner notiﬁcation
technologies on STI prevalence, the frequency of gonorrhoea outbreaks and STI reinfection rates.Methods
We examined epidemiological data to inform the development of a mathematical model in which the
presence of one organism can increase the susceptibility and the transmissibility of the other. The
deterministic, population-based model was then implemented in an individual-based manner using Rstisim
and we studied basic aspects of the effects of different testing and treatment strategies in separate models
that either assumed that chlamydia and gonorrhoea are transmitted independently or included an
interaction between the organisms.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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We found two recent studies that give some support to the hypothesis that there is a biological interaction
between chlamydia and gonorrhoea infections. In one study, increased gonorrhoea organism loads were
found in women who were co-infected with chlamydia.107 The authors hypothesised that this could
increase the chances of gonorrhoea transmission. In another, laboratory study, mice were infected with
Chlamydia muridarum and gonorrhoea. The authors found that chlamydia-induced host alterations of the
immune response could enhance gonoccocal infection.108 Studying infections at the individual level is
important to propose different mechanisms for interactions between the two infections. However, it is
important to ﬁnd out if the interaction hypothesis is supported by epidemiological data about co-infection.Epidemiological data about co-infection
One of the most detailed studies on co-infections with chlamydia and gonorrhoea was done by Lycke
et al.6 The study comprised women and men attending two outpatient STI clinics in Goteborg, Sweden.
The authors tested 155 women with 156 male sex partners and 211 men with 237 female partners for
chlamydia and gonorrhoea. Index patients were infected with at least one of the organisms. The data in
this study were used to calculate the risk of infection in sexual partners of the index patient. The observed
levels of concordant infections suggest a lower risk of transmission of chlamydia than of gonorrhoea.
We then calculated the relative risk of being infected with one organism in partners who were infected
with the other organism, compared with those who were not infected with the other organism (Table 13).
There was statistical evidence that the risk of gonorrhoea infection was higher in partners who were
chlamydia positive than those who were chlamydia negative in both women and men. The relative risk of
chlamydia infection in partners who were gonorrhoea positive compared with those who were gonorrhoea
negative was of a similar magnitude, but CIs included 1. These data are consistent with the hypothesisTABLE 13 Relative risk of having chlamydia/gonorrhoea in partners who are gonorrhoea/chlamydia positive
compared with those who are gonorrhoea/chlamydia negative
Having gonorrhoea in partners who are chlamydia positive compared with those who are chlamydia negative
Gonorrhoea positive, n Gonorrhoea negative, n Relative risk (95% CI)
Female partner of gonorrhoea-positive male index case
Chlamydia positive 38 8 1.27 (1.02 to 1.58)
Chlamydia negative 43 23
Male partner of gonorrhoea-positive female index case
Chlamydia positive 18 1 1.28 (1.07 to 1.52)
Chlamydia negative 52 18
Having chlamydia in partners who are gonorrhoea positive compared with those who are gonorrhoea negative
Chlamydia positive, n Chlamydia negative, n Relative risk (95% CI)
Female partner of chlamydia-positive index case
Gonorrhoea positive 21 19 1.18 (0.83 to 1.66)
Gonorrhoea negative 63 78
Male partner of chlamydia-positive index case
Gonorrhoea positive 13 33 1.38 (0.73 to 2.60)
Gonorrhoea negative 16 62
Numbers are calculated from the data published in Lycke et al.6
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50that the transmission of one infection is increased when the other infection is already present in the
susceptible person (increased susceptibility), although there might be other explanations that could give
rise to the observed pattern of co-infection.
Transmission dynamic model
We describe the transmission of chlamydia and gonorrhoea in a heterosexual population of 16- to
29-year-old women and men in Britain. Gonorrhoea transmission is disproportionately concentrated in a
small group of individuals with high levels of sexual partner change. Therefore, we cannot assume a
homogeneous population as in the previous chapters where we considered chlamydia transmission alone.
Instead, we follow the structure from Hethcote and Yorke109 and Garnett et al.37 and assume four different
sexual activity classes. The sexual partner change rates for each risk class (ci) are parameterised with sexual
behaviour data from Natsal-2. Maximum likelihood estimation is used to obtain the proportion of
individuals in each sexual activity class, Ni, together with the corresponding partner change rate, ci.92 Data
for women and men are pooled (i.e. we assume the same sexual behaviour for both sexes). Assuming that
the realised number of heterosexual partners during 1 year for individuals of risk class i follows a Poisson
distribution with mean ci, the proportion of individuals in each sexual activity class, starting from the
lowest activity, is 80.5%, 17.8%, 1.5% and 0.2%. The corresponding heterosexual partner change rates
are 0.3, 2.35, 10.17 and 34.78 per year. Sexual mixing between individuals of different sexual activity
classes can be varied between proportionate and fully assortative through a mixing coefﬁcient, ε.37
We chose ε = 0.1, i.e. close to proportionate (random) mixing, which ensures that the pattern of
chlamydia and gonorrhoea infections among individuals with different number of sex partners matches
observed data.37,48
The infectious duration of gonorrhoea has not been established. Many gonorrhoea infections are
symptomatic and short, but some last for several months.37 We made the simplifying assumption that the
average duration of gonorrhoea infection in women and men is 3 months. Whether or not spontaneous
resolution of chlamydia infection is followed by a period of immunity is a matter of debate.96,110 Assuming
no development of immunity resulted in unrealistically high chlamydia prevalence rates in individuals with
high sexual activity. Since this is not consistent with population-based data from Natsal-2,48,77 we assumed
that spontaneous clearance of chlamydia infection is followed by an average duration of immunity of
1 year. This resulted in a distribution of chlamydia infections that closely resembles the one presented in
Figure 12. We also assume 1 month of immunity after spontaneous resolution of gonorrhoea infection.
Per-partnership transmission probabilities are adjusted so that the endemic prevalence of chlamydia and
gonorrhoea are 3%77 and 0.5%,26 respectively. The prevalence of gonorrhoea was estimated from the US
National Health and Nutrition Examination Survey since there are no national population-based data for
the UK. In the model variant where we assume that the two infections transmit independently, the
per-partnership transmission probabilities for chlamydia and gonorrhoea are 38% and 62.5%, respectively.
The assumed transmission probability for chlamydia is lower than that estimated in Modelling the
transmission dynamics of C. trachomatis because we explicitly include individuals with high levels of sexual
partner change, who are expected to have lower numbers of sex acts per partnership. In the ‘interaction
model’ variant, the transmission probabilities for one organism are increased by a certain factor if the other
organism is present in the person who transmits (transmissibility), or in the person who is at risk of the
infection (susceptibility). The baseline transmission probabilities are then reduced slightly so that all models
result in the same endemic prevalence of chlamydia and gonorrhoea.
Women and men stay in the population after 14 years on average and, on leaving, are replaced by new
individuals. The newly arriving individuals in the two lowest risk classes are considered to start their
sexually active life on entry to the model and are fully susceptible to both infections. In contrast, the newly
arriving individuals in the two highest risk classes (1.7% of all individuals entering the population) are
considered to represent imported cases who are co-infected with chlamydia and gonorrhoea. This
assumption is necessary to prevent permanent extinction of gonorrhoea infections in the stochastic,
individual-based implementation of the model.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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population-based modelling approach does not, however, allow partner notiﬁcation to be implemented
or the stochastic effects of outbreaks to be investigated. We therefore implemented the full model
structure in an individual-based modelling framework using Rstisim (see Individual- and population-level
effects of partner notification for C. trachomatis), which allows individuals and partnerships be tracked
so that partner notiﬁcation can be implemented as an integral part of managing chlamydia and
gonorrhoea infections.Reinfection model
The probability of reinfection of index cases by their (as-yet) untreated partners can be calculated
as follows:
pr = pp  pi  f  β /ðf  β þ δþ σÞ, ð2Þ
where pp is the probability that the index case is in an ongoing sexual partnership and pi is the probability
that the partner is infected. After the index case is successfully treated, she or he will engage in new sex
acts with a frequency f where the infection can transmit at a per-sex act transmission probability β.
Transmission can occur until the partner is in treatment after an average delay of 1/δ or the sexual
partnership dissolves at rate σ.Results
Co-infection with chlamydia and gonorrhoea
Figure 19 shows the predicted percentages of the model population infected with chlamydia and
gonorrhoea. If chlamydia and gonorrhoea transmit independently (0% increase in susceptibility and
transmissibility), 25.2% of those infected with gonorrhoea are also infected with chlamydia and the
prevalence of gonorrhoea in those infected with chlamydia is 4.2%. These percentages are lower than
those observed in the empirical studies.26,27 The rates of co-infection increase, particularly for co-infection
with chlamydia in those who are infected with gonorrhoea, when we increase the susceptibility and
transmissibility in the model. If the risk of transmitting and acquiring one infection when the other
infection is also present is increased by 50%, the predicted co-infection rate increases to 36.8% and
6.2%, respectively, and are more consistent with the observed data.26,27
We consider two scenarios for investigating the effects of cotreatment for chlamydia and gonorrhoea:
a scenario with no interaction between the two infections and a scenario in which the presence of the
other organism enhances the transmissibility and the susceptibility of an infection by 50%.Increase in susceptibility and transmissibility (%)
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FIGURE 19 Rates of co-infection with chlamydia and gonorrhoea. Increasing the susceptibility and transmissibility of
one organism if the other organism is present results in an increase in co-infection rates, particularly the rate of
chlamydia positivity in those who are infected with gonorrhoea.
51
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Althaus et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TRANSMISSION MODELLING AND THE IMPACT OF PARTNER NOTIFICATION
52Screening and partner notification for chlamydia and gonorrhoea
We investigated the effects of testing and treating index patients and their partners for chlamydia and
gonorrhoea (Table 14). Partner notiﬁcation takes place as an integral part of a screening strategy, which
detects index patients. The combined intervention results in a reduction in the prevalence of chlamydia
and gonorrhoea. The new steady-state prevalence is usually reached about 5 years after starting
the intervention.
The probability of successful treatment is estimated as the product of antibiotic treatment efﬁcacy and the
probability that the patient becomes reinfected by an untreated partner. APT is assumed to increase the
probability of successful treatment by increasing the probability that the partner receives treatment,
reducing the time to treatment of the partner and reducing the risk of reinfection in the index case and
partner. Scenarios 1 and 2 (see Table 14) involve screening for chlamydia only with the addition of
standard patient referral (scenario 1) or APT (scenario 2). In scenarios 3 (routine testing of partners for
chlamydia and gonorrhoea) and 4 (APT for chlamydia and gonorrhoea), all individuals who receive
screening are tested for chlamydia and gonorrhoea and, if positive, treated. If the test result yields at least
one positive test, the most recent partners are also treated for chlamydia and gonorrhoea.
Figures 20a–d show the effects of the scenarios in the models with and without interactions and in the
population overall and those in the highest risk class. With a screening interval of 5 years (screening rate
0.2 per year), scenario 1 (screening plus standard patient referral) can reduce the prevalence of chlamydia
in the general population by about one-third (see Figure 20a). This is consistent with the expected effect of
chlamydia screening (see Modelling the transmission dynamics of C. trachomatis and Individual- and
population-level effects of partner notification for C. trachomatis). Scenario 2 (screening plus APT) results
in slightly lower chlamydia prevalence than scenario 1. Interestingly, in the model where the infections
co-interact, we observe a small reduction in gonorrhoea prevalence, although treatment (with or without
testing) is performed only for chlamydia (see Figure 20c and d). Hence, interactions between chlamydia
and gonorrhoea could potentially help to indirectly reduce the prevalence of gonorrhoea in a population
that is tested and treated for chlamydia.
Routine testing for chlamydia and gonorrhoea (scenarios 3 and 4) further reduces the prevalence of
gonorrhoea (see Figure 20c and d). Cotesting for gonorrhoea has a negligible impact on reducing the
prevalence of chlamydia in the model where we assume interactions between the two infections (see
Figure 20a and b), due to the low prevalence of gonorrhoea. APT (scenarios 2 and 4) always results in
lower prevalence rates of chlamydia and gonorrhoea compared with standard patient referral (scenarios 1
and 3), particularly for chlamydia but also for gonorrhoea in the case where the two infections interact.
This exempliﬁes the improved clinical effectiveness of APT over standard patient referral for bacterial STIs.
Figure 21 shows the results of the same scenarios, assuming that individuals receive screening at intervals
of 2 years. The pattern of results is the same but effects are stronger.TABLE 14 Testing and treatment strategies for index cases and their most recent partners
Scenario
Treated successfully (%)
Index patient Most recent partner
Chlamydia Gonorrhoea Chlamydia Gonorrhoea
1: Current practice for chlamydia 70 0 30 0
2: APT for chlamydia 90 0 60 0
3: Routine testing for chlamydia and gonorrhoea 70 70 30 30
4: APT for chlamydia and gonorrhoea 90 90 60 60
The percentages represent the probabilities of successful treatment. Note that this is a combination of the treatment in
index cases and the possibility of reinfection by their partners.
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FIGURE 20 Effects of screening and partner notification for chlamydia (a and b) and gonorrhoea (c and d), assuming
that the average screening interval for all individuals is 5 years. The prevalence rates of four different scenarios are
contrasted with those in absence of any intervention. Strategy 1, routine testing for chlamydia; strategy 2, APT for
chlamydia; strategy 3, routine testing for chlamydia and gonorrhoea; strategy 4, APT for chlamydia and gonorrhoea.
Overall (a and c): general population of 16- to 29-year-olds. High risk (b and d): individuals with 10 new heterosexual
partners per year (1.5% of the general population).
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FIGURE 21 Effects of screening and partner notification for chlamydia (a and b) and gonorrhoea (c and d), assuming
that the average screening interval for all individuals is 2 years. The prevalence rates of four different scenarios are
contrasted with those in absence of any intervention. Strategy 1, routine testing for chlamydia; strategy 2, APT for
chlamydia; strategy 3, routine testing for chlamydia and gonorrhoea; strategy 4, APT for chlamydia and gonorrhoea.
Overall (a and c): general population of 16- to 29-year-olds. High risk (b and d): individuals with 10 new heterosexual
partners per year (1.5% of the general population).
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DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2It is surprising that the prevalence of gonorrhoea cannot be lowered through widespread screening at
intervals of 2 years (screening rate 0.5 per year). This goes counter to the usual observation that for STIs
with very low endemic prevalence rates, only minor interventions can result in extinction. In our model,
however, about one imported case per month is co-infected with chlamydia and gonorrhoea (in a total
population of 10,000 individuals), which keeps gonorrhoea infections at an endemic level.
Gonorrhoea prevalence can be subjected to strong ﬂuctuations with occasional outbreaks in a population.
Partner notiﬁcation strategies that provide treatment without STI testing might facilitate outbreaks. We
calculated the yearly prevalence of gonorrhoea in the total population, and deﬁned an outbreak when the
prevalence exceeded 0.5%, which was the baseline prevalence in the model population (Figure 22). The
frequency of outbreaks increased very slightly, compared with no intervention, only in the model that
assumed no interaction between infections. In the model that incorporated an interaction, both APT and
standard partner notiﬁcation strategies resulted in a reduced frequency of gonorrhoea outbreaks. The
greatest reduction in gonorrhoea outbreaks was found in the model in which the two infections interact
and in which individuals are tested for chlamydia and gonorrhoea using APT (scenario 4).
Reinfection of index cases
The transmission dynamic model assumes that sexual partnerships are instantaneous events. Therefore, we
cannot directly investigate the outcome of reinfection of treated index cases by their untreated partners.
Instead, we use a simpliﬁed model that investigates rates of reinfection with chlamydia and gonorrhoeaScenario
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FIGURE 22 Outbreak frequency of gonorrhoea. (a) 5-year screening interval; (b) 2-year screening interval.
Gonorrhoea prevalence is measured once a year and an outbreak is defined when the observed annual prevalence in
the general population exceeds 0.5%. The prevalence rates of four different scenarios are contrasted to those in
absence of any intervention. Strategy 1, routine testing for chlamydia; strategy 2, APT for chlamydia; strategy 3,
routine testing for chlamydia and gonorrhoea; strategy 4, APT for chlamydia and gonorrhoea. Overall: general
population of 16- to 29-year-olds. High risk: individuals with 10 new heterosexual partners per year (1.5% of the
general population).
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56only. We generated 1000 parameter sets by randomly drawing from the following distributions: the
probability that index cases are in an ongoing partnership is uniformly distributed between 0 and 1;
the probability that partners are infected with chlamydia is uniformly distributed between 60% and 70%;7
the probability that partners are infected with gonorrhoea is uniformly distributed between 70% and
80%;6 the frequency of sex acts is uniformly distributed between once a day and once a week; the per-sex
act transmission probability is uniformly distributed between 6% and 16.7%;48 the per-sex act transmission
probability for gonorrhoea is assumed to be twice that of chlamydia; and the duration of sexual
partnerships is uniformly distributed between 1 week and 6 months.48
We calculated the reinfection rates for chlamydia and gonorrhoea for different delays of partner referral
(Figure 23). Reducing the delay between index case and partner treatment from 14 days111 to 1 or 3 days20
substantially reduces the rates of reinfection. For chlamydia, the median reinfection rates from the 1000
parameter combinations are 7.6%, 2.3% and 0.8% for decreasing delays of partner referral. For
gonorrhoea, the corresponding rates are 14.6%, 5.4% and 2.1%.
Discussion
There is some evidence from epidemiological and animal studies suggesting an interaction between
chlamydia and gonorrhoea infections.6,107,108 Observed co-infection rates cannot be obtained in
mathematical models that assume that gonorrhoea and chlamydia are transmitted independently. The
results from a model show that a potential interaction between the two organisms can inﬂuence the effect
of testing and treating index cases and their partners for chlamydia and gonorrhoea. Overall, we found
that cotesting and cotreatment for gonorrhoea can lower its prevalence in the general population as
well as in individuals with high sexual activity. However, the level of reduction is not as pronounced as
for chlamydia, which is partly explained by the ongoing import of new infected cases. In terms of
partner notiﬁcation, APT reduced infection prevalence more than standard patient referral. In addition,Partner notification delay (days)
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FIGURE 23 Reinfection rates of treated index cases by their untreated partners. (a) Chlamydia; and (b) gonorrhoea.
The figures show box plots of 1000 different parameter combinations.
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untreated partners.
To our knowledge, this study presents the ﬁrst mathematical model of chlamydia and gonorrhoea
infection that describes the observed co-infection rates. While biological co-interactions between
chlamydia and gonorrhoea are a plausible mechanism, there might be other explanations that could
explain the high rates of co-infection. For example, the speciﬁc group of individuals who are co-infected
with chlamydia and gonorrhoea could be a subpopulation that has both frequent sex partner change rates
and low usage of condoms. Chlamydia infections might be able to reach a very high prevalence in this
kind of population. Also, highly assortative mixing by certain behavioural or demographic characteristics
could increase rates of co-infection. These and other mechanisms should be further investigated with
mathematical models to better understand the observed co-infection rates of chlamydia and gonorrhoea
but also of other STIs such as syphilis and HIV.
We kept our modelling approach deliberately simple so that we could study general principles of the effect
of interactions between chlamydia and gonorrhoea on the impact of interventions. First, we considered a
general heterosexual population of 16- to 29-year-olds. Gonorrhoea infections and co-infection rates are
higher in men who have sex with men than in the general heterosexual population, but should be studied
in a separate model. Second, we ignored age structure in the level of sexual activity, but we believe that
the four risk groups describe the heterogeneity in sexual activity and the transmission of chlamydia and
gonorrhoea reasonably well. The model could be developed further by adding different ethnic or
social groups among whom chlamydia and gonorrhoea rates vary.43 Third, we ignored differences in
disease-speciﬁc parameters among women and men; biological interactions between the two organisms
could differ between the two sexes. These additional complexities will be important to consider in future
modelling studies of the nature of chlamydia and gonorrhoea co-infection.
The ﬁndings from this study suggest that, if there is a strong biological interaction between chlamydia and
gonorrhoea, treating chlamydia infections should help to reduce the overall prevalence of gonorrhoea.
Although an association between trends of chlamydia prevalence and gonorrhoea prevalence has not
been observed empirically, it might be possible to investigate whether or not gonorrhoea incidence rates
have declined in populations that were regularly tested for chlamydia. The model results suggest that APT
should be favoured over standard patient referral because it results in lower infection prevalence and can
substantially reduce reinfection of index cases from their untreated partners. However, future work is
required to obtain better estimates of the probabilities of successful treatment of index cases and their
partners, given a speciﬁc partner notiﬁcation technology. Furthermore, the risks of not testing for HIV in
partners treated via APT should be explored in modelling studies. Finally, we found that a strategy of dual
testing and treating in the general heterosexual population had a modest impact on reducing the
prevalence of gonorrhoea. The model did not investigate the numbers of false positive test results,
however, which might counteract the beneﬁts, particularly in low prevalence settings.57
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notiﬁcation
The previous chapters present studies about the clinical effectiveness of partner notiﬁcation technologies.In this chapter we present two studies examining different aspects about the economic evaluation of
partner notiﬁcation.Outcomes for the economic evaluation of partner notiﬁcation
technologies: systematic review
Introduction
This section outlines the challenges of measuring the cost-effectiveness of partner notiﬁcation using the
outcome of cost per QALY. In a systematic review of economic evaluations of interventions to prevent
chlamydia infections,112 we identiﬁed three studies published up to 2004 that evaluated partner
notiﬁcation. One presented the outcome as major outcomes averted113 and two reported short-term
outcomes.58,114 None reported cost per QALY.Objective
To describe alternative approaches that have been used to assess and value the quality of life associated
with the reproductive sequelae of chlamydia infection in women.Methods
We conducted a systematic review of published literature. We followed a two-stage process for screening
the results of electronic database searches, as in the earlier review.112Search methods
Six electronic databases were searched from 1980 up to 31 December 2011 [EMBASE; MEDLINE; Web of
Knowledge ISI Proceedings; NHS Economic Evaluation Database (NHS EED); Database of Abstracts of
Reviews of Effects (DARE); and HTA]. We also searched the reference lists of potentially relevant papers.
Keywords included Chlamydia trachomatis, gonorrhoea, PID, cervicitis, ectopic pregnancy, economic
evaluation, cost–utility analysis, cost-effectiveness analysis and quality of life. The search strategy is
included in Appendix 3.Inclusion and exclusion criteria
Participants were men and/or women undergoing any form of intervention to prevent chlamydia. Primary
studies were those that measured HRQL for patients with chlamydia and associated sequelae, PID, ectopic
pregnancy, infertility, chronic pelvic pain and epididymitis. Papers were excluded if they were not written
in English.Selection of studies
One investigator (PA) reviewed the titles and abstracts and a subset of these were checked independently
against the inclusion criteria (TER).115 One reviewer (PA) categorised studies according to the type of
economic evaluation, based on their titles and abstracts. The full texts of potentially relevant studies
were read and those that measured HRQL for patients with chlamydia and its associated sequelae
were retained.
Data were extracted about study characteristics, study participant characteristics, health states examined,
instruments used and results.59
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60Data synthesis
Data were tabulated and the ﬁndings of individual studies compared narratively.Results
The electronic database search identiﬁed 3534 published studies. From these, 1178 studies were
duplicates. Titles and abstracts were reviewed for the remaining 2356 studies. Hand searching of
bibliographies from published literature identiﬁed one additional study. Seventeen studies were considered
potentially relevant. Of these, eight studies were excluded because they did not discuss the instruments
and techniques available for eliciting the value of health states for avoiding chlamydia. No studies were
excluded on the grounds of language. Figure 24 shows the ﬂow of papers retrieved and included.
Characteristics of included studies
The nine included publications116–124 reported on eight separate studies measuring HRQL for
chlamydia-associated sequelae in women. Ness et al.124 reported the study design for the PID Evaluation
and Clinical Health (PEACH) study, for which ﬁndings among women with and without chronic pelvic pain
were reported by Haggerty et al.117,122 There were no studies about epididymitis. There were no studies
from Europe; only one study was done outside the USA.121 Table 15 shows the characteristics of studies
and participants.
Instruments used for health-related quality-of-life measurement and health
state valuation
Several different generic multi-attribute instruments, questionnaires or parts of questionnaires were used
to measure HRQL (Table 16). Generic instruments have two components: a system to describe health or
the impact on the quality of life and an algorithm to assign values to the descriptive system.125 Health state
descriptive systems are made up of a number of multilevel dimensions that uniquely describe health
states. The scales used are transformed to scales that range from 0 to 100, with 100 denoting
optimal functioning.
For HRQL measurement, four publications from three studies used only generic instruments: the PEACH
study117,122 used the Medical Outcomes Study (MOS) Short Form questionnaire-36 items (SF-36); Smith
et al.118 used the Short Form questionnaire-12 items (SF-12); and the USA Institute of Medicine (IoM)
study116 used the Health Utilities Index Mark 2 (HUI2) instrument. Kuppermann et al.119 used a
combination of generic instruments and questionnaires in different groups enrolled in their studyTotal hits
(n = 3534)
Titles and abstracts
screened
(n = 2356)
Full text screened
(n = 17)
Data extraction
Publications (n = 9)
Studies (n = 8)
Excluded
Duplicates (n = 1178)
Excluded
Not relevant (n = 2340)
Hand-searching
included (n = 1)
Excluded
Did not meet inclusion
criteria (n = 8 )
FIGURE 24 Flow chart of included studies.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 15 Summary of study and participant characteristics
First author, year Country Perspective
Age
(years)
Participant
characteristics Number
Haggerty 2003117 USA Patient 14–37 Pelvic pain after PID
lasting ≥ 6 months
Pelvic pain, n = 202
No pelvic pain,
n = 345
Haggerty 2005122 USA Patient 14–37 PID n = 780
IoM 1999116 USA Society Not
reporteda
IoM committee
membersa
Not reporteda
Kuppermann
2007119
USA Society 31–54 Non-cancerous pelvic
problems in last 12 months
n = 1493
Pelvic pain only n = 272
Mathias 1996120 USA Patient 18–50 Pelvic pain lasting
≥ 6 months
Pelvic pain, n = 773
No pelvic pain,
n unclear
Romão 2009121 Brazil Patient 18–45 Pelvic pain ≥ 6 months
requiring treatment
Pelvic pain, n = 52
No pelvic pain,
n = 54
Smith 2008118 USA Patient > 18 History of PID PID, n = 56
No PID, n = 150
Trent 2011123 USA Society 12–19 Healthy adolescents n = 134
> 18 Parents of healthy
adolescents
n = 121
a IoM Committee Members valued health states; the number and their ages are not reported. The values were then
applied to the population estimated to be infected with chlamydia.
DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2TTABLE 16 Summary of studies assessing outcomes of chlamydia infection and selected ﬁndings
First author, year Complication Instrument Findings Comment
Haggerty 2003117 Chronic pelvic
pain after PID
SF-36 SF-36 physical health
mean 65.1 (SD 13.4)
5 days after enrolment
with PID
Mean 75.8 (SD 15.7) 32 months after PID
SF-36 mental health
mean 60.8 (SD 15.0)
5 days after enrolment
with PID
Mean 68.1 (SD 16.6) 32 months after PID
Haggerty 2005122 PID SF-36 SF-36 physical health
median 70
At baseline PID diagnosis
SF-36 mental health
median 68
IoM 1999116 PID HUI2 QALY weight
0.46–0.83
Different weights for scenarios
from inpatient treatment with
surgery to outpatient treatment
only; duration 2 days to 4 weeks
continued
61
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TABLE 16 Summary of studies assessing outcomes of chlamydia infection and selected ﬁndings (continued )
First author, year Complication Instrument Findings Comment
Chronic pelvic
pain
QALY weight 0.60 5-year lag after PID; duration
remaining lifetime
Ectopic
pregnancy
QALY weight 0.58 5-year lag after PID;
duration 4 weeks
Infertility QALY weight 0.82 5-year lag after PID; duration
remaining lifetime
Kuppermann
2007119
Pelvic pain
only
SF-36, SF-12,
questionnaire,
TTO
SF-12 physical health
mean 45 (SE 1)
Additional results presented
for groups with other causes
of non-cancerous pelvic pain
SF-12 mental health
mean 43 (SE 1)
Current health utility
0.83 (SE 0.01)
Mathia 1996120 Chronic pelvic
pain
Questionnaire General health
mean 70.5
Questionnaire based on a
component of the MOS
long form
Romão 2009121 Chronic pelvic
pain
Questionnaire Physical health median,
with anxiety 43
Additional results for social
and environmental domains
and in women with and
without depressionMedian, no anxiety 57
Psychological health
median, with anxiety 46
Median, no anxiety 71
Smith 2008118 Ectopic
pregnancy
SF-12, VAS,
TTO
With PID VAS mean
0.55 (SD 0.20)
Additional results for women
without PID, TTO in women
with and without PID for all
complications, and SF-12 in
women with and without PID
Pelvic pain With PID VAS mean
0.45 (SD 0.22)
Infertility With PID VAS mean
0.53 (SD 0.29)
Trent 2011123 Ectopic
pregnancy
VAS, TTO Adolescents VAS mean
55 (SD 25.4); parents
VAS mean 73 (SD 23.8)
Additional results for TTO
Chronic pain Adolescents VAS
mean 48 (SD 25.4);
parents VAS mean 61
(SD 23.8)
Infertility Adolescents VAS mean
59 (SD 23.6); parents
VAS mean 68 (SD 27.1)
SE, standard error; TTO, time trade-off; VAS, visual analogue scale.
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62(MOS SF-12, SF-36, MOS health distress scale, MOS sexual problems scale and a pelvic problem impact
questionnaire). Mathias et al.120 used a questionnaire including selected subscales from the MOS
quality-of-life scales and questions about pelvic pain. Ramão et al.121 administered questionnaires alone
[WHO quality-of-life score and Hospital Anxiety and Depression Scale (HADS)].
Four studies used valuation techniques to elicit health state utilities. Kupperman et al.119 used the time
trade-off (TTO) metric to value women’s current health state with non-cancerous pelvic problems;
Ramão et al.121 used visual analogue scales (VASs) to assess intensity of pelvic pain; Smith et al.118 andNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2Trent et al.123 used both VAS and TTO methods to value the same ﬁve PID-associated health states
(see Table 16).
Only one study provided QALY weights. The study was commissioned by the IoM to develop an analytical
framework for priority setting of vaccine research and development.116 To estimate utilities, the experts
incorporated quality-of-life weights from the Canadian National Population Health Survey and further
estimated utilities based on expert opinion using the HUI2126 instrument for women who experienced
chlamydia infection, its complications and the time spent in each state. The committee applied the
resulting QALY weights to the estimated the number of adults they expected to be infected with
chlamydia in that year. Of note, the HUI2 was developed to measure the global burden of childhood
cancer and further adverse events as a result of cancer and its treatment.126
Findings and assumptions about health states are not necessarily consistent between studies, especially
when study designs differ. For example, in the cross-sectional IoM study,116 expert valuations resulted in a
QALY weight of 0.60 for pelvic pain, lasting the rest of a woman’s life (see Table 16). In a cross-sectional
study, Smith et al.118 obtained similarly low utility values when asking women with and without PID to
value a hypothetical scenario of chronic pelvic pain using VAS. They also assumed that chronic pelvic pain
was a long-term health state. Haggerty et al.117 found in a longitudinal study, however, that HRQL scores
on the SF-36 improve over time in women both with and without pelvic pain after PID.
Valuations of health states also differed depending on the method used and the study population. Smith
et al.118 and Trent et al.123 both found lower utility valuations with TTO than with VAS. Trent et al.123
also found that adolescents, compared with parents, had signiﬁcantly lower mean valuations for each
health state.Discussion
This systematic review found only one study that provides QALY weights for reproductive tract
complications of chlamydia infection. No studies measuring HRQL or health state valuations among
women in the UK or in the rest of Europe were found.
The main strength of this study is the comprehensive literature search. We do not think that our search
strategy missed major studies. Nevertheless, the only study that reported QALY weights was published in a
book chapter and was identiﬁed from reference lists of other studies and not from an electronic database
search. Weaknesses of the study relate to difﬁculties in drawing conclusions from the small number of
studies retrieved.
To our knowledge, this is the ﬁrst systematic review to give a critical appraisal of methods used to elicit
HRQL information for the economic evaluation of interventions for chlamydia prevention. The studies
included in this review demonstrate many of the methodological debates about health state valuation.125
We reviewed studies that collected data from patients, healthy adults and experts. Torrance et al.127
suggest that judgements made by experts may be a starting point and are quick to collect. Experts might,
however, have different views from those of patients. A major weakness of the IoM study was the lack of
detail describing the elicitation process and the size, make-up and selection process of the expert panel,
and so the potential for bias in the results cannot be assessed. Current NICE guidelines128 state that HRQL
should be elicited directly from patients with the condition and the utilities should be based on public
preferences using the European Quality of Life-5 Dimensions.
Partner notiﬁcation works by reducing the duration of a STI, which is already a temporary health state and
might be asymptomatic. Valuing temporary health states is challenging, particularly when most HRQL
instruments have been designed to measure health states resulting from chronic or terminal diseases such
as arthritis and cancer. This review did not identify any studies explicitly valuing the temporary health state
of chlamydia infection in the absence of complications, although the two-stage approach used by Smith
et al.118 appears to have implicitly addressed this. Although STIs do cause physical and emotional damage,63
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64complications typically occur in the future and can also be temporary. Costs and beneﬁts in the future are
valued less than those occurring in the present, and so preventative interventions for curable STIs are less
likely to appear cost-effective than those for ongoing chronic conditions.
Chronic pelvic pain might be easier to assess using currently available instruments. The valuations that we
reviewed suggested a substantial detrimental impact on quality of life.116 Scenarios describing chronic
pelvic pain suggest, however, that it is usually very severe and long lasting. Evidence from longitudinal
studies117 and from TTO studies118 suggests, however, that both the duration and the severity might have
been overestimated. An additional challenge for estimating QALYs is that the fraction of chronic pelvic
pain attributable to chlamydia and other STIs is unknown.
This review has implications for future research. HRQL data for chlamydia and its complications should be
collected in the UK using appropriate instruments and study populations. Better QALY estimates for
outcomes associated with chlamydia are also needed. The methods used to derive the IoM estimates are
not transparent and do not meet current NICE guidelines. Based on the results of this systematic review, it
was not possible to draw a ﬁrm conclusion about the most appropriate techniques for measuring HRQL
and for valuing outcomes associated with chlamydia. We did not conduct a formal cost-effectiveness
evaluation of partner notiﬁcation because of the unresolved methodological challenges and the absence of
appropriate evidence.Costs and cost-effectiveness of different strategies for
chlamydia screening and partner notiﬁcation: an economic and
mathematical modelling study
Introduction
Partner notiﬁcation for chlamydia in community health service settings should take place as often as in
genitourinary medicine clinics in England because of the large number of cases diagnosed through the
NCSP. The standards for partner notiﬁcation outcomes in the NCSP are the same as in UK genitourinary
medicine clinics (see Clinical effectiveness of partner notification technologies: systematic review):
0.6 partners per index conﬁrmed treated (0.4 in inner cities).45 The number of partners treated per index,
however, has fallen from a high of > 0.55 in 2006–7 to just under 0.4 in 2010–11. There is no standard
protocol for providing partner notiﬁcation services in community settings such as general practice and
community Contraceptive And Sexual Health (CASH) services (also known as family planning clinics).
Different areas operate with very different models of partner notiﬁcation, ranging from minimal
involvement of health-care professionals to active follow-up of index cases and their partners in order to
conﬁrm that partners have been treated. Chlamydia Screening Ofﬁces (CSOs), which are part of NCSP
infrastructure in some areas, can provide more intensive support.
We have shown that chlamydia positivity rates of sexual partners of index cases with chlamydia are 5 to
10 times higher than in the general population (see Individual- and population-level effects of partner
notification for C. trachomatis). Partner notiﬁcation is therefore efﬁcient for case ﬁnding. The UK National
Audit Ofﬁce published estimates of the cost of a chlamydia-screening test in 2009, using NCSP data from
PCTs; these were updated in the chlamydia cost-guidance initiative. The National Audit Ofﬁce reported an
average cost per screen of £45 in 2009, although a wide range of costs was reported in different PCTs.129
There were no published data on the cost of partner notiﬁcation.
The coverage of chlamydia screening in all settings in 2011–12 was > 30% in women in all PCTs but
< 20% in men.130 Improving overall screening coverage will therefore depend on increasing the percentage
of young men being screened. Given the renewed focus of the NCSP on effective management of positive
individuals and their partners, monitored by the diagnostic rate indicator,130 information about the relative
costs and cost-effectiveness of expanding screening coverage and partner notiﬁcation services in the NCSP
is needed.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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To improve estimates of the relative costs of opportunistic chlamydia screening and partner notiﬁcation in
the context of the English NCSP.Methods
We used a simple spreadsheet model to investigate the costs of screening and partner notiﬁcation for
chlamydia. The spreadsheet was developed to help local areas explore their own situation within the
context of the national picture and help them plan service provision for chlamydia screening and partner
notiﬁcation activities, based on NCSP data for 2008–9.31 The model is freely available (www.bmj.com/
content/342/bmj.c7250?tab=related#datasupp). The spreadsheet model 2008–9 estimates cost per
individual tested; cost per positive diagnosis; total cost of screening; number screened; number infected;
and sex ratio of those tested and treated.
For this project, we updated the spreadsheet using NCSP data for 2010–11. We then examined a range of
scenarios, based on parameter estimates derived from other studies in this project (see Partner notification
outcomes for chlamydia in UK genitourinary medicine clinics; Estimating the likely public health impact of
partner notification for a clinical service: an evidence-based algorithm; and Modelling the transmission
dynamics of C. trachomatis). For each scenario we compared the cost-effectiveness of two interventions
using the cost per positive chlamydia case diagnosed: increased partner notiﬁcation efﬁcacy and increased
coverage of primary chlamydia screening in men.Summary of methods to estimate partner notification costs for
programme areas
The costs of partner notiﬁcation for chlamydia were estimated from an analysis of data collected for the
costing guidance initiative of the NCSP.131 In brief, staff from CSO teams and NCSP service providers in
seven PCTs in England took part in semi-structured interviews in 2008–9 and provided data about partner
notiﬁcation outcomes in their areas. Three of these areas were selected as reﬂecting partner notiﬁcation
activities at low, medium and high intensity of clinical effort. Where data were missing or unavailable,
assumptions were based on feedback from staff. In the modelled settings, partner notiﬁcation was
delivered by the co-ordinating CSO team and by the individual screening/treatment venues.
Costs from both sites were estimated and included in the model. To capture the costs of delivering partner
notiﬁcation in genitourinary medicine clinics (in practice, many positive clients were referred to for
treatment and partner notiﬁcation), a proportion of the national genitourinary medicine tariff was taken
(estimated to be 33% of the treatment visit).131 This was also done for general practice and pharmacy
locally enhanced service payments if they were explicitly used for treatment as per their agreement. If a
screening test was delivered through a CASH service, this was based on the block contract. National costs
of delivering screening (marketing, co-ordination, etc.) were excluded.
The time taken for particular activities included direct and indirect clinical time (i.e. cost per minute)
multiplied by the number of minutes for a particular activity. Consumable unit costs were also included
(telephone, fax, etc.). The indirect and overhead costs of running CSOs as part of local NCSP infrastructure
were also included in the total costs. Costs were estimated from the health-care provider perspective.
The model uses a bottom-up approach to estimate the total cost of screening and partner notiﬁcation
activities. The costs for four steps were estimated for CSO involvement: initial contact with positive index
case; provider referral; partners calling the CSO; and following up index cases and partners and for
involvement of the screening venue. The costs are given in Table 17. The cost of partner notiﬁcation per
index case in the high intensity setting was highest (£27) and was applied in all scenarios as a maximum.
Our deﬁnition of effective partner notiﬁcation is the number of partners appropriately treated (i.e. treated
presumptively, or tested negative, or known to have been treated already) per index case. We chose this
deﬁnition to match the NCSP deﬁnition as closely as possible. The partner notiﬁcation technologies used in65
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TABLE 17 Cost of partner notiﬁcation activity for chlamydia in three modelled programme areas of NCSP in
England. Costs in GBP (£), 2008–9
Low intensity Medium intensity High intensity
Cost
(£)
Proportion of
positives (%)
Cost
(£)
Proportion of
positives (%)
Cost
(£)
Proportion of
positives (%)
CSO
Initial contact with
positive index client
2.76 100 2.16 100 3.17 100
Provider referral NA NA 16.64 4 19.73 5
Partners call in NA NA 12.67 10 NA NA
Follow-up positives NA NA NA NA 7.85 100
Follow-up partners NA NA NA NA 27.37 5
Other sites
CASH 4.67 75 9.62 30 10.84 24
General practice 10.42 3 6.94 5 6.94 9
Pharmacy NA NA 2.50 1 NA 2
Genitourinary medicine 45.67 5 45.67 1 45.67 14
Brook young people’s clinics NA NA 15.85 33 11.56 36
Othera NA 4 NA NA NA 11
No partner notiﬁcation NA 13 NA 30 NA 4
Total cost per partner
per index case
9.01 12.90 26.96b
GBP, Great British Pounds; NA, not applicable.
a Although there was activity through other channels, there were no costs associated with it.
b If 100% provider referral and follow-up of partners is assumed for the high-intensity scenario, the estimated cost of
partner notiﬁcation per positive index increases to £71.70.
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66practice were a mixture of patient referral, enhanced patient referral and provider referral, but the speciﬁc
arrangements varied between clinics.Summary of results 2008–9
The published paper presented data for 2008–9.31 In 2008–9, the cost of screening was estimated at
about £46.3M in total, and £506 per infection treated. The model results suggest that increasing partner
notiﬁcation efﬁcacy from the baseline 0.4 partners per index case to 0.8 partners would cost £3.3M at a
cost per infection diagnosed of £449. In contrast, increasing male screening coverage from the baseline
value of 8% to 24% (to match female coverage) would cost an extra £22.9M and increase the cost per
infection treated to £528. Increasing screening coverage to 24% in men would cost over six times as much
as increasing partner notiﬁcation to 0.8 but treat only twice as many additional infections.Updated data for costing tool
The costing tool was updated to include a calculation of overall coverage of screening and the diagnosis
rate per 100,000 target population. This is a new indicator, developed at the Health Protection Agency
(now Public Health England) for monitoring NCSP performance, and is likely to become one of the
quality outcome indicators. The diagnosis rate is calculated as (number of diagnoses/total target
population) × 100,000; overall coverage is calculated as number of screening tests done/total
target population.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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In 2010–11 the reported coverage of chlamydia screening in NCSP settings in England was 25% (35%
including tests in genitourinary medicine clinics) compared with 16% in 2008–9 (Table 18).132 The
percentage of positive tests in all non-genitourinary medicine clinic settings was 7.3% in 2008–9 in both
sexes.133 The chlamydia positivity in 2010–11 was 4.6% in men (PCT range 1.5–13.1%) and 5.6% in
women (PCT range 2.8–9.4%). The number of partners notiﬁed per index was 0.4 and 89% of positive
index cases received documented treatment.
Table 18 shows the baseline costs, estimated in 2008–9, applied to NCSP coverage and positivity data in
2010–11, assuming 100% index treatment. The total estimated cost would have been £696 per infection
treated (including those treated through partner notiﬁcation). This rise in the cost per positive reﬂects the
higher number of tests but lower positivity observed in 2010–11 compared with 2008–9. We optimistically
assumed that all index cases were treated, even if they were not documented; however, if the reported
failure of treatment in 11% of cases represents positives who did not receive their results and treatment,
this means that almost 10,000 index cases (plus their partners) did not receive treatment and the screening
effort was totally wasted. This would increase the cost per positive identiﬁed to £782.Scenario analysis
Table 19 shows additional scenarios, using a range of estimates for partner notiﬁcation efﬁcacy (number of
partners treated per index; values used 0.4, 0.6, 0.9, 1.2); percentage of partners infected (0.5, 0.65, 0.7);ABLE 18 Updated baseline model inputs and outputs for screening and partner notiﬁcation NCSP 2010–11.
dapted from BMJ, Costs and cost effectiveness of different strategies for chlamydia screening and partner
otiﬁcation: an economic and mathematical modelling study, Turner K, Adams E, Grant A, Macleod J, Bell G,
larke J, et al., vol. 342, pp. c7250, 2011, with permission from BMJ Publishing Group Limited31
Assumptions 2010–11a Women Men Total
Target population (aged 15–24 years) 3,442,300 3,442,300 6,884,600
Coverage 33% 17% 25%
Number screened 1,129,035 597,465 1,726,500
Number diagnosed 63,226 27,483 90,709
Number identiﬁed by partner notiﬁcation who receive
appropriate care (partner notiﬁcation efﬁcacy 0.4)
10,993 25,290 36,283
Number identiﬁed by partner notiﬁcation who are infected 7146 16,439 23,584
Cost of screening and partner notiﬁcation combined, £M 50.5 29.0 79.5
Cost per positive, £ 718.1 659.4 695.6
Positivity (combined partner notiﬁcation and screen) 6.2% 7.1% 6.5%
Proportion of prevalent infections treated (assuming 5%
prevalence in 15- to 24-year-olds)
– – 33.2%
Percentage of total budget used for partner notiﬁcation – – 5.2%
Ratio women to men tested – – 1.83
Ratio women to men infected and treated – – 1.60
a Assumptions about NCSP coverage, positivity and partner notiﬁcation outcomes based on NHS Vital Signs
2010–11 data.132
Baseline model assumptions: partner notiﬁcation efﬁcacy 0.4 (median NCSP value); cost of screen £43.65 (adjusted to
remove partner notiﬁcation costs); cost of partner notiﬁcation £114. Positivity 5.6% in women and 4.6% in men screened.
Positivity 65% in partners of positive index cases (men and women). Assumed 100% index treatment.T
A
n
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and screening coverage [proportion of target population screened in year (men 8%, women 24%; both
TABLE 19 Scenario analyses to investigate effects of partner notiﬁcation efﬁcacy, partner positivity and screening
coverage on the cost per positive of screening
Scenario number
Parameter
combination 1 2 3 4 5 6 7 8 9
PN efﬁcacya 1.2 0.9 0.9 0.6 0.4 0.4 0.6 0.6 0.4
Partner positivity 50% 50% 65% 65% 65% 70% 70% 70% 70%
Screening coverage 20% 20% 20% 20% 20% 20% 20% 16%b 30%
Total cases identiﬁed
through PN
92,273 69,205 69,205 46,137 30,758 30,758 46,137 36,582 46,137
Total infected and
treated (screening
plus PN)
123,031 111,497 121,877 106,883 96,887 98,425 109,190 86,576 147,637
Total cost of
screening, £M
36.9 36.9 36.9 36.9 36.9 36.9 36.9 29.5 55.4
Total cost of PN, £M 10.5 7.9 7.9 5.3 3.5 3.5 5.3 4.2 5.3
Total cost of PN plus
screening, £M
47.4 44.8 44.8 42.2 40.4 40.4 42.3 33.7 60.6
Cost per infection
treated, £
385.43 401.71 367.50 394.45 417.05 410.53 386.11 389.14 410.53
Proportion of
prevalent infections
treated
40.0% 36.3% 39.6% 34.8% 31.5% 32.0% 35.5% 28.2% 48.0%
Diagnosis rate
(screening only)
1250 1250 1250 1250 1250 1250 1250 991 1875
Diagnosis rate
(PN plus screening)
2000 1813 1982 1738 1575 1600 1775 1408 2401
PN, partner notiﬁcation.
a Partners treated per index case.
b Per cent overall (8% in men, 24% in women).
Baseline model assumptions: PN efﬁcacy 0.4 (median NCSP value); cost of screen £45; cost of partner notiﬁcation £114.
Positivity 7.7% in women and 6.4% in men screened (2008–9 data). Positivity 65% in partners of positive index cases
(men and women).
ECONOMIC EVALUATION OF PARTNER NOTIFICATION
6820%, both 30%)].
Any combination of parameters can be fed into the model: a small selection of parameter combinations
are presented here as examples. In scenarios 1–7 the underlying screening coverage remains constant, and
as the partner notiﬁcation efﬁcacy or partner positivity increase, the total number of infections treated
increases. Hence, the total diagnosis rate increases and the cost per positive decreases. Increasing either
partner notiﬁcation efﬁcacy or partner positivity reduces the cost per positive case identiﬁed. As partner
positivity has been shown in modelling studies to be insensitive to the underlying prevalence, efforts to
improve partner notiﬁcation efﬁcacy are likely to result in greater cost-effectiveness (i.e. reduced cost per
positive case identiﬁed regardless of other infection dynamics).
In general this model suggests that it is more cost-efﬁcient to increase partner notiﬁcation for chlamydia
positive patients rather than screening greater numbers of low-risk individuals. For example, increasing theNIHR Journals Library www.journalslibrary.nihr.ac.uk
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overall diagnosis rate from 1575 to 1982: a 26% increase.Discussion
The spreadsheet model suggests that increasing the efﬁcacy of partner notiﬁcation costs less per new
positive case diagnosed than increasing the coverage of chlamydia screening in men or in both sexes. The
conclusions are unchanged when using updated data from the NCSP for 2010–11 and applying a range of
parameter estimates for different components of the model.
A limitation of this simple static model is that it is not possible to estimate long-term cost-effectiveness
within this model framework; that would require a transmission dynamic model. We took a conservative
approach to determining the relative cost-effectiveness of partner notiﬁcation by using the highest
estimated cost of providing partner notiﬁcation services. We also intentionally excluded the effects of
partner notiﬁcation on preventing reinfection in treated index cases. Including lower costs of partner
notiﬁcation and the costs averted by preventing reinfection would make partner notiﬁcation more cost-
effective. We took the cost perspective of the health service and restricted ourselves to consideration of
the costs of screening and partner notiﬁcation, and excluded patient costs, the costs of reinfection and the
cost of complications arising from the initial infection.
Of note, as long as the positivity of those screened opportunistically remains proportionately much lower
than that of partners of infected persons (e.g. ∼5% screen positivity vs. ∼30–60% partner positivity),
investing in effective partner notiﬁcation is a good use of resources. A modelling study has shown that the
proportion of partners of an index case who are infected with chlamydia is consistently about 30%. This
proportion is insensitive to the underlying population or network prevalence. In contrast, the positivity in
those screened is sensitive to the underlying prevalence in the population, changing in line with changes
to underlying prevalence.
As the number of index cases is small compared with the number screened, the cost of partner notiﬁcation
is a fraction of the total cost of screening. This remains true even if we make pessimistic assumptions
about the cost of partner notiﬁcation. In fact, partner notiﬁcation can probably be done effectively at very
low cost if most notiﬁcations are managed through patient referral (with appropriate motivation and
support) plus effective use of web and text-messaging technologies to provide results and information to
patients and their partners as well as efﬁcient monitoring and follow-up of outcomes.
There are, however, implications and challenges for services implementing the NCSP. There can be
confusion about the deﬁnition of partner notiﬁcation outcome measures and denominator populations.
Better information and support in providing these data would improve the quality of monitoring outcomes
of partner notiﬁcation in the NCSP.
In Chapter 3 (see Individual- and population-level effects of partner notification for C. trachomatis), we
showed that the most recent partner is the most likely to be infected and the probability declines with
time since end of partnership. In addition, we have shown that infected casual or irregular partners are
more likely to transmit the infection to other people (see Chapter 2, Estimating the likely public health
impact of partner notification for a clinical service: an evidence-based algorithm).9 Therefore, even if
beneﬁt to the index case of treating past partners is limited, the wider population gains more beneﬁt. In
this model, we do not distinguish between types of partnership, but it seems likely that increasing the
effectiveness of partner notiﬁcation will result in a reduction in partner positivity as more non-regular
partners are included.
Improving the diagnosis rate will be a key indicator of programme performance and monitoring. We
demonstrate that signiﬁcant improvements can be made to this outcome measure through improved case
management and partner management.69
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This monograph presents the results of systematic reviews, secondary data analysis, and static anddynamic modelling studies, which address different aspects of the clinical effectiveness and cost-
effectiveness of traditional and new partner notiﬁcation technologies for curable STIs. Here we summarise
and synthesise the ﬁndings of these studies and give recommendations for future research.Summary of ﬁndingsA systematic review and meta-analysis of randomised controlled trials of the effectiveness of different
partner notiﬁcation technologies (see Chapter 2, Clinical effectiveness of partner notification technologies:
systematic review) provide strong evidence that EPT is more effective than simple patient referral in
reducing reinfection in the index cases with curable STIs (RR 0.71, 95% CI 0.56 to 0.89) and there was no
evidence that EPT was better than enhanced patient referral (RR 0.96, 95% CI 0.60 to 1.53).44 Findings
about the effect of different technologies on intermediate outcomes of partner notiﬁcation were
inconsistent. The evidence was insufﬁcient to determine which method of enhanced patient referral was
most effective in particular settings, or to compare the impact on other outcomes including longer-term
sequelae in index patients or partners, or on population transmission. There was insufﬁcient evidence to
assess whether or not EPT has the potential unintended consequence of reducing HIV and STI testing and
counselling in partners. APT has not yet been evaluated in randomised controlled trials.
In routine practice, traditional partner notiﬁcation technologies practised in specialist genitourinary
medicine clinics result in few partners being documented as being tested and treated.45 A secondary
analysis of UK clinical audit data (see Chapter 2, Partner notification outcomes for chlamydia in UK
genitourinary medicine clinics) showed a median of 0.47 partners tested for chlamydia per index case and
0.60 partners treated per index case. Partner notiﬁcation outcomes were lower in London than elsewhere
(median number tested per index case 0.3 vs. 0.52) and in men who have sex with men compared with
heterosexual men (adjusted OR 0.34, 95% CI 0.17 to 0.68) but improved as clinic volume (numbers of
cases of chlamydia diagnosed) increased (p for trend 0.031). These levels of intermediate outcomes of
partner notiﬁcation are low, but are comparable with levels achieved in the randomised controlled trials
that we reviewed.44
In the absence of empirical data about the effects of partner notiﬁcation on preventing secondary cases of
chlamydia, we used a published algorithm,9 which we adapted using routinely available data and
parameter estimates developed for this project (see Chapter 2, Estimating the likely public health impact of
partner notification for a clinical service: an evidence-based algorithm). Two new indicators, the AROT and
its reciprocal, the NNTIT, helped to assess the public health impact of traditional partner notiﬁcation
strategies targeted at different types of sexual partnerships. The NNTIT was lower for casual than regular
partners, indicating that fewer casual than regular partners need to be traced and treated to prevent a
secondary case. Although this simple algorithm has a number of limitations, it provides a basic tool,
available online, to support public health-based decision-making at local clinic level.
In Chapter 3 (see Modelling the transmission dynamics of C. trachomatis), we reviewed uncertainties in
parameter estimates in mathematical models of C. trachomatis transmission and predictions of the impact
of screening and partner notiﬁcation interventions. We used existing data in simple deterministic models to
improve estimates of the mean duration of untreated chlamydia infection (433 days, 95% CI 420 to
447 days)46 and the per-partnership transmission probability (55.5%, per-sex act probability 9.5%).47
Detailed investigation of three individual-based models of C. trachomatis transmission showed that
differences in sexual partnership dynamics and in infection parameter estimates partly explained the
differences in model predictions of preventative interventions.4871
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72Based on our ﬁndings in Chapter 3 (see Modelling the transmission dynamics of C. trachomatis), we
developed a new individual-based model to investigate the effects of partner notiﬁcation technologies on
case ﬁnding and on population prevalence (see Individual- and population-level effects of partner
notification for C. trachomatis). The model was of a general heterosexual population with homogeneous
mixing and concurrent sexual partnerships.49 Partner notiﬁcation was examined within the context of
ongoing chlamydia screening. The model was parameterised using sexual behaviour data from Natsal-2
and calibrated to a steady state chlamydia prevalence of 3%. The model predicted that 68% of current
partners of index cases would be infected and that contact tracing periods of up to 18 months would
identify > 10% positivity in notiﬁed partners. At a chlamydia screening rate of 0.1 per year without partner
notiﬁcation, chlamydia prevalence is reduced to about 70% of the baseline value after 5 years. If each
partner is successfully treated with a probability of 50%, notiﬁcation of the current partner is sufﬁcient to
achieve most of the additional reduction (to about 60% of the baseline) in population prevalence. The
reduction in prevalence was greater at higher levels of screening uptake and partner notiﬁcation success.
Also in Chapter 3 (see The effects of traditional and new partner notification technologies for
C. trachomatis and N. gonorrhoeae), we developed a dual infection model of both C. trachomatis
infection and N. gonorrhoeae infection to investigate the consequences of different partner notiﬁcation
strategies on infection prevalence, reinfection of index cases and missed STI diagnoses. Partner notiﬁcation
strategies that give treatment for chlamydia without testing for gonorrhoea might miss cases of
gonorrhoea and lead to outbreaks in high-risk areas. Epidemiological data suggest an interaction between
chlamydia and gonorrhoea. To reproduce observed patterns of co-infection, the model had to assume that
being infected with either chlamydia or gonorrhoea increased susceptibility to the other. In the model,
cotesting and treatment reduced the prevalence of both infections. The effect of APT compared with
standard patient referral was minor in reducing the prevalence of both infections at the population level,
although in shortening the time to treatment reinfection, rates were substantially reduced. We did not
explore the impact on HIV infection.
In Chapter 4 (see Outcomes for the economic evaluation of partner notification technologies: systematic
review), we examined aspects of the economic evaluation of partner notiﬁcation. Our systematic review of
HRQL studies for chlamydia infection found few robust and validated tools. The only published QALY
estimates were judged to be of insufﬁcient quality to be used in cost-effectiveness studies of partner
notiﬁcation. Based on this ﬁnding and the challenges in demonstrating an effect of partner notiﬁcation on
reducing chlamydia prevalence or reproductive tract damage primary end points, we decided not to
evaluate cost-effectiveness using QALYs.
We measured costs of chlamydia screening and traditional partner notiﬁcation, cost per individual tested
and cost per positive diagnosis in the context of the NCSP in England (see Chapter 4, Costs and cost-
effectiveness of different strategies for chlamydia screening and partner notification: an economic and
mathematical modelling study).31 We used a static model, implemented in a simple spreadsheet, to assess
two different interventions. We found that doubling the efﬁcacy of partner notiﬁcation (from 0.4 to
0.8 partners per index case) would reduce the costs per infection diagnosed for a limited additional
investment. In contrast, increasing the screening coverage of men to the same level as for women would
require an investment of six times more money but lead to only twice as many additional infections
being treated.Synthesis of ﬁndingsPartner notiﬁcation is an integral part of the management and control of curable STIs. Randomised
controlled trials show that EPT strategies can reduce reinfection in index cases with curable STIs and there
was no statistical evidence of a difference in index case reinfection rates between EPT and enhanced
patient referral. APT has not yet been evaluated in randomised controlled trials. In a mathematical model,NIHR Journals Library www.journalslibrary.nihr.ac.uk
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substantially reduces the risk of reinfection of an index case with chlamydia or gonorrhoea.
Partner notiﬁcation is used as a method for identifying new STI cases: 60–70% of individuals attending STI
clinics as partners of index cases with chlamydia are themselves infected, and 70–80% of those attending
as partners of index cases with gonorrhoea are themselves infected. Our individual-based mathematical
model of chlamydia transmission predicted this level of chlamydia infection well. When implementing
partner notiﬁcation in the model, a look-back period of up to 18 months continued to identify sexual
partners with a > 10% probability of being infected, and so current UK guidelines with a recommended
look-back period of 6 months provide a reasonable balance of identifying new cases with the realistic
chance that they can be traced. As an addition to a population screening programme, the ﬁndings from
our static modelling of outcomes and costs suggest that partner notiﬁcation is more cost-effective, in
terms of restricted outcomes, for case ﬁnding than increasing screening coverage. Our systematic review
found insufﬁcient evidence to conduct a full cost-effectiveness analysis about QALYs for the reproductive
tract complications of chlamydia.
Partner notiﬁcation in genitourinary medicine clinics has the potential to interrupt chlamydia transmission if
efforts are directed to casual and ex-regular partners of index cases (about two-thirds of partners in our
study) who are likely to contribute to spread networks for STI transmission.5 The NNTIT, estimated using
our algorithm, is low compared with that for regular partners. These results were derived from a static
model. The beneﬁts of this model are that the data required to populate the spreadsheet can be easily
obtained and entered. The disadvantage is that there are strong assumptions about the numbers of
transmissions to secondary cases, which can only be fully taken into account in a dynamic model. The
effect on prevalence in the general population, however, is likely to be modest. In our individual-based
model, treating the current partner reduces chlamydia prevalence but treating previous partners does not
reduce population prevalence further in the presence of ongoing chlamydia screening at a rate of at least
0.1 per year. This ﬁnding reﬂects the parameterisation using general population sexual behaviour data
from Natsal-2 data; about two-thirds of people are in an ongoing (assumed equivalent to ‘regular’)
partnership and levels of concurrent partnerships are low.
Accelerated partner therapy has the potential to reduce the population prevalence of chlamydia and
gonorrhoea more than traditional methods requiring attendance at a health service setting. This conclusion
from a dynamic modelling study assumes that APT both reduces the probability of reinfection in the index
case and increases the number of partners treated. In our mathematical model, APT did not increase the
risk of gonorrhoea outbreaks if partners were treated for the same STI as index cases. The risk of
gonorrhoea outbreaks was lower with APT when partners were also tested for STI. In all models, effects
were stronger when rates of STI screening were higher and when a biological interaction between
chlamydia and gonorrhoea was assumed. The effects of APT on gonorrhoea infections are relevant only in
areas where the prevalence if gonorrhoea is high. The harms resulting from the low positive predictive
value of testing for gonorrhoea in the general population in low prevalence settings might outweigh the
beneﬁts of the modest predicted reduction in gonorrhoea prevalence. The beneﬁts of APT on reducing the
prevalence of curable STIs might be outweighed if HIV infections, which would have been diagnosed in
partners notiﬁed by traditional technologies, are missed. In practice, very few partners reached by APT take
up the offer of additional STI testing.20 This is particularly worrying because curable urethral and cervical
STIs are cofactors for HIV acquisition and transmission.134
The cost-effectiveness of APT has not been determined. We found insufﬁcient evidence about HRQL and
QALYs for chlamydia infection and its consequences to examine the cost per QALY of introducing APT
compared with traditional partner notiﬁcation technologies. A cost–consequence analysis of the ﬁrst
exploratory trial of APT in England showed the potential for APT to be cost–effective. The cost per partner
treated was slightly higher but reached more partners for APT Hotline [£54.42 (95% CI £43.83 to £65.21)
per partner, to treat 35% of contactable partners] and APT Pharmacy [£53.29 (95% CI £42.85 to £63.73)
per partner, to treat 34% of contactable partners] compared with routine partner notiﬁcation [£45.8973
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74(95% CI £36.90 to £54.88 per partner) to treat 11% of contactable partners].135 Our analysis of the cost-
effectiveness of traditional partner notiﬁcation methods also suggests that there are potential gains of
investing in partner notiﬁcation. Using a restricted outcome, we show that partner notiﬁcation costs less
per additional new chlamydia infection detected than increasing the coverage of screening in the NCSP.
Traditional partner notiﬁcation methods work best in genitourinary medicine clinics outside London and
those with a larger case load, and are less effective for men who have sex with men. EPT is not
recommended for men who have sex with men because of a lack of evidence of effectiveness. One small
randomised controlled trial examined different combinations of partner notiﬁcation technologies on
intermediate outcomes in men who have sex with men. Rates of testing for HIV and syphilis were lower in
partners of men who received EPT than in partners of men who received traditional partner notiﬁcation.56
The risk of missing HIV infections in men who have sex with men is considered to outweigh the beneﬁts of
reaching sexual partners, many of whom are reported to be untraceable using traditional partner
notiﬁcation methods.
Finally, the studies in this project offer advances in the mathematical modelling of bacterial STIs and maybe
also in basic science. We have provided reﬁned parameter estimates for the transmissibility and duration of
asymptomatic chlamydia infection, which can be used in future studies. By investigating inconsistencies in
model predictions from different individual-based models of chlamydia transmission, we showed the
importance of representing key aspects of sexual partnership dynamics accurately. We also avoided using
mathematical models for investigating the effects of partner notiﬁcation technologies that could have
given misleading results. Our development of a model of chlamydia and gonorrhoea co-infection found
that an interaction to increase the susceptibility to chlamydia in the presence of gonorrhoea and vice
versa was necessary to achieve levels of single and co-infections that are consistently observed in
epidemiological studies.Implications for health carel A range of enhanced patient referral methods is available. Genitourinary medicine clinics have staff
with the skills and resources for conducting enhanced patient referral. Patients with curable STIs in
primary care and community sexual health services should also be able to receive enhanced patient
referral as part of their management. Support from health advisers in genitourinary medicine clinics
and training for staff in primary and community health-care services might need to be strengthened.
l The ﬁndings of two studies in this monograph emphasise the importance of sexual history taking. First,
sexual histories need to cover look-back periods that identify previous partners because our
mathematical model predicted high percentages of sexual partners infected with chlamydia as far back
as 18 months or three previous partners. Second, it is important to ﬁnd out the type of sexual
partnerships of index cases. The need for health adviser support for notifying casual partners should be
considered because of the potential gains in interrupting transmission.
l The analysis of audit data shows that the outcomes of partner notiﬁcation in genitourinary medicine
clinics remain modest. The studies in this monograph show evidence of the gains of improving
outcomes. The economic evaluation suggests that relative costs (per case identiﬁed) of increasing
the success of partner notiﬁcation are less than the costs of increasing the coverage of
chlamydia screening.
l APT is a technology that is still being developed in the UK. The implications for routine partner
notiﬁcation practice will not become clear until a formal evaluation in a randomised controlled trial
with biological outcomes has been conducted.
l Although we examined the risk of gonorrhoea outbreaks as an unintended consequence of APT, this
technology also has implications for the underdiagnosis and undertreatment of other STIs, which we
did not consider. First, there are missed opportunities for diagnosing HIV infection and the importance
of STI testing needs to be explained to partners receiving APT. Second, if an index case has chlamydia
and gonorrhoea but either he or she was not tested for gonorrhoea or the test gave a false-negativeNIHR Journals Library www.journalslibrary.nihr.ac.uk
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gonorrhoeae (with or without chlamydia co-infection), macrolide resistance could be encouraged if
given to a partner who is co-infected and does not receive adequate treatment for gonorrhoea. Third,
treatment for uncomplicated chlamydia and/or gonorrhoea will not be adequate treatment if a female
partner has PID.
l The ﬁndings about the effects and impact of partner notiﬁcation technologies cannot be generalised to
men who have sex with men, as there is limited trial evidence and because the mathematical
modelling studies modelled a general heterosexual population. However, the audit showed that
partner notiﬁcation outcomes were worse in men who have sex with men. We show ﬁndings for a
population of high-risk individuals within a general population; these should be interpreted cautiously
when applied to speciﬁc populations at high risk or in high-prevalence areas.Recommendations for research1. A randomised controlled trial of the effects of APT compared with traditional partner notiﬁcation
technologies should be conducted, with follow-up measuring biological end points beyond 3 months.
Determining whether or not the magnitude of beneﬁt found in trials of EPT can be generalised to APT
is a priority.i. Randomised trials should include interventions to increase rates of testing for other STIs and HIV in
partners notiﬁed by APT.
ii. Modelling studies of the effectiveness and cost-effectiveness of APT should be conducted alongside
a clinical trial. This should build on the dynamic models for single and dual infections developed
within this project.
2. Randomised trials to identify effective partner notiﬁcation technologies for men who have sex with men
should be conducted for both bacterial STIs and HIV.
3. Studies to collect HRQL data, including the development of appropriate tools, should be commissioned
so that QALYs for temporary and permanent health states associated with bacterial STIs, which use
methods preferred by NICE, can be determined. This is a priority so that robust cost-effectiveness
analyses of APT and of other interventions to prevent curable STIs and their consequences can
be conducted.
4. Standard sets of disease-speciﬁc parameters for bacterial STIs should be developed to help researchers
compare the performance of mathematical models and to help policy makers to interpret their outputs.
Further research to develop these for gonorrhoea, trichomonas and syphilis is needed.
5. Basic science studies are needed to investigate the possible mechanisms for a biological interaction
between the susceptibility to C. trachomatis and N. gonorrhoeae. Additional modelling studies of STI
co-infections would be valuable.75
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This protocol includes activities that were planned up to September 2010. Changes from the plannedactivities after that date are highlighted in italics.
Research objectives (amended September 2010)The overall aim of this study is to provide information for public health planning about the comparative
disease control potential and cost-effectiveness of different strategies for treating and testing the sexual
partners of people with sexually transmitted infections. This will be achieved through the following
speciﬁc objectives:
1. To provide the best available data about model parameters rapidly and efﬁciently through the use of
existing and planned datasets;
2. To compare the clinical effectiveness of different approaches to providing treatment and testing for
the partners of people with curable sexually transmitted infections by using individual-based
mathematical models.
3. To determine the cost-effectiveness of different approaches to providing treatment and testing for the
partners of people with curable sexually transmitted infections, compared with recommended practice;
4. To provide research recommendations for primary research.Research methods (amended September 2010)We propose an efﬁcient research plan that will capitalise on the existing models developed by members of
this team and described above.1–3 We will apply these models to the problem of new partner treatment
technologies, using data already collected by this group. Speciﬁc new data items will be collected by
developing novel data collection tools as part of a newly funded MRC study (PI, Mercer).
Table 1 summarises the infections, settings and scenarios to be studied during this project. The choice is
based on the incidence of infection in the general population or speciﬁc subgroups, clinical severity and
the public health consequences of failing to identify undiagnosed infection.
In the case of heterosexuals, these diseases will each be explored in two demographic populations
representing important settings for the control of sexually transmitted infections in the UK: (a) a mixed
ethnicity urban setting; (b) a largely white mixed rural and urban settings. Differences in prevalence and
incidence, risk and transmission of sexually transmitted infections in sexual networks in these populations,
which have the potential to affect the outcomes of partner testing technologies at the population level,
will then be able to be explored. In the project these populations were modelled as general and high
risk populations.
We will begin by collating secondary data to provide the best available information to inform
epidemiological and economic modelling. Two workstreams will then work in parallel: (a) baseline model
comparisons and programming; (b) collection of parameter data from ongoing studies. The main
modelling work involves an iterative process of comparison, programming and re-parameterisation for
each infection and partner management strategy to obtain the most robust range of estimates. The
scenarios below will be compared between models, for the infections described above, singly and (where
appropriate) in combination. In the project, model comparison was used for the early stages only. After
that, speciﬁc models were developed to address each research question. The economic evaluation will take
place when cost data, health state valuations, and model outputs are available, but will inform all elements91
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TABLE 1 Potential sexually transmitted infections, target populations and settings for investigation
Infection
Transmission
route
Setting for
index case
Scenarios of partner
management Actual project models
Current recommendation 1 GUM, primary
care
Treat epidemiologically and test
for index and co-infection4;5
Chlamydia Heterosexual GUM, primary
care
Treat without testing for index
or co-infection
Modelled in general and high
risk populations
Test for index and co-infection
before treating
Gonorrhoea Heterosexual GUM, primary
care
Treat without testing for index
or co-infection
Modelled in general and high
risk populations
Test for index and co-infection
before treating
MSM GUM Treat without testing for index
or co-infection
Not done, owing to lack of
time
Abbreviations: GUM – genitourinary medicine; MSM – men who have sex with men.
APPENDIX 1
92of new data collection. An economic evaluation using health state valuations could not be done, owing to
inadequate data quality.Literature reviews and other secondary data
NICE rapid review of partner notification
We will use published and unpublished data collected as part of our rapid review of partner notiﬁcation
methods (Cassell and Low),6 which contributed to the development of the NICE guidelines for preventing
sexually transmitted infections. The review includes data about: numbers of sexual partners notiﬁed and
treated per index case, according to the index infection, sexual orientation, ethnic group, and setting. We
will update the searches from August 2006 to December 2007 using published recommendations,7 and
extract data in duplicate. In the project we used the Cochrane Collaboration Sexually Transmitted
Infections Review Group review of partner notification strategies, which was being updated during the
project period.Epidemiological and economic literature reviews
We will conduct rapid searches of Medline, Embase and The Cochrane Library from January 1990 to
December 2007 based on recognised techniques,7 for information about: the prevalence of concurrent
sexually transmitted infections according to route of transmission, ethnic group, primary care and
genitourinary medicine clinic setting, probability of being tested for index and co-infections, quality of life
living with complications of chlamydia or with HIV; and costs of treatment for complications of sexually
transmitted infections. Owing to time constraints, the project included only a systematic review of studies
of quality of life for reproductive tract complications of chlamydia in women.Surveillance data
We will use the Avon System for Surveillance of Sexually Transmitted Infections (ASSIST) (Cassell
and Low)8 to determine the distribution of sexually transmitted infections according to clinical setting of
diagnosis. This database contains information from 2000 to 2004 about all tests for sexually transmitted
infections in the former Avon Health Authority area and we have comparable data from Brent Primary
Care Trust in London. These UK settings represent metropolitan, urban and rural areas, and areas of ethnic
heterogeneity. This data source was not required.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18020 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 2Patient Access to care for Sexually Transmitted Infections (PATSI)
This completed study, funded by the MRC and led by Cassell (with Garnett, Mercer, White), collected data
about consultations from eight genitourinary medicine clinics in England, including patient preferences
about clinical setting, delays in care-seeking, risk behaviour during care-seeking, and types of care offered
by GPs. This data source was not required.Public health decision support tool for population-specific sexual health
service planning
This newly funded MRC study, led by Mercer (with Cassell, Ward, White, Low) will collect and analyse new
survey and clinical data about modiﬁable aspects of sexual health service provision in genitourinary
medicine and primary care settings that affect the control of sexually transmitted infections. The project
begins in October 2008, so the timing of data collection and analysis ﬁts well with this project. We will
collect data from patients and providers about existing partner testing and treatment practices and
outcomes. Further data from the analysis of large primary care databases up to 2005, such as the General
Practice Research Database (GPRD) are also available (from Cassell and Mercer).Mathematical modelling
We will use three existing UK-developed models of chlamydia and/or gonorrhoea transmission. Our
modelling approach takes into account uncertainty in a) parameter estimates and b) model structure in
existing and is informed by methods described by Brisson and Edmunds9 and Koopman.10 We are currently
pioneering this technique in our ongoing work to improve the value of modelling studies for public health
decision-making about chlamydia screening.11 Given the variability in outputs (Figure 1), the use of
multiple models will improve the robustness of the inferences that can be drawn by allowing differences
between models to be explained.
Model comparison: We will begin by comparing in detail the structures, baseline assumptions and
predictions of the existing models using features common to all models, for example, predicted chlamydia
prevalence in heterosexuals by age and sex following epidemiological treatment and testing for 100%,
50% and 20% of current partners. This will allow a ‘diagnosis’ of parameter and model differences that
are likely to result in differences in outputs. Each model offers different advantages and disadvantages,
which are relevant to the project’s objectives. For example, the ClaSS project model models the incidence
of infertility dynamically over time, which is important for estimating the long term impact of partner
testing and treatment technologies. The first round of model comparison found that none of the available
individual based models was suitable, and that improved estimates were needed for some parameters.
Models specific to each study question were then developed. The Imperial College and HPA models have
already been developed to consider both chlamydia and gonorrhoea, expediting investigation of the
effects of co-infection with two key infections. Each team will then program their model to give a
population that includes the possibility of studying multiple infections, hetero and homosexual
partnerships, ethnic heterogeneity, genitourinary medicine and primary care treatment settings, partnership
network structure and complications. The Imperial College model could not be developed further, owing
to changes in staff.
Clinical outcomes: The main modelling work will focus on determining the most plausible internally and
externally consistent estimates of the outcomes important of public health decision making: total and age
and sex speciﬁc transmissions and complications prevented and, for the urban mixed population, outcomes
in both black and white ethnic groups. For each selected infection and partner testing scenario, we will
follow a similar process to determine the impact on both the index infection and co-infections with respect
to the effects of, a) seeking care for one infection and having others diagnosed, b) co-treatment, and
c) lost opportunities to diagnose and treat other infections. For example, for chlamydia we would examine
outcomes for, a) base case (epidemiological treatment with testing for index and co-infections), b) the
index patient’s current partner treated for chlamydia on the same day but not tested for co-infections,
c) current partner being tested for chlamydia but not treated until results are known. We will conduct an
iterative process of model comparison, diagnosis, re-parameterisation and programming. At each stage93
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94differences between model outputs will be discussed, and reasons explored. We will test alternative
assumptions about parameter values, for example, the uptake of different strategies, in sensitivity analyses.
We will explore differences due to model structure by modifying one model to reproduce the structure of
the one (or ones) from which it differs. If ﬁnal model outputs converge to produce similar predictions, the
ﬁnal output will be the average from all three models. If ﬁnal outputs remain different, with no available
empirical data to help determine the most plausible outputs, we will present a low, middle and upper
estimate. The numbers of infections and complications averted will be used in the economic evaluation.
Models specific to each study question were developed. Complications were not modelled, owing to
lack of time.Economic evaluation and health state valuation
We will use published sources to estimate the costs of antibiotic treatment, face-to-face consultation,
telephone consultation, hospital and/or outpatient treatment for tubal infertility, ectopic pregnancy, pelvic
inﬂammatory disease, HIV infection at 2009 Sterling prices.1;12;13Cost-effectiveness analysis
The cost-effectiveness analysis will be from the health service perspective using current NICE
recommendations for the discounting of future costs and outcomes.14 We will use model data for the
numbers of infections averted, cases of infertility and HIV averted by adopting different partner testing
strategies. Uncertainty will be explored using appropriate sensitivity analysis given the nature of the
models. Incremental cost effectiveness ratios, comparing costs of one intervention with the current
standard of care, will be presented in pounds Sterling per major outcome averted and per QALY. A
cost-effectiveness analysis using cost per QALY could not be done, owing to inadequate data quality.
Economic evaluations were done using intermediate outcomes.Ethical arrangementsMercer is responsible for obtaining ethical committee approval for her project.ReferencesNIHRLow N, McCarthy A, Macleod J, Salisbury C, Campbell R, Roberts TE et al. Epidemiological, social,
diagnostic and economic evaluation of population screening for genital chlamydial infection. Health
Technol Assess 2007; 11(8):1–184.
Turner KM, Adams EJ, Gay N, Ghani AC, Mercer C, Edmunds WJ. Developing a realistic sexual network
model of chlamydia transmission in Britain. Theor Biol Med Model 2006; 3:3.
White PJ, Golden MR, Turner KM, Mercer CH, Ward H, Garnett GP. Can patient delivered partner
therapy help us regain control of sexually transmitted infections in the UK? Sex Transm Infect 2006;
82(Suppl 2):A2.
British Association of Sexual Health and HIV Clinical Effectiveness Group. 2006 UK national guideline
for the management of genital tract infection with Chlamydia trachomatis. http://www.bashh.org/
guidelines [cited 2012 Nov. 2].
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Reproduced from Ferreira A, Young T, Mathews C, Zunza M, Low N. Strategies for partner notiﬁcationfor sexually transmitted infections, including HIV. Cochrane Database Syst Rev 2013; 10:CD002843
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Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.Database: The Cochrane Library 2011, Issue 1 (2001–12)
Date: 22 March 2011, 29 January 2012 and 31 August 2012ID Search
#1 MeSH descriptor Sexually Transmitted Diseases explode all trees
#2 MeSH descriptor Herpes Genitalis, this term only
#3 MeSH descriptor Chancroid, this term only
#4 MeSH descriptor Chlamydia trachomatis, this term only
#5 MeSH descriptor Gonorrhea, this term only
#6 MeSH descriptor Syphilis, this term only
#7 MeSH descriptor Lymphogranuloma Venereum, this term only
#8 MeSH descriptor Granuloma Inguinale, this term only
#9 MeSH descriptor Calymmatobacterium, this term only
#10 MeSH descriptor Treponema pallidum, this term only
#11 MeSH descriptor Condylomata Acuminata, this term only
#12 MeSH descriptor Human papillomavirus 6 explode all trees
#13 MeSH descriptor Hepatitis B explode all trees
#14 MeSH descriptor Trichomonas Vaginitis, this term only
#15 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14)
#16 sexually transmitted disease*:ti,ab,kw OR sexually transmissible disease*:ti,ab,kw OR sexually transmitted
infection*:ti,ab,kw OR sexually transmissible infection*:ti,ab,kw OR sexually transmitted infectious disease*:ti,ab,
kw OR sexually transmissible infectious disease*:ti,ab,kw OR sexually transmitted disorder*:ti,ab,kw OR sexually
transmissible disorder*:ti,ab,kw OR STI:ti,ab,kw OR STIs:ti,ab,kw OR STD:ti,ab,kw OR STIs:ti,ab,kw OR venereal
disease*:ti,ab,kw OR venereal infection*:ti,ab,kw OR venereal disorder*:ti,ab,kw OR genital herpes:ti,ab,kw OR
herpes genitalis:ti,ab,kw OR genital infection*:ti,ab,kw OR genital disorder*:ti,ab,kw
#17 herpes simplex:ti,ab,kw OR herpes virus:ti,ab,kw OR HSV-1:ti,ab,kw OR HSV-2:ti,ab,kw OR chancroid*:ti,ab,kw OR
haemophilus ducreyi:ti,ab,kw OR chlamydia infection*:ti,ab,kw OR chlamydia trachomatis:ti,ab,kw OR
gonorrhoea*:ti,ab,kw OR gonorrhea*:ti,ab,kw OR syphilis:ti,ab,kw OR syphillis:ti,ab,kw OR condylomata lata:ti,ab,
kw OR chancre*:ti,ab,kw OR lymphogranuloma venereum:ti,ab,kw OR granuloma inguinale:ti,ab,kw OR
donovania:ti,ab,kw OR donovanosis:ti,ab,kw OR calymmatobacterium granulomatis:ti,ab,kw OR klebsiella
granulomatis:ti,ab,kw OR klebsiella granulomatis:ti,ab,kw OR treponema pallidum:ti,ab,kw OR genital wart*:ti,ab,
kw OR venereal wart*:ti,ab,kw OR hpv-6:ti,ab,kw OR hpv-11:ti,ab,kw OR hpv6:ti,ab,kw OR human papillomavirus:
ti,ab,kw OR hepatitis b:ti,ab,kw OR trichomonas vaginitis:ti,ab,kw OR genital ulcer*:ti,ab,kw OR anogenital ulcer*:
ti,ab,kw OR anorectal ulcer*:ti,ab,kw OR anorectal ulcer*:ti,ab,kw OR penile ulcer*:ti,ab,kw
#18 (#15 OR #16 OR #17)
#19 MeSH descriptor HIV Infections explode all trees
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ID Search
#20 MeSH descriptor HIV explode all trees
#21 hiv OR hiv-1* OR hiv-2* OR hiv1 OR hiv2 OR HIV INFECT* OR HUMAN IMMUNODEFICIENCY VIRUS
OR HUMAN IMMUNEDEFICIENCY VIRUS OR HUMAN IMMUNE-DEFICIENCY VIRUS OR HUMAN IMMUNO-
DEFICIENCY VIRUS OR HUMAN IMMUN* DEFICIENCY VIRUS OR ACQUIRED IMMUNODEFICIENCY SYNDROME OR
ACQUIRED IMMUNEDEFICIENCY SYNDROME OR ACQUIRED IMMUNO-DEFICIENCY SYNDROME OR ACQUIRED
IMMUNE-DEFICIENCY SYNDROME OR ACQUIRED IMMUN* DEFICIENCY SYNDROME
#22 MeSH descriptor Lymphoma, AIDS-Related, this term only
#23 (#19 OR #20 OR #21 OR #22)
#24 (#18 OR #23)
#25 MeSH descriptor Contact Tracing, this term only
#26 partner notiﬁcation:ti,ab,kw OR partner notiﬁcations:ti,ab,kw OR contact tracing:ti,ab,kw OR expedited partner:ti,
ab,kw OR patient delivered:ti,ab,kw OR referral:ti,ab,kw OR referrals:ti,ab,kw OR partner tracing:ti,ab,kw
#27 (#25 OR #26)
#28 (#24 AND #27)
#29 (#24 AND #27), from 2001 to 2011
MeSH, medical subject heading.
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Databases searched were MEDLINE, EMBASE, ISI Web of Knowledge, NHS EED, DARE and HTA, from1980 to 31 December 2011.# Term
#1 Chlamydia.mp. or exp CHLAMYDIA/ or CHLAMYDIA TRACHOMATIS/
#2 Gonorrhea.mp. or exp GONORRHEA/
#3 Pelvic inﬂammatory disease.mp. or exp pelvic inﬂammatory disease/
#4 PID.mp. or exp pelvic inﬂammatory disease/
#5 Cervicitis.mp. or exp uterine cervicitis/
#6 Chronic pelvic pain.mp.
#7 Ectopic pregnancy.mp. or exp ectopic pregnancy/
#8 Epididymitis.mp.
#9 Economic evaluation.mp. or economic evaluation/
#10 Cost-utility analysis.mp. or "cost utility analysis"/
#11 Cost-effectiveness analysis.mp. or "cost effectiveness analysis"/
#12 Quality of life.mp. or "quality of life"/
#13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
#14 9 or 10 or 11
#15 13 and 14
#16 14 and 15
#17 15 or 16Categories used for study selection
A. Strictly primary research study (original data collected for the study) for costs and outcomes, which
reports on costs or utilisation of care, quality of life of individuals with chlamydia, and includes a formal
economic evaluation.
B. Combination of primary and secondary research studies, which reports on the costs or utilisation of
care but HRQL of life is not based on primary research, and includes a formal economic evaluation.
C. Study discusses economic aspects of care, contains useful primary and secondary cost or utilisation data
but not an economic evaluation.
D. Study is not a full economic evaluation but has primary data on outcome valuation (instruments and
techniques for health state valuation for eliciting the value for avoiding chlamydia).
E. Study discusses economic aspects of policies for care and does not ﬁt into categories A to D.
F. Study has no relevance to the instruments and techniques available for eliciting the value of the health
state for avoiding chlamydia.
Studies categorised as A, B, C or D were considered potentially relevant and were reviewed in full. Studies
in categories E and F were excluded.99
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